---
document_datetime: 2023-09-21 20:19:16
document_pages: 100
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0091-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-3820-ii-0091-epar-assessment-report-variation_en.pdf
version: success
processing_time: 174.142458
conversion_datetime: 2025-12-28 02:03:39.314133
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

10 December 2020 EMA/CHMP/33664/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name : pembrolizumab

Procedure No. EMEA/H/C/003820/II/0091

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure...........................................................7                    |                                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation................................................................................................    | 7                                                                                                      |
| 1.2. Steps taken for the assessment of the product.......................................................                 | 7                                                                                                      |
| 2. Scientific discussion                                                                                                  | ............................................................................................8          |
| 2.1. Introduction......................................................................................................   | 8                                                                                                      |
| 2.1.1. Problem statement..........................................................................................        | 8                                                                                                      |
| 2.1.2. About the product                                                                                                  | ..........................................................................................13           |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                          | ......14                                                                                               |
| 2.1.4. General comments on compliance with                                                                                | GCP.......................................................14                                           |
| 2.2. Non-clinical aspects...........................................................................................14    |                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                          | ........................................................14                                             |
| 2.3. Clinical aspects.................................................................................................14  |                                                                                                        |
| 2.3.1. Introduction                                                                                                       | ..................................................................................................14   |
| 2.3.2. Pharmacokinetics                                                                                                   | ...........................................................................................15          |
| 2.3.1. Pharmacodynamics.........................................................................................21        |                                                                                                        |
| 2.3.2. Discussion on clinical pharmacology..................................................................22            |                                                                                                        |
| 2.3.3. Conclusions on clinical pharmacology................................................................23             |                                                                                                        |
| 2.4. Clinical efficacy.................................................................................................23 |                                                                                                        |
| 2.4.1. Dose response study(ies)                                                                                           | ................................................................................23                     |
| 2.4.2. Main study                                                                                                         | ....................................................................................................24 |
| 2.4.3. Discussion on clinical efficacy...........................................................................64       |                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy....................................................................68         |                                                                                                        |
| 2.5. Clinical safety...................................................................................................68 |                                                                                                        |
| 2.5.1. Discussion on clinical safety.............................................................................89       |                                                                                                        |
| 2.5.2. Conclusions on clinical safety                                                                                     | ...........................................................................92                          |
| 2.5.3. PSUR cycle....................................................................................................92   |                                                                                                        |
| 2.6. Risk management plan                                                                                                 | ......................................................................................93               |
| 2.7. Changes to the Product Information                                                                                   | ....................................................................95                                 |
| 2.7.1. User consultation                                                                                                  | ...........................................................................................95          |
| 2.7.2. Additional monitoring......................................................................................96      |                                                                                                        |
| 3. Benefit-Risk Balance..........................................................................................96       |                                                                                                        |
| 3.1. Therapeutic Context..........................................................................................96      |                                                                                                        |
| 3.1.1. Disease or condition                                                                                               | .......................................................................................96              |
| 3.1.2. Available therapies and unmet medical need......................................................96                 |                                                                                                        |
| 3.1.3. Main clinical studies........................................................................................96    |                                                                                                        |
| 3.2. Favourable effects.............................................................................................96    |                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects                                                               | ............................................97                                                         |
| 3.4. Unfavourable effects                                                                                                 | .........................................................................................97            |
| 3.5. Uncertainties and limitations about unfavourable effects.........................................98                  |                                                                                                        |
| 3.6. Effects Table                                                                                                        | ....................................................................................................98 |
| 3.7. Benefit-risk assessment and discussion................................................................99             |                                                                                                        |
| 3.7.1. Importance of favourable and unfavourable effects                                                                  | .............................................99                                                        |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance  ...........................................  99

3.8. Conclusions  ......................................................................................................  99

4. Recommendations ...........................................................................................  100

5. EPAR changes ..................................................................................................  100

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                                                   |
|----------------|----------------------------------------------------------------------------------------------|
| 1L             | First-line (participants who have not received prior therapy)                                |
| 2L             | Second-line therapy (participants who have received 1 prior therapy)                         |
| 2L+            | Second-line or later therapy (participants who have received 1 or more prior therapies)      |
| 3L             | Third-line (participants who have received 2 prior therapies)                                |
| 3L+            | Third-line or later therapy (participants who have received 2 or more prior therapies)       |
| ADA            | Antidrug antibodies                                                                          |
| AE(s)          | Adverse event(s)                                                                             |
| AEOSI          | Adverse event(s) of special interest                                                         |
| ASaT           | All subjects as treated                                                                      |
| ASCO           | American Society of Clinical Oncology                                                        |
| BCG            | Bacillus Calmette-Guerin                                                                     |
| cHL            | Classic Hodgkin's lymphoma                                                                   |
| CHMP           | Committee for Medicinal Products for Human Use                                               |
| CI             | Confidence interval                                                                          |
| CIS            | Carcinoma in situ                                                                            |
| CR             | Complete response (per RECIST)                                                               |
| CRC            | Colorectal carcinoma                                                                         |
| CSR            | Clinical Study Report                                                                        |
| DCR            | Disease control rate (per RECIST)                                                            |
| dMMR           | Deficient mismatch repair                                                                    |
| DNA            | Deoxyribonucleic acid                                                                        |
| DOR            | Duration of response (per RECIST)                                                            |
| ECOG           | Eastern Cooperative Oncology Group                                                           |
| EMA            | European Medicines Agency                                                                    |
| EMA/SAWP       | European Medicines Agency/Scientific Advice Working Party                                    |
| EMEA           | European Medicines Evaluation Agency                                                         |
| EOP1           | End of Phase 1                                                                               |
| EORTC QLQ      | European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire |
| E-R            | Exposure response                                                                            |

<div style=\"page-break-after: always\"></div>

## Abbreviation Definition

| ESMO    | European Society for Medical Oncology                                                           |
|---------|-------------------------------------------------------------------------------------------------|
| EU      | European Union                                                                                  |
| FDA     | Food and Drug Administration                                                                    |
| FOLFIRI | Irinotecan (180 mg/m 2 ); leucovorin (calcium folinate) 400 mg/m 2 ; 5-fluorouracil 2400 mg/m 2 |
| GCP     | Good Clinical Practice                                                                          |
| GI      | Gastrointestinal                                                                                |
| HCC     | Hepatocellular carcinoma                                                                        |
| HL      | Hodgkin lymphoma                                                                                |
| HNSCC   | Head and neck squamous cell carcinoma                                                           |
| HR      | Hazard ratio                                                                                    |
| HTA     | Health Technology Assessment                                                                    |
| IA1/IA2 | Interim analysis 1/2                                                                            |
| IgG     | Immunoglobulin G                                                                                |
| IHC     | Immunohistochemistry                                                                            |
| IV      | Intravenous                                                                                     |
| KM      | Kaplan-Meier                                                                                    |
| KRAS    | Kirsten rat sarcoma                                                                             |
| LSM     | Least-squares method                                                                            |
| mAb     | Monoclonal antibody                                                                             |
| M&S     | Modeling and Simulation                                                                         |
| MCC     | Merkel cell carcinoma                                                                           |
| mFOLFOX | Oxaliplatin (85 mg/m 2 ); leucovorin (calcium folinate) 400 mg/m 2 ; 5-fluorouracil 2400 mg/m 2 |
| MMR     | Mismatch repair                                                                                 |
| MSI     | Microsatellite instability                                                                      |
| MSI-H   | Microsatellite instability-high                                                                 |
| NCCN    | National Comprehensive Cancer Network                                                           |
| NMIBC   | Non-muscle invasive bladder cancer                                                              |
| NRAS    | Neuroblastoma RAS                                                                               |
| NSCLC   | Non-small cell lung cancer                                                                      |
| ORR     | Objective response rate (per RECIST)                                                            |
| OS      | Overall survival                                                                                |

<div style=\"page-break-after: always\"></div>

## Abbreviation Definition

| PCR    | Polymerase chain reaction                     |
|--------|-----------------------------------------------|
| PD-1   | Programmed cell death-1                       |
| PD-L1  | Programmed cell death ligand 1                |
| PD-L2  | Programmed cell death ligand 2                |
| PFS    | Progression-free survival (per RECIST)        |
| PK     | Pharmacokinetic                               |
| PMBCL  | Primary mediastinal large B-cell lymphoma     |
| PMDA   | Pharmaceuticals and Medical Devices Agency    |
| PMR    | Post-marketing requirement                    |
| PR     | Partial response (per RECIST)                 |
| PRO    | Patient-reported outcomes                     |
| PS     | Performance status                            |
| Q2W    | Every 2 weeks                                 |
| Q3W    | Every 3 weeks                                 |
| Q6W    | Every 6 weeks                                 |
| QoL    | Quality of life                               |
| QTc    | QT [interval] corrected for heart rate        |
| RCC    | Renal cell carcinoma                          |
| RECIST | Response Evaluation Criteria in Solid Tumours |
| RSD    | Reference Safety Dataset                      |
| SAE(s) | Serious adverse event(s)                      |
| SCLC   | Small-cell lung cancer                        |
| SD     | Stable disease (per RECIST)                   |
| sJNDA  | Supplementary Japan New Drug Application      |
| SOC    | Standard of care                              |
| TTD    | Time to deterioration                         |
| TTP    | Time to progression                           |
| US     | United States                                 |
| VAS    | Visual analog scale                           |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 29 June 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

C.I.6 -Extension of indication to include first-line treatment of unresectable or metastatic microsatellite instability-high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults for Keytruda based on the results from KEYNOTE-177 (an international, randomised, open-label Phase 3 trial of pembrolizumab versus chemotherapy in MSI-H or dMMR Stage IV Colorectal Carcinoma).  As a consequence, sections 4.1, 4.2, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, a minor correction has been made in section 4.4, 'Immune related endocrinopathies' subsection. Version 29.1 of the RMP has also been submitted.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0043/2018 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received Scientific Advice from the CHMP in 2015 on the design elements of the clinical trial KEYNOTE-177, which is the pivotal study for this application (procedure EMEA/H/SA/2437/8/2015/II).

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Armando Genazzani

Co-Rapporteur:

Jan Mueller-Berghaus

<div style=\"page-break-after: always\"></div>

| Timetable                                                                              | Actual dates      |
|----------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                        | 29 June 2020      |
| Start of procedure:                                                                    | 18 July 2020      |
| Co-Rapporteur's preliminary assessment report circulated on:                           | 14 September 2020 |
| Rapporteur's preliminary assessment report circulated on:                              | 14 September 2020 |
| PRAC Rapporteur's preliminary assessment report circulated on:                         | 16 September 2020 |
| PRAC Rapporteur's updated assessment report circulated on:                             | 9 October 2020    |
| PRAC RMP advice and assessment overview adopted by PRAC on:                            | 1 October 2020    |
| Joint Rapporteur's updated assessment report circulated on:                            | 9 October 2020    |
| Request for supplementary information and timetable adopted by the CHMP on:            | 15 October 2020   |
| MAH's responses submitted to the CHMP on:                                              | 20 October 2020   |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on:  | 19 November 2020  |
| Joint Rapporteur's preliminary assessment report on the MAH's responses circulated on: | 26 November 2020  |
| PRAC RMP advice and assessment overview adopted by PRAC on:                            | 26 November 2020  |
| Joint Rapporteur's updated assessment report on the MAH's responses circulated on:     | 4 December 2020   |
| CHMP opinion:                                                                          | 10 December 2020  |

## 2. Scientific discussion

## 2.1. Introduction

The MAH for Keytruda is applying for an extension of indication of pembrolizumab as first line treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults, based on the results of the open-label international randomized phase 3 trial KEYNOTE-177 of pembrolizumab versus chemotherapy in MSI-H or dMMR Stage IV Colorectal Carcinoma.

## 2.1.1. Problem statement

## Disease or condition

The claimed therapeutic indication at the time of submission was:

'KEYTRUDA as monotherapy is indicated for the first-line treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults'

During the procedure, the MAH updated the sought indication as follows:

'KEYTRUDA as monotherapy is indicated for the first-line treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults'

<div style=\"page-break-after: always\"></div>

## Epidemiology and risk factors, screening tools/prevention

Colorectal cancer ranks third in terms of incidence and second in terms of mortality worldwide 1 . Approximately 12-15% of all CRC and 4% of metastatic CRC are characterized as microsatellite instability-high (MSI-H) and/or mismatch repair-deficiency (dMMR). 2

## Biologic features, aetiology and pathogenesis

Mismatch repair proteins (MMR) repair insertions or deletions in microsatellites, which are repetitive DNA units. MLH1, MSH2, MSH6 and PMS2 are known MMR gene products. Dysfunction of this system is known as deficient mismatch repair (dMMR), which leads to the insertion of deletion of the repeating nucleotides microsatellites during DNA replication and accumulation of mutations due to failure to correct errors in nucleotide repeat. This form of genomic instability is called microsatellite instability (MSI).

MSI-H/dMMR has been observed in many types of cancer including CRC, gastric, endometrial, biliary, urinary tract, ovarian and breast tumours. Some tumour types have noticeably higher MSI-H prevalence than others (endometrial and colon cancer in particular), being the overall prevalence in stage IV cancers of approximately 5%. 3

There are two forms of MSI colorectal cancer: (1) the hereditary type, caused by the deficiency of MMR system resulting from a germline mutation in MMR genes predisposing to Lynch syndrome (LS) or hereditary non-polyposis colorectal cancer, which is the most common hereditary colon cancer syndrome, inherited in an autosomal dominant pattern; (2) the sporadic form, which is related to the somatic inactivation of the same pathway, most commonly through hypermethylation (epigenetic inactivation) of the MLH1 gene, leading to sporadic MSI/dMMR CRC.

Recent studies highlighted genetic diversity and distinct patterns in CRC with MSI, suggesting substantial heterogeneity, also based on MSI etiology. 4

Methylation of the MLH1 promoter region in the sporadic form is strongly associated with the BRAF V600E gene mutation. The presence of the BRAF V600E mutation in CRC essentially excludes Lynch syndrome, except for rare cases associated with PMS2 germ-line mutation. While BRAF V600E mutation has a negative prognostic impact in proficient MMR CRC, data on the role of BRAF in relation to MMR status are scarce and the impact of BRAFV600E mutation on MSI CRCs remains controversial. 5  By contrast, KRAS mutations (in codons 12 or 13) are inversely correlated with MSI-H status. 6

## Clinical presentation, diagnosis and stage/prognosis

The MSI-high (MSI-H) phenotype is characterized by clinical and pathologic features distinct from those observed in microsatellite stable (MSS) CRC. MSI-H CRCs are usually diagnosed at younger age and at an earlier stage than MSS CRC, with a predominance in the right colon. The sporadic form is however characterized by older age at diagnosis than the hereditary one and it's more often associated with

1  Bray F et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J for Clin. 2018;68:394 -424.

2  Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther. 2018 Sep;189:45-62.

3  Le et al. Mismatch repair deficiency predicts response of solid tumours to PD-1 blockade. Science 2017;357:409-413.

4  Battaglin F et al. Microsatellite Instability in Colorectal Cancer: Overview of Its Clinical Significance and Novel Perspectives. Clin Adv Hematol Oncol 2018;16(11):735-747.

5  Cohen R et al. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. Eur J Cancer 2017; 86:266e274.

6  Gelsomino F et al. The evolving role of microsatellite instability in colorectal cancer:A review. Canc Treat Rev 2016;51:19-26.

<div style=\"page-break-after: always\"></div>

female sex and cigarette smoking. 8  Regardless whether hereditary or sporadic, MSI-H CRCs are histologically characterized by great production of mucin with extracellular accumulation, signet ring and medullary types, often admixed, with increased numbers of tumour-infiltrating lymphocytes and prominent Crohn's-like lymphoid reaction. 7

Patients with Lynch syndrome have an increased risk of synchronous or metachronous tumours, as well as higher risk for the development of extracolonic cancer, in particular endometrial carcinoma, and also cancers of the small bowel, stomach, genitourinary system and biliary tract.

With regard to the molecular diagnosis, MMR or MSI status can be determined by examining either: (1) protein expression by IHC staining for 4 MMR proteins (MLH1/MSH2/MSH6/PMS2) on tumour samples to identify negative or loss of staining (i.e. loss of protein expression) that characterize dMMR as a surrogate for MSI; or (2) molecular DNA testing PCR-based microsatellite instability analysis evaluating a specific panels of microsatellite markers to identify instability in selected loci. In general, tumours are classified as MSI-H (including MMR deficient) when expression of at least 1 of 4 MMR proteins is not detectable by IHC, or when 30% or more of the loci show instability. Both methods are sensitive and specific for MSI detection and have a high concordance rate. Although both IHC- and PCR-based approaches are currently considered the standard for MSI detection, several studies have proposed other methods such as NGS. 6   8 These tests are performed directly on tumour samples.

International guidelines (ESMO, NCCN, ASCO) recommend MMR/MSI testing with either an MMR protein IHC-based assay or PCR-based MSI loci for all patients with CRC in clinical decision making, and that 'IHC for MMR and DNA analysis for MSI are different assays and measure different biological effects caused by deficient mismatch repair function'. Patients determined to have defective MMR status are biologically the same population as those with MSI-H status.  9 10 11

Findings from a pooled analysis of four phase 3 studies in participants with metastatic CRC treated with first-line SOC therapies, showed that the median PFS and OS were significantly worse for participants with MSI-H/dMMR CRC compared with participants whose tumours were microsatellite stable (PFS: HR=1.33; 95% CI:1.12-1.57; OS: HR=1.35;95% CI:1.13-1.61) 12  (see table below).

The underlying hypothesis for studies with anti PD-1/PD-L1 antibodies in MSI-H/dMMR cancer is that MSIH/dMMR cancers are characterized by a high burden of somatic mutation and tumour-specific neoantigen load mediated by MSI and common defects in MMR, which can be recognized by the patient's immune system. 6  In this subset of MSI-H/dMMR cancer patients a large number of activated CD8 positive cytotoxic T cells and a cytokine-rich environment have been observed, associated with upregulated expression of PD-1 and PD-L1 and others checkpoints (e.g. CTLA-4). As a result, the MSI-H/dMMR phenotype represents a unique immunobiology that implicates the role of lymphocyte infiltration, high mutational load, and responsiveness to immune checkpoint blockade that can be addressed by anti-PD-1 therapy. Not all patients with MSI-H tumours, however, respond to immunotherapy, suggesting that a deeper understanding of immune-related mechanisms in MSI-H CRC is required.  13

7  Gatalica Z et al. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Fam Cancer. 2016; 15: 405-412.

8  Jonathan A Nowak JA et al. Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. J Mol Diagn. 2017 Jan;19(1):84-91.

9  Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Ovcol 2016;27:1386-1422.

10  Balamana J et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2013;24 (Supplement 6): vi73-vi80.

11  NCCN Guidelines version 4.2020 Colon Cancer

12  Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014 Oct 15;20(20):5322-30.

13  Olivera AF et al. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. Front Oncol 2019;9:396.

<div style=\"page-break-after: always\"></div>

## Management

The outcome of patients with mCRC has clearly improved during recent years with median survival now reaching 30 months in clinical trials. The treatment of mCRC patients should be seen as a continuum of care in which the determination of the goals of the treatment is important: prolongation of survival, cure, improving tumour-related symptoms, stopping tumour progression and/or maintaining quality of life. 14

Patients are treated according to international guidelines for colorectal cancer. Combination chemotherapy of FOLFOX (oxaliplatin, 5-FU, and leucovorin/folinic acid) or FOLFIRI (irinotecan, 5-FU, and leucovorin/folinic acid) are established first-line SOC chemotherapy options for metastatic CRC. Both are partners for biologicals, but have a different toxicity profile, and may be used depending on the physician's recommendation and regional preference. Capecitabine per OS can be used instead of IV 5-FU in combination with oxaliplatin. Monoclonal antibodies against vascular endothelial growth factor VEGF (bevacizumab) and against the epidermal growth factor receptor EGFR (cetuximab, panitumumab) are approved for use in combination with chemotherapy as first-line treatment in CRC, since they improve the outcome of mCRC. A summary of approved treatments for first-line treatment of metastatic CRC is presented in table below.

Although there are currently available treatment options, the presence of additional effective therapies in this targeted advanced setting is welcomed.

Table:  'Summary and Pooled Analyses of Clinical Outcomes in First-line dMMR Versus pMMR CRC Patients in Phase 3'

|                |                                                                                 |                                                   | dMMR           | Efficacy in dMMR CRC   | Efficacy in dMMR CRC   | Efficacy in pMMR CRC   | Efficacy in pMMR CRC   |
|----------------|---------------------------------------------------------------------------------|---------------------------------------------------|----------------|------------------------|------------------------|------------------------|------------------------|
| Trial name     | Regimen                                                                         | Agents                                            | Prevalence     | PFS mo. (95% CI)       | OS mo. (95% CI)        | PFS mo. (95% CI)       | OS mo. (95% CI)        |
| CAIRO          | Combination vs. sequential (XELOX, IRI)                                         | Capecitabine, irinotecan, oxaliplatin             | 18/322 (5.6%)  | 5.7 (4.2-8.8)          | 14.8 (12.0- 26.0)      | 6.9 (6.2-7.9)          | 17.9 (16.1- 19.2)      |
| CAIRO2         | XELOX+bev vs. XELOX, bev+cetu                                                   | Capecitabine, oxaliplatin, bevacizumab, cetuximab | 29/516 (5.6%)  | 7.5 (6.4-10.5)         | 15.6 (12.9- 22.3)      | 10.5 (9.6- 11.4)       | 22.0 (20.3- 24.1)      |
| COIN           | XELOX/FOLFOX Â± cetu                                                             | Capecitabine, oxaliplatin, 5FU, cetuximab         | 65/1461 (4.4%) | 5.7 (5.4-6.1)          | 10.7 (9.3- 13.0)       | 6.5 (6.2-6.8)          | 16.0 (15.0- 16.9)      |
| FOCUS          | Sequential vs. upfront combination doublet (5FU+oxaliplatin or 5FU +irinotecan) | 5FU, oxaliplatin, irinotecan                      | 41/764 (5%)    | 8.1 (6.5-9.1)          | 16.6 (13.6- 21.7)      | 8.0 (7.4-8.3)          | 15.5 (14.5- 16.6)      |
| Pooled dataset |                                                                                 |                                                   | 153/3063 (5%)  | 6.2 (5.9-7.0)          | 13.6 (12.4- 15.6)      | 7.6 (7.3-8.0)          | 16.8 (16.3- 17.5)      |

Data are from Venderbosch et al, 2014. 13

14  Van Cutsem E et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(suppl 3):iii1-iii9.

<div style=\"page-break-after: always\"></div>

Table: Summary of First-line Therapies for Metastatic CRC (regardless of MMR status)

| Approved Therapies                                                                                                                      | Regimen                                                                                                                                 | Median OS                                                                                                                               | Median PFS/TTP                                                                                                                          | Objective Response Rates                                                                                                                | Publication                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FOLFOX                                                                                                                                  | Oxaliplatin 5-FU Leucovorin/folinic acid                                                                                                | 15 months                                                                                                                               | TTP 7 months                                                                                                                            | 34%                                                                                                                                     | Colucci G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005 Aug 1;23(22):4866-75.                                                                                                                                                              |
| FOLFIRI                                                                                                                                 | Irinotecan 5-FU Leucovorin/folinic acid                                                                                                 | 14 months                                                                                                                               | TTP 7 months                                                                                                                            | 31%                                                                                                                                     | Colucci G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005 Aug 1;23(22):4866-75.                                                                                                                                                              |
| FOLFOX (or XELOX) + Bevacizumab                                                                                                         | Oxaliplatin 5-FU Leucovorin/folinic acid Bevacizumab                                                                                    | 21.3 months                                                                                                                             | PFS 9.4 months                                                                                                                          | 49%                                                                                                                                     | Saltz LB, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 Apr 20;26(12):2013-9. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110. J Clin Oncol. 2009 Feb 1;27(4):653.                                                                                                 |
| FOLFIRI+ Bevacizumab                                                                                                                    | Irinotecan 5-FU Leucovorin/folinic acid Bevacizumab                                                                                     | 20.3 months 25 months                                                                                                                   | PFS 10.6 months                                                                                                                         | 44.8% 58%                                                                                                                               | Heinemann V et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1065-75. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42. |
| FOLFOX+ Cetuximab                                                                                                                       | Oxaliplatin 5-FU Leucovorin/folinic acid Cetuximab                                                                                      | 18.3 months                                                                                                                             | PFS 7.2 months                                                                                                                          | 46%                                                                                                                                     | OPUS study                                                                                                                                                                                                                                                                                                                                                                                        |
| FOLFIRI+ Cetuximab                                                                                                                      | Irinotecan, 5-FU Leucovorin/folinic acid Cetuximab                                                                                      | 19.9 months 28.7 months                                                                                                                 | PFS 8.9 months                                                                                                                          | 46.9% 62%                                                                                                                               | Van Cutsem et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2;360(14):1408-17.                                                                                                                                                                                                                                                     |
| Capecitabine                                                                                                                            | Monotherapy                                                                                                                             | 392 days                                                                                                                                | TTP 4.6 months                                                                                                                          | 25.7%                                                                                                                                   | Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer. 2002;38:15-20.                                                                                                                                                                                                                                                  |
| Abbreviations: 5-FU=5 fluorouracil; CRC=Colorectal cancer; OS=Overall survival; PFS=Progression-free survival; TTP=Time to progression. | Abbreviations: 5-FU=5 fluorouracil; CRC=Colorectal cancer; OS=Overall survival; PFS=Progression-free survival; TTP=Time to progression. | Abbreviations: 5-FU=5 fluorouracil; CRC=Colorectal cancer; OS=Overall survival; PFS=Progression-free survival; TTP=Time to progression. | Abbreviations: 5-FU=5 fluorouracil; CRC=Colorectal cancer; OS=Overall survival; PFS=Progression-free survival; TTP=Time to progression. | Abbreviations: 5-FU=5 fluorouracil; CRC=Colorectal cancer; OS=Overall survival; PFS=Progression-free survival; TTP=Time to progression. | Abbreviations: 5-FU=5 fluorouracil; CRC=Colorectal cancer; OS=Overall survival; PFS=Progression-free survival; TTP=Time to progression.                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

Table: Overview of Studies in First-line Treatment of Advanced or Metastatic CRC

| Treatment Arm                                                           | Sample size                 | Median PFS Months (95% CI)        | ORR (95% CI)                        | Study name           |
|-------------------------------------------------------------------------|-----------------------------|-----------------------------------|-------------------------------------|----------------------|
| Cetuximab + FOLFIRI                                                     | 599                         | 8.9 (8.0 - 9.5)                   | 46.9% (42.9 - 51.0)                 | CRYSTAL              |
| FOLFIRI                                                                 | 599                         | 8.0 (7.6 - 9.0)                   | 38.7% (34.8 - 42.8)                 | CRYSTAL              |
| Panitumumab + FOLFOX4                                                   | 325 (KRAS WT) 221 (KRAS MT) | 10.0 (9.3 - 11.4) 7.4 (6.9 - 8.1) | 57% (51.5 - 62.6) 40% (33.4 - 46.9) | PRIME                |
| FOLFOX4                                                                 | 331 (KRAS WT) 219 (KRAS MT) | 8.6 (7.5 - 9.5) 9.2 (8.1 - 9.9)   | 48% (42.0 - 53.1) 41% (34.1 - 47.7) | PRIME                |
| Cetuximab + mFOLFOX/ FOLFIRI                                            | 578 (KRAS WT)               | 10.5                              | 59.6%                               | CALGB80405           |
| Bevacizumab + mFOLFOX/ FOLFIRI                                          | 559 (KRAS WT)               | 10.6                              | 55.2%                               | CALGB80405           |
| Bevacizumab + FOLFOXIRI                                                 | 252                         | 12.1 (10.9-13.2)                  | 53.1% (58.8-70.9)                   | TRIBE                |
| Bevacizumab + FOLFIRI                                                   | 256                         | 9.7 (9.3-10.9)                    | 65.1% (46.8-59.3)                   | TRIBE                |
| Bevacizumab + XELOX/FOLFOX4                                             | 699                         | 9.4                               | 47%                                 | NO16966 / XELOX-1,   |
| XELOX/FOLFOX4                                                           | 701                         | 8.0                               | 49%                                 | NO16966 / XELOX-1,   |
| Cetuximab + FOLFIRI                                                     | 297 (KRAS WT)               | 10.0 (8.8 - 10.8)                 | 62% (56.2 - 67.5)                   | FIRE-3 / AIO KRK0306 |
| Bevacizumab + FOLFIRI                                                   | 295 (KRAS WT)               | 10.3 (9.8 - 11.3)                 | 58% (52Â·1 - 63Â·7)                   | FIRE-3 / AIO KRK0306 |
| FOLFIRI with crossover to FOLFOX6 (upon progression or due to toxicity) | 109                         | 8.5 (7.0 - 9.5)                   | 56% (47 - 65)                       | FRE-GERCOR-C97-3     |
| FOLFOX6 with crossover to FOLFIRI (upon progression or due to toxicity) | 111                         | 8.0 (6.2 - 9.4)                   | 54% (45 - 63)                       | FRE-GERCOR-C97-3     |

## 2.1.2. About the product

Keytruda (pembrolizumab) is a humanized mAb IgG4/kappa isotype directed against PD-1. By blocking the interaction between PD-1 and its ligands PD-L1/2, pembrolizumab enhances T cell lymphocyte activity with consequent stimulation of the immune-mediated anti-tumour activity. Pembrolizumab also modulates the level of IL2, TNFÎ±, IFNÎ³, and other cytokines. The antibody potentiates existing immune responses in the presence of antigen only; it does not non-specifically activate T cells.

Pembrolizumab is currently approved in EU for the treatment of melanoma, NSCLC, RCC, HNSCC, urothelial cancer, and cHL. Pembrolizumab has been approved both as monotherapy and in combination with other agents.

The  scope  of  this  variation  is  to  include  a  new  indication  for  Keytruda  for  the  first-line  treatment  of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults. The proposed indication is based on the results from of a single pivotal study, KEYNOTE-177, an ongoing  open-label,  2-arm,  randomized  (1:1),  multicentre,  international,  phase  3  trial  evaluating  the efficacy and safety of pembrolizumab monotherapy (200 mg Q3W) versus SOC chemotherapies (mFOLFOX6 or  FOLFIRI  alone  or  in  combination  with  bevacizumab  or  cetuximab)  as  first  line  treatment  for  locally confirmed  dMMR  or  MSI-H  stage  IV  CRC.  A  total  of  307  patients  were  randomized  to  one  of  the  two treatment arms.

The MAH applied for the following indication:

Keytruda  as  monotherapy  is  indicated  for  the  first-line  treatment  of  unresectable  or  metastatic

<div style=\"page-break-after: always\"></div>

microsatellite instability-high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults.

The CHMP agreed to the following indication:

Keytruda as monotherapy is indicated for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Scientific advice was obtained from the CHMP on 22-OCT-2015 (EMEA/H/SA/2437/8/2015/II) on the design of KEYNOTE-177 study. With regard to the inclusion/exclusion criteria, the CHMP commented that excluding patients with ECOG PS 2 was not considered necessary. About the comparator, while all the 6 proposed regimens individually were deemed acceptable, it was advised to reduce the number of possible investigator choice chemotherapies to 4 or 2, in order to reduce heterogeneity. The final design however retained all the 6 comparators. PFS was proposed as primary endpoint for the study, with OS as a key secondary endpoint, and collection of PFS2 data was ensured (in the current design PFS and OS are dual primary instead). The CHMP considered this acceptable, provided sufficiently mature OS data were submitted. In this regard, the CHMP recommended to perform the primary PFS analysis with the interim OS analysis after further maturity of the study. The MAH followed such advice, by increasing the maturity of final PFS analysis (i.e. OS IA) compared to the original design.

## 2.1.4. General comments on compliance with GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH. The assessment of KN177 data did not raise concern over GCP compliance leading to request for GCP inspection.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable.

## 2.2.1. Ecotoxicity/environmental risk assessment

According to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00) proteins are exempted from the submission of ERA studies because they are unlikely to result in significant risk to the environment. Pembrolizumab is a protein, therefore an ERA has not been submitted by the MAH. This is acceptable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## Â· Tabular overview of clinical studies

| Study Number/ Status   | Design                                                                        | Population                                                                                                                                                                                                                                                                                                                                                                                                                               | Dosage,Regimen                                                                                                                                                                                                            | Primary Efficacy Endpoint(s)   |
|------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| KEYNOTE-177 Ongoing    | Phase 3, randomized, international- based, multicenter study                  | Participantswhohavepreviously untreatedlocally advanced unresectable or metastatic(Stage IV)MSI-H CRC (Total enrollment = 307)                                                                                                                                                                                                                                                                                                           | Group 1: Pembrolizumab (MK-3475) 200 mg IVQ3W OR Group 2: SOC: Investigator's choice of the following: mFOLFOX6,or mFOLFOX6+bevacizumab, or mFOLFOX6+ cetuximab, or FOLFIRI, or FOLFIRI+bevacizumab, or FOLFIRI+cetuximab | PFS, OS                        |
| KEYNOTE-164 Ongoing    | Phase 2, multicenter, nonrandomized, open-label multicohort, single-arm study | Patients with locally advanced unresectable or metastatic MSI-H/dMMR CRC must have received 1 line of prior therapy Cohort A (n=61):Participants havingreceivedâ¥2Lprior therapy: prior fluoropyrimidine+oxaliplatin (â¥1L) AND prior fluoropyrimidine+ irinotecan(â¥1L) Cohort B (n=63): Participants having received â¥1L prior therapy: prior fluoropyrimidine + oxaliplatin OR prior fluoropyrimidine + irinotecan +/-anti-VEGF/EGFR mAb | Pembrolizumab (MK-3475) 200 mg IV Q3W                                                                                                                                                                                     | ORR                            |

## 2.3.2. Pharmacokinetics

Comprehensive review of the key clinical pharmacology findings for pembrolizumab as monotherapy (200 mg Q3W dosing regimen) from melanoma, NSCLC, HNSCC, HL, UC, GEJ adenocarcinoma and HCC indications have been discussed extensively in previous submissions. The key clinical pharmacology characteristics are summarized in the current and EU SmPC.

Clinical pharmacology results specific to this submission include:

- PK data of pembrolizumab at 200 mg Q3W from adults with MSI-/dMMR CRC (KEYNOTE-177).
- A proposed additional dosing regimen of 400 mg Q6W for pembrolizumab selected using Modeling &amp; Simulation analyses, primarily based on PK exposure matching with approved Q3W dosing regimens.

## Pharmacokinetics in Subjects with MSI-H/dMMR CRC

PK samples with a 20-Nov-2017 visit cut-off date were measured for a total of 126 subjects in KEYNOTE177. The PK analysis was constructed from the final locked SDTM datasets using SAS version 9.4 and contains observed MK-3475 serum concentrations and actual elapsed blood sampling times relative to the corresponding time of dose.

PK sampling schedule in KEYNOTE-177 200 mg Q3W: Pre-dose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at cycles 1,2,4,6,8,12 and every 4 cycles thereafter. Post-dose samples (Cmax) were drawn at cycle 1 and cycle 8 within approximately 30 minutes after the end of MK-3475 infusion. Additional PK samples were drawn at 24 hours, between 72 and 168 hours and at 336 hours after cycle 1 dosing. PK samples were also collected at discontinuation of pembrolizumab and 30 days after discontinuation of pembrolizumab.

<div style=\"page-break-after: always\"></div>

## RESULTS

Individual Predose serum pembrolizumab concentration-time profiles with meanÂ± SE profile overlaid (linear-linear and log-linear scale) and arithmetic mean (SE) predose serum pembrolizumab concentration-time profile following multiple 200 mg IV administration Q3W to subjects in KEYNOTE-177 (linear-linear scale) are shown below:

Figure 1 Individual and Arithmetic Mean (Â±SE)Predose Serum Concentrations of Pembrolizumab Following Multiple 200 mg I.V. Administrations Q3W to Subjects in KEYNOTE-177 (a) Linear scale, (b) Log scale

<!-- image -->

(b) Log scale

<!-- image -->

Note: Grey lines represent individual concentration observations.Black dashed lines represent arithmetic mean concentrations and error bars are associated Â± SE.Actual PK drawtimes data were used for this analysis

Data Source-[05H0W5:analysis-p177crcpkdm03]

<div style=\"page-break-after: always\"></div>

Figure 2 ArithmeticMean(Â±SE)PredoseSerumConcentrationsof PembrolizumabFollowing Multiple 200 mg I.V. Administrations Q3W to Subjects inKEYNOTE-177 (Linear scale)

<!-- image -->

Note:This plot is Arithmetic mean with SE.X-axis is in days; Data Source-[05H0W5: analysis-p177crcpkdm03]

Summary descriptive statistics of the PK concentrations by cycle and relative time to pembrolizumab dosing are presented below:

Table 2 Summary Statistics of Pembrolizumab Predose (Ctrough), Postdose (Cmax) and Post Cycle 1 Serum ConcentrationValues Following Administration of Multiple 200 mg I.V. Doses with a 3 Week Dosing Interval in KEYNOTE-177Subjects

| Cycle              | NOMTAFD (day)     | N                 | GM(%CV) (Î¼g/mL)   | AM(SD) (Î¼g/mL)    | Min (Î¼g/mL)       | Median (Î¼g/mL)    | Max (Î¼g/mL)       |
|--------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Predose (Ctrough)  | Predose (Ctrough) | Predose (Ctrough) | Predose (Ctrough) | Predose (Ctrough) | Predose (Ctrough) | Predose (Ctrough) | Predose (Ctrough) |
| Cycle 1 (Week 0)   | 0                 | 118               |                   | 0.00 (0.0)        | 0.00              | 0.00              | 0.00              |
| Cycle 2 (Week 3)   | 21                | 96                | 13.2 (46)         | 14.4 (5.9)        | 3.64              | 13.9              | 35.5              |
| Cycle 4 (Week 9)   | 63                | 75                | 26.0 (51)         | 28.9 (13)         | 7.41              | 27.5              | 67.2              |
| Cycle6(Week15)     | 105               | 70                | 32.8 (49)         | 36.0 (15)         | 8.07              | 35.4              | 69.9              |
| Cycle 8 (Week 21)  | 147               | 53                | 32.9 (49)         | 36.2 (15)         | 9.76              | 34.7              | 68.5              |
| Cycle 12 (Week 33) | 231               | 31                | 40.9 (31)         | 42.5 (12)         | 19.8              | 41.0              | 66.3              |
| Cycle 16 (Week 45) | 315               | 18                | 41.1 (40)         | 44.0 (17)         | 17.1              | 40.6              | 80.6              |
| Cycle 20 (Week 57) |                   | 13                | 38.4 (41)         | 40.8 (13)         | 14.5              | 40.2              | 62.4              |
| Cycle 24 (Week 69) | 483               | 5                 | 39.5 (31)         | 41.0 (13)         | 29.9              | 35.7              | 59.6              |
| Postdose (Cmax)    | Postdose (Cmax)   | Postdose (Cmax)   | Postdose (Cmax)   | Postdose (Cmax)   | Postdose (Cmax)   | Postdose (Cmax)   | Postdose (Cmax)   |
| Cycle 1 (Week 0)   | 0                 | 115               | 65.0 (26)         | 67.1 (17)         | 36.4              | 65.7              | 113               |
| Cycle 8 (Week 21)  | 147               | 50                | 91.6 (42)         | 98.5 (36)         | 30.4              | 91.6              | 185               |
| Post Cycle 1       | Post Cycle 1      | Post Cycle 1      | Post Cycle 1      | Post Cycle 1      | Post Cycle 1      | Post Cycle 1      | Post Cycle 1      |
| Cycle 1 (Week 0)   | 1                 | 109               | 48.8 (27)         | 50.5 (13)         | 23.7              | 48.4              | 103               |
|                    | 5                 | 112               | 27.8 (32)         | 29.1 (9.0)        | 9.45              | 27.8              | 56.7              |
|                    | 14                | 105               | 17.7 (37)         | 18.8 (6.3)        | 4.55              | 17.6              | 37.7              |

NOMTAFD =Nominal time after first pembrolizumab administration; GM = Geometric Mean; %CV = Geometric Coefficient of Variation; SD=Standard Deviation; AM =Arithmetic Mean; Results for time points withNâ¥3.

DataSource-[05H0W5:analysis-p177crcpkdm03]

<div style=\"page-break-after: always\"></div>

Over the course of clinical development of pembrolizumab, PK has been robustly characterised. Using a dataset with sample size of 2993 participants, a time-dependent PK model was created to describe the PK profile as indicated in the USPI and EU SmPC. This model is used as the reference PK model to support pembrolizumab submissions across indications worldwide. Observed pembrolizumab concentration data in KEYNOTE-177 where pembrolizumab was administered to subjects with microsatellite instability-high colorectal carcinoma are overlaid on the simulated profile using the reference model as shown in the following figure:

Figure 3 Observed Concentration Data in KEYNOTE-177 Subjects Receiving 200 mg Q3WPembrolizumab with ReferencePK Model-Predicted PharmacokineticProfile for 200 mg Q3WDose regimen

KEYNOTE-177 MK-3475 Cycle 1

<!-- image -->

## KEYNOTE-177SteadyState MK-3475

<!-- image -->

Footnote Overlay plot:

steady state (at and after cycle8).Symbols are individual observed data(nominal time)from subjects inKEYNOTE-177; black dashed line is median predicted concentrations from the model for a regimen of 200 mg Q3W and the grey shaded area represents the 90% prediction interval; plots are displayed on log scale. Samples with a time after 1ast dose &gt; 21 days are not included in the plots;RLTVTM=Relative time to dose.

Data Source-[05H0W5:analysis-p177crcpkdm03]

<div style=\"page-break-after: always\"></div>

## PK Comparison with monotherapy indications

Comparison of KEYNOTE-177 observed concentration values with other monotherapy indications: KEYNOTE-024, KEYNOTE-045, KEYNOTE-048, KEYNOTE-052, KEYNOTE-055, KEYNOTE-087, KEYNOTE158, KEYNOTE-164, and KEYNOTE-177 subjects.

Table 3 Summary Statistics of Pembrolizumab Observed Serum Concentration Values Following Administration of Multiple I.V. Doses of 200 mg Q3W in Studies KN024,KN045,KN048,KN052,KN055,KN087,KN158,KN164 and KN177

| Time point       | Study/Indication   |   N | GM (%CV) (Î¼g/mL)   | AM (SD) (Î¼g/mL)   |    Min |   Median |   Max |
|------------------|--------------------|-----|--------------------|-------------------|--------|----------|-------|
| Cycle 1 Postdose | KN024 NSCLC        | 147 | 67.5 (23)          | 69.3 (16)         | 36.6   |     66.8 | 132   |
| Cycle 1 Postdose | KN045 UC           | 247 | 65.7 (26)          | 67.9 (18)         | 33.9   |     65.9 | 144   |
| Cycle 1 Postdose | KN0481LHNSCC       | 495 | 61.8 (29)          | 64.2 (18)         |  9.48  |     61.7 | 165   |
| Cycle 1 Postdose | KN052 UC           | 298 | 58.0 (28)          | 60.2 (17)         | 22.8   |     57.4 | 148   |
| Cycle 1 Postdose | KN055 HNSCC        |  43 | 56.5 (28)          | 58.9 (21)         | 33.1   |     54.9 | 162   |
| Cycle 1 Postdose | KN087 HL           | 195 | 60.7 (28)          | 63.1 (18)         | 31.2   |     61.3 | 183   |
| Cycle 1 Postdose | KN158 MSIH         |  90 | 64.4 (27)          | 66.7 (18)         | 31.2   |     65.2 | 133   |
| Cycle 1 Postdose | KN164 MSIH         |  56 | 62.2 (28)          | 64.6 (19)         | 34.9   |     61.2 | 150   |
| Cycle 1 Postdose | KN177 CRC          | 115 | 65.0 (26)          | 67.1 (17)         | 36.4   |     65.7 | 113   |
| Cycle 2 Predose  | KN024NSCLC         | 132 | 11.1 (54)          | 12.3 (4.7)        |  0.535 |     12.2 |  28.5 |
| Cycle 2 Predose  | KN045 UC           | 233 | 13.1 (47)          | 14.2 (4.9)        |  0.475 |     13.9 |  29.3 |
| Cycle 2 Predose  | KN0481LHNSCC       | 458 |                    | 13.4 (4.6)        |  0     |     13.2 |  29.6 |
| Cycle 2 Predose  | KN052 UC           | 286 | 11.1 (42)          | 11.9 (4.4)        |  2.07  |     11.5 |  26.2 |
| Cycle 2 Predose  | KN055 HNSCC        |  40 | 10.7 (47)          | 11.8 (5.2)        |  3.45  |     11.6 |  33.1 |
| Cycle 2 Predose  | KN087 HL           | 200 | 14.4 (40)          | 15.4 (5.1)        |  3.06  |     15.3 |  30   |
| Cycle 2 Predose  | KN164 MSIH         |  56 | 12.5 (35)          | 13.2 (4.6)        |  5.44  |     12.4 |  25.6 |
| Cycle 2 Predose  | KN177 CRC          |  96 | 13.2 (46)          | 14.4 (5.9)        |  3.64  |     13.9 |  35.5 |
| Cycle 8Predose   | KN024 NSCLC        |  82 | 30.6 (50)          | 33.6 (13)         |  5.26  |     32.7 |  64.1 |
| Cycle 8Predose   | KN045 UC           | 104 | 33.4 (64)          | 37.8 (17)         |  1.13  |     37.5 |  95.6 |
| Cycle 8Predose   | KN0481LHNSCC       | 235 | 34.2 (50)          | 37.5 (15)         |  1.77  |     34.8 | 127   |
| Cycle 8Predose   | KN052 UC           |  59 | 28.0 (38)          | 29.9 (10)         |  8.15  |     27.9 |  59.8 |
| Cycle 8Predose   | KN055 HNSCC        |   7 | 27.8 (41)          | 29.6 (11)         | 16.8   |     24.5 |  43.3 |
| Cycle 8Predose   | KN087 HL           |  68 | 43.9 (43)          | 47.4 (17)         | 13.9   |     47.5 |  92.4 |
| Cycle 8Predose   | KN164 MSIH         |  34 | 33.6 (43)          | 36.2 (14)         |  8.4   |     33.7 |  78.8 |
| Cycle 8Predose   | KN177 CRC          |  53 | 32.9 (49)          | 36.2 (15)         |  9.76  |     34.7 |  68.5 |

GM = Geometric Mean; %CV = Geometric Coefficient of Variation; SD = Standard Deviation; AM= Arithmetic Mean; Results for time points with N â¥3.

<div style=\"page-break-after: always\"></div>

## Figure 4 Boxplots with Serum Concentration Values of Pembrolizumab in Studies KN024,KN045,KN048,KN052,KN055,KN087,KN158,KN164 and KN177

Cycle 1 Postdose

<!-- image -->

Cycle 2Predosc

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Cycle8Predose

<!-- image -->

Pembrolizumab serum concentrations in cycle 1, 2 and 8 observed at 200 mg Q3W in MSI-H CRC patients are comparable to the range of concentrations at the same dose levels observed in patients with other types of cancer (Melanoma, NSCLC, HNSCCâ¦).

The observed concentrations in MSI-H CRC generally fall within the range of predicted concentrations, both after first dose and at steady state (at and after cycle 8) indicating that the definitive population TD PK model provides an adequate representation of the pembrolizumab pharmacokinetics in this population, in addition to other indications.

## Pharmacokinetic interaction studies

NA

## 2.3.1. Pharmacodynamics

## Dose regimen

The 200 mg Q3W dosing regimen is approved for use in multiple indications globally and is based on a large, integrated body of evidence at this dose level across indications. Furthermore, clinical response in patients from the MSI-H/dMMR CRC trials including treatment arms dosed at 200 mg Q3W (KEYNOTE177) support the favorable benefit-risk of patient outcomes at the proposed dosing regimen of 200 mg Q3W.

The proposed additional dosing regimen of 400 mg Q6W for pembrolizumab was selected using Modelling &amp; Simulation analyses, primarily based on PK exposure matching with approved Q3W dosing regimens. Specifically, the dosing regimen of 400 mg Q6W is considered adequate, given the following rationale:

- PK simulations demonstrating that in terms of pembrolizumab exposures -

<div style=\"page-break-after: always\"></div>

- Cavg over the dosing interval or AUC at 400 mg Q6W are similar to those at the approved 200 mg Q3W dose, thus bridging efficacy between dosing regimens.

- Cmin at 400 mg Q6W are ~12% lower at a mean level compared to that at the lowest clinically tested dose of 2 mg/kg Q3W, at steady state. However, in majority (&gt;99%) of patients, Cmin are generally within the range of clinical experience of Cmin achieved with 2 mg/kg or 200 mg Q3W.

- Cmax and concentrations over the entire PK profile at 400 mg Q6W are well below the Cmax and PK profile for the highest clinically tested dose of 10 mg/kg Q2W. Clinically, the observed safety profiles were similar among 2 mg/kg Q3W, 10 mg/kg Q3W, and 10 mg/kg Q2W in multiple tumour types based on randomized dose comparisons. Since the Cmax,ss (and Cavg through the dosing interval) expected at 400 mg Q6W lies within the range of those achieved at these clinically tested doses, the safety profile is expected to be comparable to the established safety profile of pembrolizumab.

Â· Exposure-Response for pembrolizumab has been demonstrated to be flat across multiple indications. OS predictions in melanoma and NSCLC demonstrate that efficacy at 400 mg Q6W is expected to be similar to that at 200 mg or 2 mg/kg Q3W, given the similar exposures among these dosing regimens. Thus, 400 mg Q6W is expected to be efficacious across indications where 200 mg (or 2 mg/kg) Q3W have demonstrated efficacy, given the generally similar PK and flat E-R for pembrolizumab across tumour types.

## Immunogenicity

The existing immunogenicity assessment for pembrolizumab for the monotherapy setting is based on a sufficiently large dataset of patients across several indications, with low observed rates of total treatment ADA across different pembrolizumab regimens (1.4 - 3.8%) as well as of neutralizing antibodies (0.4 1.6%). This analysis has not demonstrated impact on efficacy or safety, as currently summarized in the USPI and EU SmPC. This low rate of immunogenicity has been shown to be consistent across tumour type and no clinically meaningful consequences have been observed in the subjects with a positive immunogenicity reading. Based on the existing robust characterization of immunogenicity potential, alignment has been obtained with the US FDA and EMA that the current assessment of immunogenicity for pembrolizumab is adequate for non-adjuvant monotherapy settings.

## 2.3.2. Discussion on clinical pharmacology

No dose finding study was conducted for pembrolizumab monotherapy for treatment of MSI-H/dMMR mCRC. The investigated dose and schedule of pembrolizumab monotherapy for treatment of MSI-H/dMMR mCRC is the same as that approved for other monotherapy indications: 200 mg IV infusion over 60 minutes Q3W. This is considered acceptable.

The MAH presented a clinical pharmacology report on a total of 126 patients recruited in study KEYNOTE177 with a cut-off date of 20-Nov-2017. The following analyses were provided: i) descriptive PK concentrations by cycle and relative time to pembrolizumab dosing (Ctrough up to Cycle 24 and Cmax at Cycle 1 and Cycle 8), ii) observed pembrolizumab concentrations (both pre-dose and post-dose) at Cycle 1 and at steady-state overlaid on the predictions using the reference model (i.e., a time-dependent PK model constructed using sample size of 2993 participants with melanoma and NSCLC as indicated in the USPI and EU SmPC), and iii) a comparison across pembrolizumab monotherapy studies following multiple administrations of 200 mg Q3W dosing, including KEYNOTE-177.

The time course of PK samples following multiple administrations of pembrolizumab 200 mg Q3W in study KEYNOTE-177 shows a progressive increase of Ctrough that plateaued around Cycle 6 (Week 15; median:

<div style=\"page-break-after: always\"></div>

35.4 Âµ g/ml), with a slight trend in ongoing accumulation. With respect to the reference PK model, observed concentrations both at Cycle 1 and steady-state generally lay within 90% of prediction interval with only a few outliers, indicating that variability in exposure in patients with CRC is satisfactorily predicted by the definitive population PK model developed on the basis of prior monotherapy studies. Data are confirmed by the comparison across tumour types showing a similar range of peak concentrations at Cycle 1 and similar tough levels at steady state in the different studies, with the only exception for HL that was characterised by a higher level of Cmin at steady-state compared to other tumour types in line with prior findings (40 times higher according with current SmPC).

The MAH proposed an additional dosing regimen of 400 mg Q6W for pembrolizumab. This regimen was approved on 28-MAR-2019 for all monotherapy indications approved at the time based on PK and E-R bridging using M&amp;S analyses (procedure number EMEA/H/C/003820/II/0062). The established flat E-R profiles and the popPK analysis indicate that there are no major differences in pharmacokinetics of pembrolizumab in mCRC compared to other solid tumour types. Therefore, the 400 mg Q6W dosing regimen should have a similar benefit-risk profile as the 200 mg Q3W (or 2 mg/kg Q3W) dosing regimen in the clinical use of pembrolizumab in adult patients with MSI-H/dMMR metastatic CRC.

No additional assessments of the immunogenicity were performed. The observed incidences indicate a low potential of pembrolizumab to elicit anti-drug antibody formation.

## 2.3.3. Conclusions on clinical pharmacology

The clinical pharmacology profile of pembrolizumab in patients with CRC is consistent with historical data.

## 2.4. Clinical efficacy

The efficacy data supporting this extension of indication are based on the results of a single pivotal study, KEYNOTE-177 , an ongoing open-label, 2-arm, randomized (1:1), multicentre, international, phase 3 trial evaluating the efficacy and safety of pembrolizumab monotherapy (200 mg Q3W) versus SOC chemotherapies (mFOLFOX6 or FOLFIRI alone or in combination with bevacizumab or cetuximab) as first line treatment for locally confirmed dMMR or MSI-H stage IV CRC. Subjects randomized to the control arm had the option to crossover and receive pembrolizumab after PD. A total of 307 patients were randomized. Dual primary endpoints were PFS per RECIST 1.1 by BICR and OS. This submission is based on the second interim analysis (i.e. final PFS and interim OS analysis) results with data cutoff date of 19FEB-2020 (24 months after the last subject was randomized). The median follow-up duration was 28.4 months (range, 0.2 to 48.3) for the pembrolizumab group and 27.2 months (range, 0.8 to 46.6) for the SOC treatment group.

## 2.4.1. Dose response study(ies)

No dose-response studies were submitted as part of this application.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

## Title of Study

A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite InstabilityHigh (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE177)

<!-- image -->

## Methods

## Study participants

## Key Inclusion criteria:

1. Written informed consent
2. Male or female â¥ 18 years of age
3. Had locally confirmed MSI-H/dMMR Stage IV colorectal carcinoma
4. ECOG performance status of 0 or 1 within 10 days prior to treatment initiation
5. Life expectancy of at least 3 months.
6. Measurable disease at baseline based on RECIST 1.1 as determined by the local site investigator/ radiology assessment

<div style=\"page-break-after: always\"></div>

7. Female participants of childbearing potential must have had a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication

8. Female participants of childbearing potential must have been willing to use an adequate method of contraception

9. Male participants of childbearing potential must have agreed to use an adequate method of contraception

10. Adequate organ function as defined in the study protocol

## Key Exclusion criteria:

1. Received prior systemic therapy for Stage IV CRC. Prior adjuvant chemotherapy for CRC completed at least 6 months prior to randomization was allowed

2. Participating and receiving study medication in another study currently or within 4 weeks from randomization

3. Active autoimmune disease that had required systemic treatment in past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) was not considered a form of systemic treatment

4. Diagnosis of immunodeficiency or receiving systemic steroid therapy or other immunosuppressive therapy within 7 days prior to randomization

5. Radiation therapy within 4 weeks prior to randomization and had not recovered to baseline from AE due to radiation therapy. Palliative radiotherapy to peripheral sites (eg, bone metastasis) before 4 weeks have elapsed was allowed but must have had recovered from any acute AEs

6. Known active CNS metastases and/or carcinomatous meningitis. Stable previously treated brain metastases and with no use of steroids for at least 28 days prior to study initiation were allowed (carcinomatous meningitis was excluded regardless of clinical stability)

7. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization

8. Prior therapy with an immune checkpoint inhibitor (e.g., anti-PD-(L)1, anti-PD-L2, anti-CTLA-4 etc)

9. Another malignancy progressing or required active treatment. Exceptions included non-melanomatous skin cancer that has undergone potentially curative therapy and in situ cervical carcinoma

10. Live vaccine within 30 days of planned start of study medication

11. History or current evidence of any condition, therapy, or laboratory abnormality that might have confounded the results of the study, interfered with the participant's participation for the full duration of the study, or was not in the best interest of the participant to participate, in the opinion of the treating investigator

12. Known history of HIV, active chronic or acute Hepatitis B or C
13. Known history of, or evidence of interstitial lung disease or active non-infectious pneumonitis
14. Known history of active tuberculosis
15. Active infection requiring systemic therapy

16. Known psychiatric or substance abuse disorders that would have interfered with cooperation with the requirements of the study

<div style=\"page-break-after: always\"></div>

17. Was pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study up to 180 days after the last dose of study medication for SOC or 120 days for pembrolizumab

## Treatments

## Initial Treatment Phase:

- Experimental arm: Pembrolizumab 200 mg IV Q3W
- Control arm: investigator's choice of one among 6 possible regimens (mFOLFOX6, mFOLFOX6+bevacizumab, mFOLFOX6+cetuximab, FOLFIRI, FOLFIRI+bevacizumab, FOLFIRI+cetuximab).

| Study Intervention                                                                   | Dose/Potency                                                                                                                                                     | Route of Administration                                                              |
|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Pembrolizumab                                                                        | 200 mg IV Q3W                                                                                                                                                    | IV infusion                                                                          |
| mFOLFOX6                                                                             | mFOLFOX6 Q2W: Oxaliplatin 85 mg/m2 Leucovorin* 400 mg/m2 5-FU400mg/ mÂ²bolus,1200mg/mÂ²/dayx 2days continuous infusion                                             | IV infusion                                                                          |
| mFOLFOX6 + bevacizumab                                                               | mFOLFOX6 Q2W: Oxaliplatin 85 mg/m2 Leucovorin* 400 mg/m2 5-FU 400 mg/ mÂ² bolus, 1200 mg/m2/day x 2 days continuous infusion Bevacizumab 5 mg/kg                  | IV infusion                                                                          |
| mFOLFOX6 + cetuximab                                                                 | mFOLFOX6 Q2W: Oxaliplatin 85 mg/m2 Leucovorin* 400 mg/m2 5-FU 400 mg/ mÂ² bolus, 1200 mg/m2/day x 2 days continuous infusion Cetuximab: 400 mg/m2, then 250 mg/m2 | IV infusion                                                                          |
| FOLFIRI                                                                              | FOLFIRI Q2W: Irinotecan 180 mg/m2 Leucovorin* 400 mg/m2 5-FU 400 mg/m2 bolus, 1200 mg/m2/day x 2 days continuous infusion                                        | IV infusion                                                                          |
| FOLFIRI +bevacizumab                                                                 | FOLFIRI Q2W: Irinotecan 180 mg/m2 Leucovorin* 400 mg/m2 5-FU 400 mg/m2 bolus, 1200 mg/m2/day x 2 days continuous infusion Bevacizumab 5 mg/kg IV                 | IV infusion                                                                          |
| FOLFIRI +cetuximab                                                                   | FOLFIRI Q2W: Irinotecan 180 mg/m2 Leucovorin* 400 mg/m2 5-FU 400 mg/m2Â² bolus, 1200 mg/m2/day x 2 days continuous infusion Cetuximab: 400 mg/mÂ², then 250 mg/m2  | IV infusion                                                                          |
| Q2W: every 2 weeks; Q3W: every 3 weeks; IV: intravenous *or levoleucovorin 200 mg/mÂ² | Q2W: every 2 weeks; Q3W: every 3 weeks; IV: intravenous *or levoleucovorin 200 mg/mÂ²                                                                             | Q2W: every 2 weeks; Q3W: every 3 weeks; IV: intravenous *or levoleucovorin 200 mg/mÂ² |

Treatment must be discontinued for confirmed radiographic PD, unacceptable AEs, intercurrent illness that prevents further administration of treatment, consent withdrawal, investigator's decision to discontinue the subject from treatment, confirmed positive serum pregnancy test of the subject, administrative reasons, or the subject completed 35 treatments (2 years) of pembrolizumab.

Discontinuation of pembrolizumab may be considered for subjects with locally confirmed CR after at least 8 cycles (approximately 6 months), and at least 2 treatments beyond the date when the initial CR was declared.

During the study, subjects may undergo resection of the primary tumour and metastasectomy with curative intent if deemed eligible per site institutional standard after achieving a response to study medication converting unresectable to resectable. After surgery, subjects may resume the same preoperative treatment (SOC or Pembrolizumab) when clinically appropriate.

<div style=\"page-break-after: always\"></div>

Second Course Phase (pembrolizumab arm and SOC chemotherapy arm following crossover):

Subjects who stopped pembrolizumab after confirmed CR, or who completed 35 cycles of pembrolizumab with SD, PR or CR, may be eligible for retreatment with pembrolizumab (up to 17 cycles i.e. about 1 year) if they progress after stopping study treatments.

Crossover Phase (SOC chemotherapy arm):

Subjects in the chemotherapy arm with documented PD per RECIST 1.1 confirmed by BICR could be eligible for crossover to pembrolizumab (up to 17 cycles), if meeting eligibility criteria for the Crossover Phase. Surgical subjects who progress post operatively are also eligible to receive pembrolizumab in the Crossover Phase with up to 17 administrations (approximately 1 year) of pembrolizumab.

## Imaging assessment

Tumour imaging was performed every 9 weeks during study treatment. All scheduled and unscheduled images for all study subjects from the sites were submitted to the central imaging vendor.

Subjects who undergo surgical resection with curative intent while on study resumed imaging postoperatively when clinically possible to maintain the Q9W imaging schedule.

Local-site investigator assessed 1 st  PD must be verified by the central imaging vendor. If PD is confirmed centrally by RECIST 1.1, patients on chemotherapy arm may crossover to pembrolizumab (if all criteria for crossover phase are met), while patients on pembrolizumab arm should repeat imaging â¥4 weeks at site to confirm PD. If patient is clinically stable may continue pembrolizumab at investigator discretion while awaiting confirmatory tumour scan. If PD is then verified by site at repeated images, subject should discontinue pembrolizumab (unless deriving clinically meaningful benefit after consultation with the Applicant).

For all subjects, per RECIST 1.1, PR or CR should be confirmed by a repeat tumour imaging assessment.

In subjects who discontinue trial treatment without documented PD, every effort should be made to continue monitoring their disease status by radiologic imaging every 9 weeks until start of new anticancer treatment, PD, death, withdrawal of consent, loss to follow-up or the end of the study.

Evaluation of tumour response by RECIST 1.1 per the central imaging vendor is the basis for efficacy assessment in this study. irRECIST is used by site investigator/local radiology review to assess tumour response and progression, and make treatment decisions while subjects are receiving pembrolizumab. irRECIST was used to make treatment decisions beyond progression by RECIST 1.1, allowing treatment after progression if patients derived clinical benefit according to investigator.

## Objectives

Primary Objectives

- To compare progression-free survival (PFS) per RECIST 1.1 by central imaging vendor
- To compare overall survival (OS)

## Secondary Objectives

- To compare overall response rate (ORR) per RECIST 1.1 by central imaging vendor
- To evaluate the safety and tolerability profiles

<div style=\"page-break-after: always\"></div>

Exploratory Objectives

- To evaluate Progression Free Survival 2 (PFS2)
- To evaluate PFS per irRECIST by central imaging vendor
- To evaluate duration of response (DOR) per RECIST 1.1 by central imaging vendor
- To evaluate score change of health-related quality-of-life (HRQoL) using EORTC QLQ-C30 and EORTC QLQ-CR29 from baseline among subjects treated with pembrolizumab compared to SOC chemotherapies
- To characterize utilities using EuroQoL EQ-5D among subjects treated with pembrolizumab compared to SOC chemotherapies.
- To explore the relationship between genetic variation and response to the treatment(s) administered. Variation across the human genome (germline and tumour) will be analyzed for association with clinical data collected in this study.
- To evaluate the surgical conversion rate among subjects treated with pembrolizumab compared to SOC chemotherapies.

## Outcomes/endpoints

Primary endpoints (dual-primary)

- PFS per RECIST 1.1 assessed by central imaging vendor: PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded central imaging vendor review or death due to any cause, whichever occurs first
- OS: OS is defined as the time from randomization to death due to any cause

The study is considered to have met its primary objective if pembrolizumab is superior to SOC chemotherapies in either of the 2 primary endpoints.

## Secondary endpoints

- ORR per RECIST 1.1 assessed by central imaging vendor: ORR is defined as the proportion of the subjects in the analysis population who have a complete response or partial response

## Exploratory endpoints

- PFS2: PFS2 is defined as the time from randomization to disease progression on the next line of therapy, or death from any cause, whichever occurs first
- PFS per irRECIST by BICR
- DOR per RECIST 1.1 by BICR: for subjects who demonstrated CR or PR, response duration is defined as the time from the date of first response (CR or PR) until the date of first documented disease progression or death.
- Surgical conversion rate: The surgical conversion rate is the rate of subjects who become eligible and undergo resection with curative intent as a result of study therapy.

<div style=\"page-break-after: always\"></div>

- Patient Reported Outcome (PRO) endpoints:
- mean score change from baseline to Week 18 in EQ-5D VAS and utility score
- mean score change from baseline to Week 18 in QLQ-C30 global health status/QoL
- mean score change from baseline to Week 18 for QLQ-C30 functional scales (physical, role, emotional, cognitive, and social) and symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties)
- mean score change from baseline to Week 18 for QLQ-CR29 functional scales (body image, anxiety, weight, etc.) and symptom scales (urinary frequency, blood and mucus in stool, stool frequency, urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, flatulence, faecal incontinence, sore skin, embarrassment, etc.)
- number and proportions of deterioration/stable/improvement from baseline to Week 18 for QLQC30 global health status/QoL, functional scales and symptom scales
- time to deterioration for QLQ-C30 global health status/QoL, physical functioning, social functioning and fatigue
- time to deterioration for QLQ-CR29 urinary incontinence

## Sample size

The study was event-driven and planned to randomize approximately 300 subjects with 1:1 ratio into the two treatment groups: pembrolizumab and SOC.

Two interim efficacy analyses were planned in this study, one for PFS, two for OS and none for ORR. A Lan-DeMets O'Brien-Fleming alpha-spending function was constructed to implement group sequential efficacy boundaries to control the Type I error for each PFS and each OS hypothesis. The sample size calculation for the two primary hypotheses are listed:

- (1) With 209 PFS events, there was 98% power to detect a hazard ratio of 0.55 (pembrolizumab vs. SOC) at alpha = 1.25% (one-sided), assuming PFS follows an exponential distribution with a median of 10 months in the control arm, an enrolment period of 30 months from first subject randomized and minimum of 13 months follow-up after enrolment completion. The dropout rate was assumed to be 5% yearly.
- (2) With 190 OS events, there was 85% power to detect a hazard ratio of 0.62 (pembrolizumab vs. SOC) at alpha = 1.25% (one-sided) assuming OS follows an exponential distribution with a median of 24 months in the control arm, and an enrolment period of 30 months from first subjects randomized and a minimum of 33.5 months follow-up after enrolment completion. The dropout rate was assumed to be 2% yearly.

For the key secondary endpoint of ORR, which was planned to be tested if either the PFS or the OS hypothesis was rejected, there was 92% power (1-sided 2.5% alpha) to detect an 19% improvement on the experimental arm assuming the true ORR for the control arm ranges between 50%, depending on the actual percentage of subjects without prior SCT are enrolled.

<div style=\"page-break-after: always\"></div>

## Randomisation

Patients were randomized 1:1 to pembrolizumab or SOC arm centrally using an interactive voice response system/integrated web response system (IVRS/IWRS).

No stratification factors were used.

## Blinding (masking)

The study was open-label.

Independent radiologist(s) who centrally reviewed the images had no knowledge of subject treatment assignment.

## Statistical methods

## Efficacy populations

The analyses of efficacy endpoints were performed on the Intention-to-Treat (ITT) population, which includes all randomized subjects in the treatment group to which they are assigned, whether or not treatment was administered.

For the PRO assessment, the primary analysis was conducted in the quality of life related full analysis set (FAS) population, consisting of all randomized subjects who have received at least one dose of study medication, and have completed at least one PRO assessment. There is one FAS population per PRO instrument scale.

## Statistical methods

## Table: Summary of Analysis Strategy for Key Efficacy Endpoints in KEYNOTE-177

| Endpoint/Variable (Description, Time Point)   | Statistical Method                                                         | Analysis Population   | Missing Data Approach                                        |
|-----------------------------------------------|----------------------------------------------------------------------------|-----------------------|--------------------------------------------------------------|
| Primary Endpoints                             | Primary Endpoints                                                          | Primary Endpoints     | Primary Endpoints                                            |
| PFS per RECIST 1.1 by BICR a                  | Test: Log-rank test Estimation: Cox model with Efron's tie handling method | ITT                   | Primary censoring rule b                                     |
| OS                                            | Test: Log-rank test Estimation: Cox model with Efron's tie handling method | ITT                   | Censored at the date of last known contact                   |
| Secondary Endpoint                            | Secondary Endpoint                                                         | Secondary Endpoint    | Secondary Endpoint                                           |
| ORR per RECIST 1.1 by BICR                    | Test: Miettinen and Nurminen method                                        | ITT                   | Subjects with missing data are considered as non-responders. |

BICR=Blinded independent central radiology review; ITT=Intention-to-treat; ORR=Objective response rate; OS=Overall survival; PFS=Progression-free survival; RECIST= Response Evaluation Criteria in Solid Tumours.

a Surgical participants (ie, those who have surgery with curative intent) will be censored at the surgical date in the PFS analysis. An additional PFS sensitivity analysis, defined as the time from randomization to disease recurrence after surgery, was performed.

b Censored at the last disease assessment (before new anticancer treatment, if any).

<div style=\"page-break-after: always\"></div>

## Sensitivity analysis for primary endpoints

Two sensitivity analyses with different censoring rules for PFS were planned to be performed for the primary analysis, see table below. In comparison to the primary analysis, in the first sensitivity analysis subjects were censored at last disease assessment without PD, when PD/death was documented after more than one missing disease assessment. In the second sensitivity analysis, patients were considered for discontinuation of treatment or initiation of an anticancer treatment subsequent to discontinuation of study-specified treatments to be a PD event for subjects without documented PD or death.

Table: censoring rules for Primary and Sensitivity analyses of PFS

| Situation                                                                                                                                                                                             | Primary Analysis                                                                                                                                                                                      | Sensitivity Analysis 1                                                                                                                                                                                | Sensitivity Analysis 2                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| No PD and no death; newanticancertreatment is not initiated                                                                                                                                           | Censored at last disease assessment                                                                                                                                                                   | Censored at last disease assessment                                                                                                                                                                   | Censored at last disease assessment if still on study medication; progressed at treatmentdiscontinuation otherwise                                                                                    |
| No PD and no death; new anticancertreatment is initiated                                                                                                                                              | Censored at last disease assessment before new anticancertreatment                                                                                                                                    | Censored at last disease assessment before new anticancer treatment                                                                                                                                   | Progressed atdateofnew anticancer treatment                                                                                                                                                           |
| No PD and no death;â¥2 consecutive missed disease assessments                                                                                                                                          | Censored at last disease assessment                                                                                                                                                                   | Censored at last disease assessment prior to â¥2 consecutive missed visits                                                                                                                             | Censored at last disease assessment                                                                                                                                                                   |
| PDor death documented after â¤ 1 missed disease assessment                                                                                                                                             | Progressed at date of documented PD or death                                                                                                                                                          | Progressed at date of documented PD or death                                                                                                                                                          | Progressed at date of documented PD or death                                                                                                                                                          |
| PDor death documented at any time after â¥ 2 consecutive missed disease assessments                                                                                                                    | Progressed at date of documented PD or death                                                                                                                                                          | Censored at last disease assessment prior to the â¥ 2 consecutive missed disease assessment                                                                                                            | Progressed at date of documented PD or death                                                                                                                                                          |
| Note: Surgical subjects will be censored at the surgical date in the PFS primary, sensitivity 1 and 2 analyses, unless the surgery occurs after progression events or censoring points defined above. | Note: Surgical subjects will be censored at the surgical date in the PFS primary, sensitivity 1 and 2 analyses, unless the surgery occurs after progression events or censoring points defined above. | Note: Surgical subjects will be censored at the surgical date in the PFS primary, sensitivity 1 and 2 analyses, unless the surgery occurs after progression events or censoring points defined above. | Note: Surgical subjects will be censored at the surgical date in the PFS primary, sensitivity 1 and 2 analyses, unless the surgery occurs after progression events or censoring points defined above. |

Participants who had curative intent surgery were censored in the PFS analysis at the date of surgery unless a prior PD event had been noted per central review.

Sensitivity analyses for overall survival was performed, where the crossover of patients who switched to pembrolizumab after progressive disease was (1) adjusted for by appropriate methods, and (2) where patients were censored at the start of crossover treatment or the start of first subsequent immune checkpoint inhibitor treatment, whichever occurs first.

## Interim Analysis

Two interim analyses were planned. The timing of the interim analyses together with the nominal significance levels are shown in the table below. For the PFS and OS hypotheses, Lan-DeMets O'BrienFleming alpha spending function was used to construct group sequential boundaries to control the type I error. For PFS analysis the extended graphical method was planned to be used (Anderson et al, unpublished data, 2018). This means that the actual boundaries were to be adjusted using the LanDeMets O'Brien-Fleming spending function with spending time determined by the minimum of the actual information fraction and the expected information fraction.

<div style=\"page-break-after: always\"></div>

Table: timing, sample size and decision guidance

| Analysis                                                | Criteria for Conduct of Analysis                                                                                                                       | Endpoint   |   p-value? |   Approximate Efficacy Boundary (HR)* |
|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------------|
| Interim Analysis 1: Interim PFS and interim OS analysis | Tobeperformed after  1) approximately 162 PFS events have occurred;and 2)6 months after last subject randomized Expected OS events: ~95                | PFS        |     0.0046 |                                  0.66 |
| Interim Analysis 1: Interim PFS and interim OS analysis | Tobeperformed after  1) approximately 162 PFS events have occurred;and 2)6 months after last subject randomized Expected OS events: ~95                | OS         |     0.0004 |                                  0.5  |
| Interim Analysis 2: Final PFS and interim OS analysis   | To be performed after approximately209PFSevents haveoccurredor 24months after last subject randomized, whichever occurs first. Expected OS events:~135 | PFS        |     0.0111 |                                  0.73 |
| Interim Analysis 2: Final PFS and interim OS analysis   | To be performed after approximately209PFSevents haveoccurredor 24months after last subject randomized, whichever occurs first. Expected OS events:~135 | OS         |     0.0029 |                                  0.62 |
| Final Analysis: Final OS analysis                       | To be performed after approximately 1190OS events haveoccurredor12months after Interim Analysis 2, whichever occurs first.                             | OS         |     0.0115 |                                  0.72 |

*The \"p value\" and \"Approximate Efficacy Boundary (HR) for efficacy assume no re-distribution of initially assigned type I error.

## Multiplicity

The family-wise type I error rate for this study was controlled at 2.5% (one-sided), whereby the allocation to the different hypotheses was defined as shown in the following figure by Maurer and Bretz (2013):

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table: Efficacy Boundaries and Properties for Progression-Free Survival Analyses

| Analysis           | Value                |   0=0.0125 |   0=0.0249 |
|--------------------|----------------------|------------|------------|
| IA1: 78%a N: 300   | Z                    |     2.6082 |     2.2959 |
| Events: 162        | p (l-sided)b         |     0.0046 |     0.0108 |
| Month: 36          | HR at bounde         |     0.6631 |     0.6971 |
|                    | P(Cross) if HR=1d    |     0.0046 |     0.0108 |
|                    | P(Cross) if HR=0.55e |     0.8842 |     0.9354 |
| IA2 (PFS FA)       | Z                    |     2.286  |     2.0198 |
| N: 300 Events: 209 | p (1-sided)b         |     0.0111 |     0.0217 |
| Month: 46          | HR at boundc         |     0.7283 |     0.7562 |
|                    | P(Cross) if HR=1d    |     0.0125 |     0.0249 |
|                    | P(Cross) if HR=0.55e |     0.98   |     0.9902 |

Table: Efficacy Boundaries and Properties for Overall Survival Analyses

| Analysis                               | Value                |   0=0.0125 |   0=0.0249 |
|----------------------------------------|----------------------|------------|------------|
| IA1: 50%a N: 300 Events: 95 Month: 36  | Z                    |     3.3446 |     2.9649 |
| IA1: 50%a N: 300 Events: 95 Month: 36  | p (1-sided)b         |     0.0004 |     0.0015 |
| IA1: 50%a N: 300 Events: 95 Month: 36  | HR at bounde         |     0.5025 |     0.5442 |
| IA1: 50%a N: 300 Events: 95 Month: 36  | P(Cross) if HR=1d    |     0.0004 |     0.0015 |
| IA1: 50%a N: 300 Events: 95 Month: 36  | P(Cross) if HR=0.62e |     0.1552 |     0.2649 |
| IA2: 71%a N: 300 Events: 135 Month: 46 | Z                    |     2.7589 |     2.4427 |
| IA2: 71%a N: 300 Events: 135 Month: 46 | p (1-sided)b         |     0.0029 |     0.0073 |
| IA2: 71%a N: 300 Events: 135 Month: 46 | HR at boundc         |     0.6211 |     0.6567 |
| IA2: 71%a N: 300 Events: 135 Month: 46 | P(Cross) if HR=1d    |     0.003  |     0.0078 |
| IA2: 71%a N: 300 Events: 135 Month: 46 | P(Cross) if HR=0.62e |     0.51   |     0.6382 |
| Final: N: 300 Events: 190 Month: 63.5  | Z                    |     2.2724 |     2.0057 |
| Final: N: 300 Events: 190 Month: 63.5  | p (1-sided)b         |     0.0115 |     0.0224 |
| Final: N: 300 Events: 190 Month: 63.5  | HR at bounde         |     0.7185 |     0.7475 |
| Final: N: 300 Events: 190 Month: 63.5  | P(Cross) if HR=1d    |     0.0125 |     0.0249 |
| Final: N: 300 Events: 190 Month: 63.5  | P(Cross) if HR=0.62e |     0.85   |     0.9061 |

The trial initially allocates 0% to the ORR hypothesis. If null hypotheses for both OS and PFS are rejected, an ORR benefit may be tested at the 2.5% 1-sided level. If only one of the OS and PFS null hypotheses is rejected, ORR would be tested at the 0.0125% 1-sided level. The p-value from IA1 will be used to compare with Î± -levels, considering ORR data will be mature at IA1.

<div style=\"page-break-after: always\"></div>

Table: Possible Î± -levels and Approximate ORR Difference Required to Demonstrate Efficacy for ORR

| 0.                                                                                       | Power                                                                                    | ~â³ORR1                                                                                   |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| 0.0125%                                                                                  | 0.38                                                                                     | 20.37%                                                                                   |
| 2.5%                                                                                     | 0.92                                                                                     | 10.90%                                                                                   |
| â³ORR = ORR treatment arm - ORR control arm, where ORR on control arm is assumedtobe0.50. | â³ORR = ORR treatment arm - ORR control arm, where ORR on control arm is assumedtobe0.50. | â³ORR = ORR treatment arm - ORR control arm, where ORR on control arm is assumedtobe0.50. |

## Results

This submission is based on IA2 with a data cutoff date of 19-FEB-2020, which is 24 months after the last subject was randomized and after 195 PFS events had occurred.

## Participant flow

<!-- image -->

Overall, 545 patients did not meet eligibility criteria of Keynote-177. Most of the patients were not MSI-

<div style=\"page-break-after: always\"></div>

H/dMMR (n=471 (86.4%)), 4.4% had received prior systemic therapy for stage IV CRC and 3.1 % had no measurable disease at baseline.

All but 1 (in the SOC group) enrolled participants were MSI-H/dMMR.

Table: Disposition of Subjects (ITT Population)

|                                                        | Pembrolizumab                                          | Pembrolizumab                                          | SOC                                                    | SOC                                                    | Total                                                  | Total                                                  |
|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                        | n                                                      | (%)                                                    | n                                                      | (%)                                                    | n                                                      | (%)                                                    |
| Subjects in population                                 | 153                                                    |                                                        | 154                                                    |                                                        | 307                                                    |                                                        |
| Status for Trial                                       |                                                        |                                                        |                                                        |                                                        |                                                        |                                                        |
| Discontinued                                           | 58                                                     | (37.9)                                                 | 75                                                     | (48.7)                                                 | 133                                                    | (43.3)                                                 |
| Death                                                  | 56                                                     | (36.6)                                                 | 66                                                     | (42.9)                                                 | 122                                                    | (39.7)                                                 |
| Lost To Follow-Up                                      | 2                                                      | (1.3)                                                  | 0                                                      | (0.0)                                                  | 2                                                      | (0.7)                                                  |
| Withdrawal By Subject                                  | 0                                                      | (0.0)                                                  | 9                                                      | (5.8)                                                  | 9                                                      | (2.9)                                                  |
| Subjects Ongoing                                       | 95                                                     | (62.1)                                                 | 79                                                     | (51.3)                                                 | 174                                                    | (56.7)                                                 |
| Status for Study Medication in Trial Segment Treatment | Status for Study Medication in Trial Segment Treatment | Status for Study Medication in Trial Segment Treatment | Status for Study Medication in Trial Segment Treatment | Status for Study Medication in Trial Segment Treatment | Status for Study Medication in Trial Segment Treatment | Status for Study Medication in Trial Segment Treatment |
| Started                                                | 153                                                    |                                                        | 143                                                    |                                                        | 296                                                    |                                                        |
| Completed                                              | 57                                                     | (37.3)                                                 | 0                                                      | (0.0)                                                  | 57                                                     | (19.3)                                                 |
| Discontinued                                           | 94                                                     | (61.4)                                                 | 137                                                    | (95.8)                                                 | 231                                                    | (78.0)                                                 |
| Adverse Event                                          | 22                                                     | (14.4)                                                 | 17                                                     | (11.9)                                                 | 39                                                     | (13.2)                                                 |
| Clinical Progression                                   | 9                                                      | (5.9)                                                  | 6                                                      | (4.2)                                                  | 15                                                     | (5.1)                                                  |
| Complete Response                                      | 9                                                      | (5.9)                                                  | 4                                                      | (2.8)                                                  | 13                                                     | (4.4)                                                  |
| Non-Compliance With Study Drug                         | 0                                                      | (0.0)                                                  | 1                                                      | (0.7)                                                  | 1                                                      | (0.3)                                                  |
| Physician Decision                                     | 3                                                      | (2.0)                                                  | 12                                                     | (8.4)                                                  | 15                                                     | (5.1)                                                  |
| Progressive Disease                                    | 50                                                     | (32.7)                                                 | 86                                                     | (60.1)                                                 | 136                                                    | (45.9)                                                 |
| Withdrawal By Subject                                  | 1                                                      | (0.7)                                                  | 11                                                     | (7.7)                                                  | 12                                                     | (4.1)                                                  |
| Subjects Ongoing                                       | 2                                                      | (1.3)                                                  | 6                                                      | (4.2)                                                  | 8                                                      | (2.7)                                                  |
| Status for Study Medication in Trial Segment Crossover | Status for Study Medication in Trial Segment Crossover | Status for Study Medication in Trial Segment Crossover | Status for Study Medication in Trial Segment Crossover | Status for Study Medication in Trial Segment Crossover | Status for Study Medication in Trial Segment Crossover | Status for Study Medication in Trial Segment Crossover |
| Started                                                | 0                                                      |                                                        | 56                                                     |                                                        | 56                                                     |                                                        |
| Completed                                              | 0                                                      | (0.0)                                                  | 9                                                      | (16.1)                                                 | 9                                                      | (16.1)                                                 |
| Discontinued                                           | 0                                                      | (0.0)                                                  | 30                                                     | (53.6)                                                 | 30                                                     | (53.6)                                                 |
| Adverse Event                                          | 0                                                      | (0.0)                                                  | 10                                                     | (17.9)                                                 | 10                                                     | (17.9)                                                 |
| Clinical Progression                                   | 0                                                      | (0.0)                                                  | 3                                                      | (5.4)                                                  | 3                                                      | (5.4)                                                  |
| Complete Response                                      | 0                                                      | (0.0)                                                  | 2                                                      | (3.6)                                                  | 2                                                      | (3.6)                                                  |
| Physician Decision                                     | 0                                                      | (0.0)                                                  | 1                                                      | (1.8)                                                  | 1                                                      | (1.8)                                                  |
| Progressive Disease                                    | 0                                                      | (0.0)                                                  | 14                                                     | (25.0)                                                 | 14                                                     | (25.0)                                                 |
| Subjects Ongoing                                       | 0                                                      | (0.0)                                                  | 17                                                     | (30.4)                                                 | 17                                                     | (30.4)                                                 |
| Database Cutoff Date: 19FEB2020.                       | Database Cutoff Date: 19FEB2020.                       | Database Cutoff Date: 19FEB2020.                       | Database Cutoff Date: 19FEB2020.                       | Database Cutoff Date: 19FEB2020.                       | Database Cutoff Date: 19FEB2020.                       | Database Cutoff Date: 19FEB2020.                       |

307

(43.3)

(39.7)

(0.7)

(2.9)

(56.7)

296

(19.3)

(78.0)

(13.2)

(5.1)

(4.4)

(0.3)

(5.1)

(45.9)

(4.1)

(2.7)

56

(16.1)

(53.6)

(17.9)

(5.4)

(3.6)

(1.8)

(25.0)

(30.4)

Eleven participants who were randomized to the SOC group withdrew from the study prior to starting treatment. The reasons for withdrawal were unknown (5 participants), randomized to the SOC arm (5), and administrative issues (1).

Among participants who received treatment during the initial treatment phase, more participants in the SOC group than in the pembrolizumab group discontinued due to withdrawal of consent (11 vs 1) and physician decision (12 vs 3). The reasons for withdrawal of consent in the SOC group were unknown (6 participants), no longer wanted therapy (3 participants), and pursuing surgical intervention (2 participants). The reasons for discontinuation due to physician decision included surgical resection (7 participants), status of subject not conducive to continue treatment (3 participants), and additional therapy required (2 participants).

<div style=\"page-break-after: always\"></div>

Out of 4 patients who received second-course treatment with pembrolizumab, one achieved PR upon retreatment. Out of 3 patients who stopped for progression, one had PR when retreated. The patient who discontinued due to CR had SD at retreatment. One patient who stopped pembrolizumab due to an AE (not specified) was rechallenged with SD.

Table: Summary of Subsequent Therapies (ITT Population)

|                                                          | Pembrolizumab (N=153) n (%)   | SOC (N=154) n (%)   |
|----------------------------------------------------------|-------------------------------|---------------------|
| SubjectsWhoCrossed OverfromSOC toPembrolizumab           | 0 (0.0)                       | 56 (36.4)           |
| Subjects WhoDid Not Crossed Over but Received            | 44 (28.8)                     | 44 (28.6)           |
| Subsequent Anti-Cancer Therapies Anti-PD1/PDL1 Therapies | 9 (5.9)                       | 35 (22.7)           |
| Antimuscarinic/ Non disease related medication           | 2 (1.3)                       | 0 (0.0)             |
| CD40 inhibitor                                           | 0 (0.0)                       | 1 (0.6)             |
| CTLA-4 Inhibitor                                         | 0 (0.0)                       | 4 (2.6)             |
| Chemotherapy                                             | 35 (22.9)                     | 18 (11.7)           |
| EGFR inhibitor                                           | 8 (5.2)                       | 4 (2.6)             |
| Estrogen derivative / Non disease related medication     | 1 (0.7)                       | 0 (0.0)             |
| Folic Acid derivative                                    | 24 (15.7)                     | 12 (7.8)            |
| ICOS inhibitor                                           | 1 (0.7)                       | 1 (0.6)             |
| Nucleoside Analog / Thymidine Phosphorylase inhibitor    | 1 (0.7)                       | 2 (1.3)             |
| TIM3 inhibitor                                           | 1 (0.7)                       | 1 (0.6)             |
| VEGF inhibitor                                           | 22 (14.4)                     | 11 (7.1)            |

## Recruitment

A total of 307 patients (153 in the pembrolizumab arm and 154 in the SOC arm) were randomized in 120 centers in 23 countries worldwide (Australia, Europe, Asia, America, South Africa). First patient first visit was on 30-NOV-2015.

KEYNOTE-177 study is ongoing; this report is based on the second interim analysis (i.e. final for PFS, IA for OS) with data cutoff date of 19-FEB-2020 (database lock date 16-MAR-2020).

Median duration of follow-up at the time of data cutoff was 28.4 months (range: 0.2, 48.3 months) and 27.2 months (range: 0.8, 46.6 months) in the pembrolizumab and SOC groups, respectively.

## Conduct of the study

## Protocol amendments

The original protocol is dated 11 Sep 2015. Up to the data cut-off date for this submission (19 Feb 2020), there have been 5 protocol amendments, the first 2 amendments were country-specific, while amendments 3, 4 and 5 were global.

Table: Summary of Key Changes in Protocol Amendments

|   Amendment Number | Global or Local   | Date        | Key changes                                                                                                                                                                     | Rationale                                      |
|--------------------|-------------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
|                 01 | France            | 17-MAR-2016 | â¢ Required subjects to discontinue pembrolizumab after confirmed disease progression. â¢ Clarified exclusion criterion to address contraindications to standard of care options. | As per French Health Authority (ANSM) request. |

<div style=\"page-break-after: always\"></div>

|                                                                                             |                                                                                             |                                                                                             | â¢ Addresses the need for a subject to discontinue the study if there is progression/recurrence/occurrence of another malignancy that requires active treatment                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 02                                                                                          | UK                                                                                          | 16-MAR-2016                                                                                 | â¢ Clarified exclusion criterion to address contraindications to standard of care options. â¢ Added prohibited medications for all standard of care agents according to respective SmPCs. â¢ Added cautionary information for 5-FU â¢ Added assessments for physical exam for subjects assigned to             | As per UK Regulatory Agency (MHRA) request.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 03                                                                                          | Global                                                                                      | 20-NOV-2017                                                                                 | FOLFOX-based regimens â¢ Primary objective was changed from a single PFS endpoint to dual endpoints of PFS and OS. â¢ Sample size was increased to 300. â¢ Interim and final analysis timing was updated and one IA for PFS and OS was added.                                                                 | The revisions were based on desire to add OS as a dual primary endpoint. OS power was increased to 85% to increase probability of success for this primary hypothesis. Timing of analyses changed to allow for more mature PFS and OS data to account for a potential delayed separation in survival curves observed in immune-oncology studies, while adding an interim analysis to allow for earlier stopping if this is not the case.                                                                                                                                                                                                                                                                                   |
| 04                                                                                          | Global                                                                                      | 30-APR-2018                                                                                 | â¢ The timing component of IA1 and IA2 was prolonged by 3 additional months and the alpha spending method for PFS was modified.                                                                                                                                                                             | For PFS analysis, the alpha spending function to control the Type-I error based on information fraction was replaced by a function of the minimum of the actual event information fraction and the expected event information fraction. The timing component for conducting both interim analysis 1 and interim analysis 2 was prolonged by 3 additional months. This change was made due to emerging results from multiple immunotherapy trials in which delayed treatment effects have been observed for time to event endpoints. To account for this potential effect, the timing of interim analyses 1 and 2 was changed to allow for a longer follow-up time, and the alpha spending method was modified accordingly. |
| 05                                                                                          | Global                                                                                      | 17-DEC-2019                                                                                 | â¢ The timing of IA2 and FA was changed. IA2 will be performed when approximately 209 PFS events have occurred or 24 months after last participant randomized, whichever occurs first. FA will be performed after approximately 190 OS events have occurred or 12 months after IA2, whichever occurs first. | In the event that PFS or OS events accrue slower than expected as has been shown with immunotherapy in biomarker selected populations, alternate maximum time periods are specified for the conduct of the final PFS analysis and the final OS analysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Note: Table includes protocol amendments implemented up to the data cutoff date 19-FEB-2020 | Note: Table includes protocol amendments implemented up to the data cutoff date 19-FEB-2020 | Note: Table includes protocol amendments implemented up to the data cutoff date 19-FEB-2020 | Note: Table includes protocol amendments implemented up to the data cutoff date 19-FEB-2020                                                                                                                                                                                                                | Note: Table includes protocol amendments implemented up to the data cutoff date 19-FEB-2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

## Protocol deviations

Protocol deviations were classified as per the ICH E3 classification as:

- important (those that may significantly impact the quality or integrity of key study data or that may significantly affect a participant's rights, safety, or well-being)
- clinically important (deviations that may compromise critical data analyses pertaining to primary efficacy and/or safety endpoints or the participant's safety)
- not clinically important
- not important

Patients with one or more important protocol deviations were 13 (8.5%) in the pembrolizumab arm and 17 (11%) in the SOC arm; most of these deviations pertained to reportable safety events or follow-up safety information that was reported outside the safety reporting window (6.5% and 9.1% in the pembrolizumab and SOC group, respectively). Important protocol deviations considered to be clinically important occurred in 1 patient in each arm: one clinically important deviation occurred in a participant who had a positive MSI-H status upon entering the study, but when retested centrally had a negative MSI-H status. This has been reported as due to a problem on the device used locally to perform the MSI test. The other clinically important deviation was noted in a participant who did not have measurable disease upon entering the study.

No participant data were excluded from analyses due to an important protocol deviation.

## Baseline data

## Table: subjects characteristics (ITT population)

|                           | Pembrolizumab   | Pembrolizumab   | SOC      | SOC    | Total    | Total   |
|---------------------------|-----------------|-----------------|----------|--------|----------|---------|
|                           | n               | (%)             | n        | (%)    | n        | (%)     |
| Subjects in population    | 153             |                 | 154      |        | 307      |         |
| Gender                    |                 |                 |          |        |          |         |
| Male                      | 71              | (46.4)          | 82       | (53.2) | 153      | (49.8)  |
| Female                    | 82              | (53.6)          | 72       | (46.8) | 154      | (50.2)  |
| Age (Years)               |                 |                 |          |        |          |         |
| <65                       | 80              | (52.3)          | 83       | (53.9) | 163      | (53.1)  |
| >=65                      | 73              | (47.7)          | 71       | (46.1) | 144      | (46.9)  |
| Subjects with data        | 153             |                 | 154      |        | 307      |         |
| Mean                      | 61.9            |                 | 60.6     |        | 61.2     |         |
| SD                        | 14.9            |                 | 14.8     |        | 14.8     |         |
| Median                    | 63.0            |                 | 62.5     |        | 63.0     |         |
| Range                     | 24 to 93        |                 | 26 to 90 |        | 24 to 93 |         |
| Age (Years)               |                 |                 |          |        |          |         |
| <=70                      | 105             | (68.6)          | 112      | (72.7) | 217      | (70.7)  |
| >70                       | 48              | (31.4)          | 42       | (27.3) | 90       | (29.3)  |
| Race                      |                 |                 |          |        |          |         |
| ASIAN                     | 24              | (15.7)          | 26       | (16.9) | 50       | (16.3)  |
| BLACK OR AFRICAN AMERICAN | 9               | (5.9)           | 5        | (3.2)  | 14       | (4.6)   |
| WHITE                     | 113             | (73.9)          | 116      | (75.3) | 229      | (74.6)  |

307

153

154

163

144

307

61.2

14.8

63.0

24 to 93

217

90

50

14

229

<div style=\"page-break-after: always\"></div>

14

21

259

20

4

3

48

222

37

159

148

209

88

9

1

159

148

70

237

154

153

70

5

8

224

69

71

74

3

90

306

1

| Missing                                    | 7   | (4.6)   | 7   | (4.5)   | 14   | (4.6)   |
|--------------------------------------------|-----|---------|-----|---------|------|---------|
| Ethnicity                                  |     |         |     |         |      |         |
| HISPANIC OR LATINO                         | 11  | (7.2)   | 10  | (6.5)   | 21   | (6.8)   |
| NOT HISPANIC OR LATINO                     | 128 | (83.7)  | 131 | (85.1)  | 259  | (84.4)  |
| NOT REPORTED                               | 10  | (6.5)   | 10  | (6.5)   | 20   | (6.5)   |
| UNKNOWN                                    | 2   | (1.3)   | 2   | (1.3)   | 4    | (1.3)   |
| Missing                                    | 2   | (1.3)   | 1   | (0.6)   | 3    | (1.0)   |
| Geographic Region                          |     |         |     |         |      |         |
| Asia                                       | 22  | (14.4)  | 26  | (16.9)  | 48   | (15.6)  |
| Western Europe/North America               | 109 | (71.2)  | 113 | (73.4)  | 222  | (72.3)  |
| Rest of World                              | 22  | (14.4)  | 15  | (9.7)   | 37   | (12.1)  |
| ECOG                                       |     |         |     |         |      |         |
| 0                                          | 75  | (49.0)  | 84  | (54.5)  | 159  | (51.8)  |
| 1                                          | 78  | (51.0)  | 70  | (45.5)  | 148  | (48.2)  |
| Site of Primary Tumour *                   |     |         |     |         |      |         |
| Right                                      | 102 | (66.7)  | 107 | (69.5)  | 209  | (68.1)  |
| Left                                       | 46  | (30.1)  | 42  | (27.3)  | 88   | (28.7)  |
| Other                                      | 4   | (2.6)   | 5   | (3.2)   | 9    | (2.9)   |
| Missing                                    | 1   | (0.7)   | 0   | (0.0)   | 1    | (0.3)   |
| Metastases Location                        |     |         |     |         |      |         |
| Hepatic or pulmonary                       | 86  | (56.2)  | 73  | (47.4)  | 159  | (51.8)  |
| Other Metastases                           | 67  | (43.8)  | 81  | (52.6)  | 148  | (48.2)  |
| Metastases Location                        |     |         |     |         |      |         |
| Pulmonary                                  | 36  | (23.5)  | 34  | (22.1)  | 70   | (22.8)  |
| Other                                      | 117 | (76.5)  | 120 | (77.9)  | 237  | (77.2)  |
| Diagnosed Stage                            |     |         |     |         |      |         |
| Recurrent                                  | 80  | (52.3)  | 74  | (48.1)  | 154  | (50.2)  |
| Newly diagnosed stage                      | 73  | (47.7)  | 80  | (51.9)  | 153  | (49.8)  |
| Prior Systemic Therapy                     |     |         |     |         |      |         |
| Adjuvant only                              | 33  | (21.6)  | 37  | (24.0)  | 70   | (22.8)  |
| Neoadjuvant only                           | 2   | (1.3)   | 3   | (1.9)   | 5    | (1.6)   |
| Neoadjuvant and adjuvant                   | 3   | (2.0)   | 5   | (3.2)   | 8    | (2.6)   |
| None                                       | 115 | (75.2)  | 109 | (70.8)  | 224  | (73.0)  |
| Mutation Status **                         |     |         |     |         |      |         |
| BRAF/KRAS/NRAS all wild type               | 34  | (22.2)  | 35  | (22.7)  | 69   | (22.5)  |
| KRAS/NRAS mutant and BRAF V600E not mutant | 33  | (21.6)  | 38  | (24.7)  | 71   | (23.1)  |
| BRAF V600E mutant and KRAS/NRAS not mutant | 34  | (22.2)  | 40  | (26.0)  | 74   | (24.1)  |
| BRAF V600E and KRAS/NRAS mutant            | 0   | (0.0)   | 3   | (1.9)   | 3    | (1.0)   |
| Other                                      | 52  | (34.0)  | 38  | (24.7)  | 90   | (29.3)  |
| MSI-High Status #                          |     |         |     |         |      |         |
| Positive                                   | 153 | (100.0) | 153 | (99.4)  | 306  | (99.7)  |
| Negative                                   | 0   | (0.0)   | 1   | (0.6)   | 1    | (0.3)   |
| Oncologic Surgery with Curative Intent     | ##  |         |     |         |      |         |

<div style=\"page-break-after: always\"></div>

27

280

24

283

159

148

111

160

2

34

(20.8)

(71.0)

(8.1)

| Received surgery with curative-intent Did not receive surgery with curative- intent   | 14 139   | (9.2) (90.8)        | 13 141   | (8.4) (91.6)        | 27 280    | (8.8) (91.2)        |
|---------------------------------------------------------------------------------------|----------|---------------------|----------|---------------------|-----------|---------------------|
| Prior Radiation Therapy                                                               |          |                     |          |                     |           |                     |
| Yes No                                                                                | 11 142   | (7.2) (92.8)        | 13 141   | (8.4) (91.6)        | 24 283    | (7.8) (92.2)        |
| Sum of IRC Target Lesions at Baseline                                                 | ###      |                     |          |                     |           |                     |
| <= Median > Median                                                                    | 68 85    | (44.4) (55.6)       | 91 63    | (59.1) (40.9)       | 159 148   | (51.8) (48.2)       |
| Baseline CEA Group                                                                    |          |                     |          |                     |           |                     |
| N H L                                                                                 | 50 86 1  | (32.7) (56.2) (0.7) | 61 74 1  | (39.6) (48.1) (0.6) | 111 160 2 | (36.2) (52.1) (0.7) |
| Lynch Syndrome                                                                        |          |                     |          |                     |           |                     |
| Yes                                                                                   | 28       | (18.3)              | 36       | (23.4)              | 64        | (20.8)              |
| No                                                                                    | 114      | (74.5)              | 104      | (67.5)              | 218       | (71.0)              |
| Unknown                                                                               | 11       | (7.2)               | 14       | (9.1)               | 25        | (8.1)               |

* If there were primary tumours in both left side and right side, the subject would be categorized into Other.

**  When none of BRAF V600E, KRAS and NRAS was mutant, if at least one of the mutation statuses was undetermined or missing, or the type of BRAF mutation was not V600E, the subject was categorized into Other.

# MSI status by PCR test or IHC test at local site laboratory.

## Oncologic surgery that was with curative intent and occurred after subject randomization and before initiation of new anti-cancer therapy, crossover treatment and second course treatment.

### Subjects without baseline tumour size per BICR are categorized as baseline tumour size &lt;=median. Database Cutoff Date: 19FEB2020.

## Sites of metastases:

Hepatic or pulmonary 86 (56.2) vs 73 (47.4); hepatic only 50 (32.7%) vs 39 (25.3%); pulmonary only 15 (9.8%) vs 19 (12.3%); hepatic and pulmonary 21 (13.7%) vs 15 (9.7%); pulmonary (alone or with other sites) 36 (23.5%) vs 34 (22%), in pembrolizumab vs SOC arm, respectively.

Table: Investigator's Choice of Standard of Care Treatment (ASaT Population)

|                              | SOC (N=143)                  | SOC (N=143)                  |
|------------------------------|------------------------------|------------------------------|
|                              | n1                           | (%)                          |
| FOLFIRI                      | 16                           | 11.2                         |
| FOLFIRI+BEVACIZUMAB          | 36                           | 25.2                         |
| FOLFIRI+CETUXIMAB            | 11                           | 7.7                          |
| mFOLFOX6                     | 11                           | 7.7                          |
| mFOLFOX6+BEVACIZUMAB         | 64                           | 44.8                         |
| mFOLFOX6+CETUXIMAB           | 5                            | 3.5                          |
| DatabaseCutoffDate:19FEB2020 | DatabaseCutoffDate:19FEB2020 | DatabaseCutoffDate:19FEB2020 |

<div style=\"page-break-after: always\"></div>

## Determination of MSI-H/dMMR status

IHC testing was used for the majority of participants (105 pembrolizumab, 97 SOC) with far fewer participants assessed using PCR (16 participants in each treatment group) or PCR and IHC (32 pembrolizumab, 40 SOC).

## Numbers analysed

The ITT population includes 307 participants, 153 in the pembrolizumab arm and 154 in the SOC arm, which were analysed for efficacy.

## Outcomes and estimation

## Table: summary of efficacy results for KEYNOTE-177

|                                               | Pembrolizumab N=153   | SOC N=154          |
|-----------------------------------------------|-----------------------|--------------------|
| PFS (BICR per RECIST 1.1)                     |                       |                    |
| Number of events (%)                          | 82 (53.6)             | 113 (73.4)         |
| Median in months (95% CI)                     | 16.5 (5.4, 32.4)      | 8.2 (6.1, 10.2)    |
| HR (95% CI)                                   | 0.60 (0.45, 0.80)     | 0.60 (0.45, 0.80)  |
| P-value                                       | 0.0002                | 0.0002             |
| PFS rate at 12 months (95% CI)                | 55.3 (47.0, 62.9)     | 37.3 (29.0, 45.5)  |
| PFS rate at 18 months (95% CI)                | 49.1 (40.7, 57.0)     | 26.7 (19.2, 34.7)  |
| PFS rate at 24 months (95% CI)                | 48.3 (39.9, 56.2)     | 18.6 (12.1, 26.3)  |
| OS                                            |                       |                    |
| Number of events (%)                          | 56 (36.6)             | 69 (44.8)          |
| Median in months (95% CI)                     | NR (NR, NR)           | 34.8 (26.3, NR)    |
| HR (95% CI)                                   | 0.77 (0.54, 1.09)     | 0.77 (0.54, 1.09)  |
| P-value                                       | 0.0694                | 0.0694             |
| OS rate at 12 months (95% CI)                 | 77.8 (70.3, 83.6)     | 74.0 (66.2, 80.3)  |
| OS rate at 18 months (95% CI)                 | 71.2 (63.4, 77.7)     | 65.9 (57.7, 72.9)  |
| OS rate at 24 months (95% CI)                 | 68.0 (59.9, 74.7)     | 59.8 (51.5, 67.2)  |
| ORR (BICR per RECIST 1.1, with confirmation)  |                       |                    |
| %(95% CI)                                     | 43.8 (35.8, 52.0)     | 33.1 (25.8, 41.1)  |
| Complete Responses%                           | 11.1                  | 3.9                |
| Partial Responses%                            | 32.7                  | 29.2               |
| Stable Disease%                               | 20.9                  | 42.2               |
| Progressive Disease%                          | 29.4                  | 12.3               |
| DOR (Confirmed CR or PR, BICR per RECIST 1.1) |                       |                    |
| Number of responders                          | 67                    | 51                 |
| Median in months (range)                      | NR (2.3+ - 41.4+)     | 10.6 (2.8 - 37.5+) |

<div style=\"page-break-after: always\"></div>

|                                                                                                   | Pembrolizumab N=153                  | SOC N=154                            |
|---------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------|
| Median time to response (range)                                                                   | 2.2 (1.8-18.8)                       | 2.1 (1.7-24.9)                       |
| Number (KM %) With Extended Response Duration ( â¥ 6 months)                                       | 61 (96.9)                            | 43 (87.9)                            |
| Progression-free Survival 2                                                                       |                                      |                                      |
| Median in months (95% CI)                                                                         | NR (NR, NR)                          | 23.5 (95% CI: 16.6, 32.6)            |
| HR (95% CI)                                                                                       | 0.63 (95% CI: 0.45, 0.88)            | 0.63 (95% CI: 0.45, 0.88)            |
| P-value                                                                                           | p=0.0031*                            | p=0.0031*                            |
| PRO                                                                                               |                                      |                                      |
| QLQ-C30 global health status/QoL mean score change from baseline to prespecified Week 18 (95% CI) | +3.33 points (-0.05, 6.72)           | -5.63 points (-9.32, -1.94)          |
| LS mean difference in global health status/QoL score (95% CI)                                     | 8.96 points (4.24, 13.69) p=0.0002*  | 8.96 points (4.24, 13.69) p=0.0002*  |
| Time to deterioration# in global health status/QoL                                                | HR=0.61 (95% CI 0.38-0.98) p=0.0195* | HR=0.61 (95% CI 0.38-0.98) p=0.0195* |
| Time to deterioration# in physical functioning                                                    | HR=0.50 (95% CI 0.32-0.81) p=0.0016* | HR=0.50 (95% CI 0.32-0.81) p=0.0016* |
| Time to deterioration# in social functioning                                                      | HR=0.53 (95% CI 0.32-0.87) p=0.0050* | HR=0.53 (95% CI 0.32-0.87) p=0.0050* |
| Time to deterioration# in fatigue                                                                 | HR=0.48 (95% CI 0.33-0.69) p<0.0001* | HR=0.48 (95% CI 0.33-0.69) p<0.0001* |
| Time to deterioration# in urinary incontinence                                                    | HR=0.43 (95% CI 0.14-1.31) p=0.0637* | HR=0.43 (95% CI 0.14-1.31) p=0.0637* |

Abbreviations: BICR=Blinded independent central review; CI=Confidence interval; CR=Complete response; DOR=Duration of response; HR=Hazard ratio; KM=Kaplan-Meier; LS=least squares; N=Number; NR=Not reached; ORR=Objective response rate; OS=Overall survival; PFS=Progression-free survival; PR=Partial response; PRO=Patient-reported outcomes; QLQ=Quality of life questionnaire; QoL=Quality of

Life; RECIST 1.1=Response Evaluation Criteria in Solid Tumours Version 1.1; SOC=Standard of care.

* not controlled for multiplicity

# deterioration defined as the time to first onset of a decrease of &gt;10 points with confirmation

Database Cutoff Date: 19FEB2020.

Data Source:  [Ref. 5.3.5.1: P177V01MK3475: Table 11-2], [Ref. 5.3.5.1: P177V01MK3475: Table 11-8], [Ref. 5.3.5.1: P177V01MK3475: Table 11-9], [Ref. 5.3.5.1: P177V01MK3475: Table 11-10], [Ref. 5.3.5.1: P177V01MK3475: Table 14.2-9], [Ref. 5.3.5.1: P177V01MK3475: Table 14.2-18], [Ref. 5.3.5.1: P177V01MK3475: Table 14.2-19], [Ref. 5.3.5.1: P177V01MK3475: Table 14.2-20], [Ref. 5.3.5.1: P177V01MK3475: Table 14.2-21], [Ref. 5.3.5.1: P177V01MK3475: Table 14.2-22], [Ref. 5.3.5.1: P177V01MK3475: Table 14.2-23], [Ref. 5.3.5.1: P177V01MK3475: Table 14.2-30].

## Primary endpoints (dual primary)

## Â· Progression Free Survival (PFS)

At the IA2 (i.e. final analysis for PFS), pembrolizumab provided a statistically significant and clinically meaningful improvement in PFS per RECIST 1.1 by BICR compared to SOC.

<div style=\"page-break-after: always\"></div>

## Table: Analysis of Progression-Free Survival (Primary Analysis) By Central Imaging Vendor per RECIST 1.1 (ITT Population)

55.3 (47.0, 62.9)

37.3 (29.0, 45.5)

0.60 (0.45, 0.80)

0.0002

| Treatment             | N                     | Number of Events (%)   | Person- Months        | Event Rate/ 100 Person- Months   | Median PFS â  (Months) (95% CI)   | PFS Rate at Month 12 in% â  (95% CI)   |
|-----------------------|-----------------------|------------------------|-----------------------|----------------------------------|----------------------------------|---------------------------------------|
| Pembrolizumab         | 153                   | 82 (53.6)              | 2238.8                | 3.7                              | 16.5 (5.4, 32.4)                 | 55.3 (47.0, 62.9)                     |
| SOC                   | 154                   | 113 (73.4)             | 1487.3                | 7.6                              | 8.2 (6.1, 10.2)                  | 37.3 (29.0, 45.5)                     |
|                       |                       |                        |                       |                                  | Hazard Ratio â¡ (95% CI) â¡        | p-Value Â§                             |
| Pembrolizumab vs. SOC | Pembrolizumab vs. SOC | Pembrolizumab vs. SOC  | Pembrolizumab vs. SOC | Pembrolizumab vs. SOC            | 0.60 (0.45, 0.80)                | 0.0002                                |

## Table: Summary of Event and Censoring Description for Progression-Free Survival (Primary Analysis) By Central Imaging Vendor per RECIST 1.1 (ITT Population)

|                                                   | Pembrolizumab (N=153) n (%)    | SOC (N=154) n (%)              |
|---------------------------------------------------|--------------------------------|--------------------------------|
| Subjects with Events                              | 82 (53.6)                      | 113 (73.4)                     |
| Documented progression                            | 65 (42.5)                      | 86 (55.8)                      |
| Death                                             | 17 (11.1)                      | 27 (17.5)                      |
| Subjects Censored                                 | 71 (46.4)                      | 41 (26.6)                      |
| Curative-intentsurgery                            | 12 (7.8)                       | 12 (7.8)                       |
| New anti-cancer therapy                           | 5 (3.3)                        | 15 (9.7)                       |
| Last radiologic assessment showing no progression | 53 (34.6)                      | 10 ( 6.5)                      |
| No adequatepost-baseline imaging assessment       | 1 (0.7)                        | 4 (2.6)                        |
| DatabaseCutoff Date:19FEB2020.                    | DatabaseCutoff Date:19FEB2020. | DatabaseCutoff Date:19FEB2020. |

## Table: analysis of PFS rate over time (primary analysis) by central imaging vendor per RECIST 1.1 (ITT population)

|                                                                                           | Pembrolizumab (N=153) % (95% CI)t   | SOC (N=154) %(95%CI)f   |
|-------------------------------------------------------------------------------------------|-------------------------------------|-------------------------|
| Progression-Free Survival rate at time point                                              |                                     |                         |
| 6months                                                                                   | 57.6 (49.3, 65.0)                   | 59.7 (51.1,67.3)        |
| 9months                                                                                   | 56.8 (48.5,64.3)                    | 45.5 (36.9, 53.7)       |
| 12months                                                                                  | 55.3 (47.0, 62.9)                   | 37.3 (29.0, 45.5)       |
| 18months                                                                                  | 49.1 (40.7, 57.0)                   | 26.7 (19.2, 34.7)       |
| 24months                                                                                  | 48.3 (39.9,56.2)                    | 18.6 (12.1, 26.3)       |
| From product-limit (Kaplan-Meier) method for censored data. DatabaseCutoffDate:19FEB2020. |                                     |                         |

<div style=\"page-break-after: always\"></div>

Figure: Kaplan-Meier Estimates of Progression-Free Survival (Primary Analysis) By Central Imaging Vendor per RECIST 1.1 (ITT Population)

<!-- image -->

Database Cutoff Date: 19FEB2020.

## Â· Overall Survival (OS)

At the IA2 (i.e. interim analysis for OS), the statistical significance criterion for OS was not met when compared to the p-value boundary of 0.0053.

Table: Analysis of Overall Survival (ITT Population)

| Treatment             | N                     | Number of Events (%)   | Person- Months        | Event Rate/ 100 Person- Months   | Median OS â  (Months) (95% CI)   | OS Rate at Month 12 in% â  (95% CI)   |
|-----------------------|-----------------------|------------------------|-----------------------|----------------------------------|---------------------------------|--------------------------------------|
| Pembrolizumab         | 153                   | 56 (36.6)              | 3794.5                | 1.5                              | NR (NR, NR)                     | 77.8 (70.3, 83.6)                    |
| SOC                   | 154                   | 69 (44.8)              | 3430.2                | 2.0                              | 34.8 (26.3, NR)                 | 74.0 (66.2, 80.3)                    |
|                       |                       |                        |                       |                                  | Hazard Ratio â¡ (95% CI) â¡       | p-Value Â§                            |
| Pembrolizumab vs. SOC | Pembrolizumab vs. SOC | Pembrolizumab vs. SOC  | Pembrolizumab vs. SOC | Pembrolizumab vs. SOC            | 0.77 (0.54, 1.09)               | 0.0694                               |

NR = Not reached.

Database Cutoff Date: 19FEB2020.

77.8 (70.3, 83.6)

74.0 (66.2, 80.3)

0.77 (0.54, 1.09)

0.0694

<div style=\"page-break-after: always\"></div>

Figure: Kaplan-Meier Estimates of Overall Survival (ITT Population)

<!-- image -->

Database Cutoff Date: 19FEB2020.

## Key secondary endpoint

## Â· Overall Response Rate (ORR)

Based on protocol-specified multiplicity strategy, if ORR by BICR per RECIST 1.1 was not significant at IA1, ORR at IA1 could be tested following a statistically significant PFS or OS hypothesis test at IA2 or final analysis. Because PFS was statistically significant at IA2, ORR at IA1 was formally tested and statistical significance was not demonstrated, as the p-value of 0.0582 for ORR at IA1 was above the p-value boundary of 0.000125.

Only 2 cases of pseudoprogression were identified in the pembrolizumab arm.

Table: Analysis of Best Overall Response By Central Imaging Vendor per RECIST 1.1 (ITT Population)

0.0275

|               |     |                               |                                         | Difference in %vs. SOC   | Difference in %vs. SOC   |
|---------------|-----|-------------------------------|-----------------------------------------|--------------------------|--------------------------|
| Treatment     | N   | Number of Objective Responses | Objective Response Rate (%) (95% CI * ) | Estimate (95% CI) â       | p-Value â¡                |
| Pembrolizumab | 153 | 67                            | 43.8 (35.8,52.0)                        | 10.7 (-0.2,21.3)         | 0.0275                   |
| SOC           | 154 | 51                            | 33.1 (25.8,41.1)                        |                          |                          |

<div style=\"page-break-after: always\"></div>

## Table: Summary of Best Overall Response By Central Imaging Vendor per RECIST 1.1 (ITT Population)

| Response Evaluation                    | Pembrolizumab (N=153)                  | Pembrolizumab (N=153)                  | Pembrolizumab (N=153)                  | SOC (N=154)                            | SOC (N=154)                            | SOC (N=154)                            |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|                                        | n                                      | %                                      | 95% CI â                                | n                                      | %                                      | 95% CI â                                |
| Complete Response (CR)                 | 17                                     | 11.1                                   | (6.6, 17.2)                            | 6                                      | 3.9                                    | (1.4, 8.3)                             |
| Partial Response (PR)                  | 50                                     | 32.7                                   | (25.3, 40.7)                           | 45                                     | 29.2                                   | (22.2, 37.1)                           |
| Objective Response (CR+PR)             | 67                                     | 43.8                                   | (35.8, 52.0)                           | 51                                     | 33.1                                   | (25.8, 41.1)                           |
| Stable Disease (SD)                    | 32                                     | 20.9                                   | (14.8, 28.2)                           | 65                                     | 42.2                                   | (34.3, 50.4)                           |
| Disease Control (CR+PR+SD)             | 99                                     | 64.7                                   | (56.6, 72.3)                           | 116                                    | 75.3                                   | (67.7, 81.9)                           |
| Progressive Disease (PD)               | 45                                     | 29.4                                   | (22.3, 37.3)                           | 19                                     | 12.3                                   | (7.6, 18.6)                            |
| Not Evaluable                          | 3                                      | 2.0                                    | (0.4, 5.6)                             | 2                                      | 1.3                                    | (0.2, 4.6)                             |
| No Assessment                          | 6                                      | 3.9                                    | (1.5, 8.3)                             | 17                                     | 11.0                                   | (6.6, 17.1)                            |
| Only confirmed responses are included. | Only confirmed responses are included. | Only confirmed responses are included. | Only confirmed responses are included. | Only confirmed responses are included. | Only confirmed responses are included. | Only confirmed responses are included. |

## Figures: Waterfall Plot of Maximum Target Lesion Change from Baseline By Central Imaging Vendor per RECIST 1.1 (ITT Population)

<!-- image -->

## Exploratory endpoints

## Duration of response

## Table: Summary of Time to Response and Duration of Response in Subjects with Confirmed Response By Central Imaging Vendor per RECIST 1.1 (ITT Population)

51

|                                    | Pembrolizumab (N=153)   | SOC (N=154)   |
|------------------------------------|-------------------------|---------------|
| Number of subjects with response â  | 67                      | 51            |
| Time to Response (months)          |                         |               |

<div style=\"page-break-after: always\"></div>

3.6 (4.1)

43 (87.9)

27 (59.9)

19 (43.8)

11 (35.3)

9 (35.3)

| Mean (SD)                                                  | 4.0 (3.7)         | 3.6 (4.1)          |
|------------------------------------------------------------|-------------------|--------------------|
| Median (Range)                                             | 2.2 (1.8-18.8)    | 2.1 (1.7-24.9)     |
| Response Duration â¡ (months)                               |                   |                    |
| Median (Range)                                             | NR (2.3+ - 41.4+) | 10.6 (2.8 - 37.5+) |
| Number (% â¡ ) of Subjects with Extended Response Duration: |                   |                    |
| â¥6 months                                                  | 61 (96.9)         | 43 (87.9)          |
| â¥9 months                                                  | 55 (91.9)         | 27 (59.9)          |
| â¥12 months                                                 | 50 (85.1)         | 19 (43.8)          |
| â¥18 months                                                 | 45 (85.1)         | 11 (35.3)          |
| â¥24 months                                                 | 29 (82.6)         | 9 (35.3)           |

NR = Not Reached.

Database Cutoff Date: 19FEB2020.

|                                                                                 | Pembrolizumab (N=153)   | SOC (N=154)   |
|---------------------------------------------------------------------------------|-------------------------|---------------|
| Number of Subjects with Response!                                               | 67                      | 51            |
| Subjects WhoProgressed or Died (%)                                              | 13 (19.4)               | 32 (62.7)     |
| Range of DOR (months)                                                           | 3.3 to 27.0             | 2.8 to 28.8   |
| Censored Subjects (%)                                                           | 54 (80.6)               | 19 (37.3)     |
| Subjects whoreceived oncologic surgery with curative intent                     | 8 (11.9)                | 2 (3.9)       |
| Subjects who missed 2 or more consecutive disease assessments                   | 3 (4.5)                 | 1 (2.0)       |
| Subjects who started new anti-cancer treatment                                  | 1 (1.5)                 | 6 (11.8)      |
| Subjects who were lost to follow-up                                             | 0 (0.0)                 | 0 (0.0)       |
| Subjects whose last adequate assessment wasâ¥ 5 months prior to data cutoff date | 4 (6.0)                 | 1 (2.0)       |
| Ongoing response?                                                               | 38 (56.7)               | 9 (17.6)      |
| â¥6 months                                                                       | 38 (56.7)               | 9 (17.6)      |
| â¥9 months                                                                       | 38 (56.7)               | 8 (15.7)      |
| â¥12 months                                                                      | 38 (56.7)               | 8 (15.7)      |
| â¥18 months                                                                      | 34 (50.7)               | 8 (15.7)      |
| â¥24 months                                                                      | 24 (35.8)               | 6 (11.8)      |
| Range ofDOR(months)                                                             | 15.7+ to 41.4+          | 6.2+ to 37.5+ |

<div style=\"page-break-after: always\"></div>

Figure: Kaplan-Meier Estimates of Duration of Response in Subjects with Confirmed Response By Central Imaging Vendor per RECIST 1.1 (ITT Population)

<!-- image -->

Database Cutoff Date: 19FEB2020.

## Progression Free Survival 2

## Table: Analysis of Progression-Free Survival 2 By Investigator per RECIST 1.1 (ITT Population)

| Treatment           | N   | Number of Events (%)   | Person- Months   | Event Rate/ 100Person- Months   | Median PFS2 t (Months) (95% CI)   | PFS2Rate at Month 12 in % t (95% CI)   |
|---------------------|-----|------------------------|------------------|---------------------------------|-----------------------------------|----------------------------------------|
| Pembrolizumab       | 153 | 59 (38.6)              | 3650.3           | 1.6                             | NR (NR, NR)                       | 75.8 (68.2, 81.8)                      |
| SOC                 | 154 | 84 (54.5)              | 3026.4           | 2.8                             | 23.5 (16.6, 32.6)                 | 67.4 (59.2,74.2)                       |
|                     |     |                        |                  |                                 | Hazard Ratio+(95% CI)+            | p-Values                               |
| Pembrolizumabvs.SOC |     |                        |                  |                                 | 0.63 (0.45,0.88)                  | 0.0031                                 |

DatabaseCutoffDate:19FEB2020.

<div style=\"page-break-after: always\"></div>

Figure: Kaplan-Meier Estimates of Progression-Free Survival 2 By Investigator per RECIST 1.1 (ITT Population)

<!-- image -->

Database Cutoff Date: 19FEB2020.

## Patient Reported Outcome (PRO)

At baseline, the compliance rates for the EORTC QLQ-C30 were similar and above 90% in both treatment groups (92.8% vs 92.9%, respectively) and remained high at prespecified Week 18 (87.9% vs 76.6%, respectively). Compliance rates at baseline through Week 18 were similar for the EORTC QLQ-CR29 and EQ-5D.

Baseline global health status/QoL scores were similar between treatment groups. At prespecified Week 18, the mean change from baseline in the global health status/QoL score showed improvement (LS mean = 3.33 points [95% CI: -0.05, 6.72]) in the pembrolizumab group, and a decline (LS mean = -5.63 points [95% CI: -9.32, -1.94]) in the SOC group. The difference in LS means between pembrolizumab and the SOC group at Week 18 was 8.96 points (95% CI: 4.24, 13.69; two-sided nominal p=0.0002, not adjusted for multiplicity).

In the PRO FAS population with baseline assessments, based on the EORTC QLQ-C30, for participants in the pembrolizumab group compared to those in the SOC group, prolonged TTD was observed in global health status/QoL score (HR 0.61; 95% CI 0.38-0.98; one-sided nominal p=0.0195, not adjusted for multiplicity).

A greater proportion of participants in the pembrolizumab group showed improvement in global health status/QoL score and all functioning and symptom scores (except insomnia) compared to those in the SOC group, while a greater proportion of participants in the SOC group showed deterioration in global health status/QoL score and all functioning and symptom scores compared to those in the pembrolizumab group.

<div style=\"page-break-after: always\"></div>

Figure: Mean Change from Baseline and 95% CI for the EORTC QLQ-C30 Global Health Status/QoL Over Time (FAS Population with Baseline and Post-Baseline Assessment)

<!-- image -->

Database Cutoff Date: 19FEB2020.

Figure: Kaplan-Meier Estimates of Time to Deterioration for EORTC QLQ-C30 Global Health Status/QOL (FAS Population with Baseline)

<!-- image -->

Database Cutoff Date: 19FEB2020.

<div style=\"page-break-after: always\"></div>

Figure: Change from Baseline for EORTC QLQ-C30 scores at Week 18 LS Mean Change and 95% CI (FAS Population)

## Functional Scale/Global Health Status/QoL

<!-- image -->

<!-- image -->

For global health status/quality of life score and all functional scales, a higher score denotes better HRQOL or function.

For symptoms scales, a higher score denotes worse symptoms.

Database Cutoff Date: 19FEB2020.

Figure: Change from Baseline for EORTC QLQ-CR29 scores at Week 18 LS Mean Change and 95% CI (FAS Population)

## Functional Scale

<!-- image -->

<!-- image -->

For global health status/quality  of  life  score  and  all  functional scales, a higher score denotes better HRQOL or function.

For symptoms scales, a higher score denotes worse symptoms.

Database Cutoff Date: 19FEB2020.

Baseline EQ-5D VAS and utility scores were similar between treatment groups. At prespecified Week 18, the mean change from baseline in the EQ-5D VAS score showed improvement (LS mean = 4.50 points [95% CI: 1.16, 7.83]) in the pembrolizumab group, and a decline (LS mean = -2.88 points [95% CI: 6.46, 0.69]) in the SOC group. The difference in LS means between pembrolizumab and the SOC group at Week 18 was 7.38 points (95% CI: 2.82, 11.93; two-sided nominal p=0.0016, not adjusted for multiplicity), a clinically important difference. For the EQ-5D utility score, the mean change from baseline to Week 18 showed improvement (LS mean = 0.04 points [95% CI: 0.00, 0.08]) in the pembrolizumab group, and a decline (LS mean = -0.01 points [95% CI: -0.05, 0.02]) in the SOC group, although the difference was not clinically meaningful (difference in LS means = 0.05; 95% CI: 0.00, 0.10; two-sided nominal p=0.0311, not adjusted for multiplicity).

## Symptom Scale

<div style=\"page-break-after: always\"></div>

## Ancillary analyses (pre-specified)

## Sensitivity analyses for PFS

- -Sensitivity analysis using time to disease recurrence after curative-intent surgery: because some patients received surgery with curative intent (9.2% in the pembrolizumab group and 8.4% in the SOC group), a PFS sensitivity analysis (defined as PFS using time from randomization to disease recurrence after surgery for surgical participants) was performed: PFS HR= 0.60, 95%CI 0.45, 0.80.
- -PFS sensitivity analysis 1 (censors at the last disease assessment without PD when PD or death is documented after &gt;1 missed disease assessment): PFS HR=0.62, 95%CI 0.46, 0.84.
- -PFS sensitivity analysis 2 (considers discontinuation of treatment or initiation of an anticancer treatment subsequent to discontinuation of study-specified treatments, whichever occurs later, to be a PD event for participants without documented PD or death): PFS HR=0.61, 95%CI 0.48, 0.79.

## Sensitivity analysis for OS - adjustment for crossover

Sensitivity analyses were carried out to assess the impact of crossover on overall survival. Subjects in SOC arm who initiated subsequent anti-PD1/PDL1 treatment include those who crossed over from SOC to Pembrolizumab (n=56) and those who did not cross over but received subsequent anti-PD1/PDL1 treatment (n=35).

- inverse probability of censoring weighting model (IPCW): OS HR = 0.54 (95% CI: 0.27, 1.39)
- rank preserving structural failure time model (RPSFT): OS HR = 0.72 (95% CI: 0.47, 1.11)

## Subgroup analyses

## Figure: Analysis of Progression-Free Survival by Subgroup Factors By Central Imaging Vendor per RECIST 1.1 (ITT Population)

<!-- image -->

|                              |                                 | # event/N     | # event/N   | Median (Months)   | Median (Months)   | HR   | 95% CI       |     |                             |
|------------------------------|---------------------------------|---------------|-------------|-------------------|-------------------|------|--------------|-----|-----------------------------|
|                              |                                 | Pembrolizumab | SOC         | Pembrolizumab     | SOC               |      |              |     |                             |
| Overall                      |                                 | 82/153        | 113/154     | 16.5              | 8.2               | 0.60 | (0.45, 0.80) |     |                             |
| Age                          |                                 |               |             |                   |                   |      |              |     |                             |
|                              | <= 70 years                     | 51/105        | 81/112      | 28.8              | 10.2              | 0.52 | (0.37, 0.75) |     |                             |
|                              | > 70 years                      | 31/48         | 32/42       | 6.1               | 6.3               | 0.77 | (0.46, 1.27) |     |                             |
| Gender                       |                                 |               |             |                   |                   |      |              |     |                             |
|                              | Male                            | 35/71         | 56/82       | 28.8              | 10.6              | 0.59 | (0.38, 0.90) |     |                             |
|                              | Female                          | 47/82         | 57/72       | 12.5              | 5.2               | 0.58 | (0.39, 0.87) |     |                             |
| ECOG                         |                                 |               |             |                   |                   |      |              |     |                             |
|                              | 0                               | 29/75         | 61/84       | NR                | 9.1               | 0.37 | (0.24, 0.59) |     |                             |
|                              | 1                               | 53/78         | 52/70       | 4.3               | 6.3               | 0.84 | (0.57, 1.24) |     |                             |
| GeographicRegion             |                                 |               |             |                   |                   |      |              |     |                             |
|                              | Asia                            | 10/22         | 18/26       | NR                | 10.4              | 0.65 | (0.30, 1.41) |     |                             |
|                              | Western Europe/North America    | 61/109        | 85/113      | 12.5              | 8.1               | 0.62 | (0.44, 0.87) |     |                             |
|                              | Rest of World                   | 11/22         | 10/15       | 31.6              | 6.1               | 0.40 | (0.16, 0.98) |     |                             |
| Metastases                   |                                 |               |             |                   |                   |      |              |     |                             |
|                              | Hepatic metastases              | 35/50         | 33/39       | 4.8               | 6.2               | 0.76 | (0.47, 1.24) |     |                             |
|                              | Pulmonary metastases            | 9/15          | 12/19       | 2.6               | 10.9              | 1.02 | (0.42, 2.46) |     |                             |
|                              | Hepatic andpulmonary metastases | 16/21         | 15/15       | 2.2               | 6.1               | 1.18 | (0.58, 2.41) |     |                             |
|                              | Other metastases                | 22/67         | 53/81       | NR                | 9.0               | 0.30 | (0.18, 0.50) |     |                             |
| Diagnosis                    |                                 |               |             |                   |                   |      |              |     |                             |
|                              | Recurrent                       | 37/80         | 50/74       | 31.6              | 10.6              | 0.53 | (0.34, 0.82) |     |                             |
|                              | Newly diagnosed stage IV CRC    | 45/73         | 63/80       | 6.0               | 5.9               | 0.70 | (0.47, 1.04) |     |                             |
| BRAF                         |                                 |               |             |                   |                   |      |              |     |                             |
|                              | BRAF/KRAS /NRASall Wildtype     | 13/34         | 28/35       | NR                | 10.2              | 0.28 | (0.14, 0.55) |     |                             |
|                              | BRAFV600E                       | 18/34         | 33/43       | 14.5              | 6.2               | 0.48 | (0.27, 0.86) |     |                             |
| KRAS/NRAS                    |                                 |               |             |                   |                   |      |              |     |                             |
|                              | BRAF/KRAS /NRASall Wildtype     | 13/34         | 28/35       | NR                | 10.2              | 0.28 | (0.14, 0.55) |     |                             |
|                              | KRASor NRASMutant               | 23/33         | 28/41       | 4.0               | 10.4              | 1.19 | (0.68, 2.07) |     |                             |
| Site of Primary Tumor (Right | vs. Left)                       |               |             |                   |                   |      |              |     |                             |
|                              | Right                           | 53/102        | 84/107      | 16.5              | 8.1               | 0.54 | (0.38, 0.77) |     |                             |
|                              | Left                            | 26/46         | 24/42       | 17.3              | 10.3              | 0.81 | (0.46, 1.43) |     |                             |
|                              |                                 |               |             |                   |                   |      |              |     | 1 10                        |
|                              |                                 |               |             |                   |                   |      |              | 0.1 | Estimated Hazard Ratio (HR) |

<div style=\"page-break-after: always\"></div>

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate. Database Cutoff Date: 19FEB2020.

Table: Analysis of Overall Survival by Subgroup Factors (ITT Population)

<!-- image -->

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate. Database Cutoff Date: 19FEB2020.

Efficacy data according to site of metastases

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Efficacy data according to mutational status

## BRAF/KRAS/NRAS All Wild Type (34 vs 35 patients)

<!-- image -->

<!-- image -->

## KRAS/NRAS Mutant (33 vs 41 patients)

PFS (HR 1.19, 95%CI 0.68, 2.07)

ORR: 30.3% vs 26.8%

<!-- image -->

OS (0.89, 95%CI 0.45, 1.55)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Efficacy results in patients with Lynch syndrome (28 vs 36 patients):

PFS: HR 0.57 (95% CI: 0.27, 1.20)

OS: HR 0.42 (95% CI: 0.15, 1.17)

ORR: 46.4% (27.5, 66.1) vs 33.3% (18.6, 51.0)

## Multivariate Cox Regression analysis of PFS

A multivariate Cox regression analysis of PFS was performed to further investigate potential covariates of prognostic interest in CRC. Two-sided p-values of &lt;0.05 were observed for treatment by ECOG interaction and treatment by KRAS/NRAS status interaction. Multivariate Cox regression analysis was adjusted for ECOG, KRAS/NRAS status, treatment by ECOG interaction and treatment by KRAS/NRAS status interaction. The results of this analysis may suggest evidence of an interaction effect. However,

<div style=\"page-break-after: always\"></div>

this analysis was not prespecified or adjusted for multiplicity and is underpowered due to the small sample size among participants with known KRAS/NRAS mutations (N = 74), as well as the fraction of the study population (29% of participants) whose KRAS/NRAS results were either undetermined or missing.

Table: Summary of Multivariate Cox Regression Analysis for Progression-Free Survival By Central Imaging Vendor per RECIST 1.1 (ITT Population)

| Parameter                                                                                                                     | p-Value â¡   |
|-------------------------------------------------------------------------------------------------------------------------------|-------------|
| Treatment                                                                                                                     |             |
| Pembrolizumab vs. SOC (reference)                                                                                             | 0.8439      |
| Age: <= 70 years vs. > 70 years (reference)                                                                                   | 0.6719      |
| Treatment * Age                                                                                                               | 0.0958      |
| ECOG: 0 vs. 1 (reference)                                                                                                     | 0.8471      |
| Treatment * ECOG                                                                                                              | 0.0200      |
| BRAF Status: BRAF V600E vs. Other â  (reference)                                                                               | 0.3260      |
| Treatment * BRAF Status                                                                                                       | 0.2222      |
| KRAS/NRAS Status: KRAS/NRAS Mutant vs. Other Â¶ (reference)                                                                    | 0.1522      |
| Treatment * KRAS/NRAS Status                                                                                                  | 0.0018      |
| Baseline CEA: <= Median vs. > Median (reference)                                                                              | 0.2086      |
| Treatment * Baseline CEA                                                                                                      | 0.3270      |
| Baseline Tumour Size: <= Median vs. > Median (reference)                                                                      | 0.1403      |
| Treatment * Baseline Tumour Size                                                                                              | 0.1080      |
| Metastases: Hepatic Metastases vs. Pulmonary Metastases vs. Hepatic and Pulmonary Metastases vs. Other Metastases (reference) | 0.5173      |
| Treatment * Metastases                                                                                                        | 0.2106      |

â   Other includes BRAF status of wild type, undetermined, missing or non-V600E mutation.

Â¶ Other includes KRAS and/or NRAS wild type, undetermined or missing, i.e., all subjects whose KRAS and NRAS are not mutant.

â¡  Based on multivariate Cox regression model with treatment, age, ECOG, BRAF status, KRAS/NRAS status, baseline CEA, baseline tumour size, metastases, treatment by age, ECOG, BRAF status,

KRAS/NRAS status, baseline CEA, baseline tumour size and metastases interactions as covariates. Two-sided p-value based on joint test.

CEA: Carcinoembryonic Antigen

Database Cutoff Date: 19FEB2020.

## Table: Multivariate Cox Regression Analysis for Progression-Free Survival By Central Imaging Vendor per RECIST 1.1 (ITT Population)

| Parameter                                                                     | Hazard Ratio â¡ (95% CI) â¡   | p-Value â¡   |
|-------------------------------------------------------------------------------|-----------------------------|-------------|
| Treatment                                                                     |                             |             |
| Pembrolizumab vs. SOC (reference)                                             |                             | 0.0321      |
| ECOG: 0 vs. 1 (reference)                                                     |                             | 0.2334      |
| KRAS/NRAS Status: KRAS/NRAS Mutant vs. Other Â¶ (reference)                    |                             | 0.1559      |
| Treatment * ECOG                                                              |                             | 0.0362      |
| Treatment * KRAS/NRAS Status                                                  |                             | 0.0069      |
| Pembrolizumab vs. SOC for Subjects with ECOG = 0 and KRAS/NRAS Mutant         | 0.81 (0.42, 1.58)           |             |
| Pembrolizumab vs. SOC for Subjects with ECOG = 0 and KRAS/NRAS Status = Other | 0.33 (0.21, 0.53)           |             |
| Pembrolizumab vs. SOC for Subjects with ECOG = 1 and KRAS/NRAS Mutant         | 1.52 (0.84, 2.76)           |             |
| Pembrolizumab vs. SOC for Subjects with ECOG = 1 and KRAS/NRAS Status = Other | 0.62 (0.40, 0.96)           |             |

<div style=\"page-break-after: always\"></div>

- Â¶  Other includes KRAS and/or NRAS wild type, undetermined or missing, i.e., all subjects whose KRAS and NRAS are not mutant.
- â¡  Based on multivariate Cox regression model with treatment, ECOG, KRAS/NRAS status, treatment by ECOG, KRAS/NRAS status interactions as covariates. Two-sided p-value based on joint test.

Database Cutoff Date: 19FEB2020.

## Analysis of the first part of the OS curves

Figure 5 SmoothedHazardRateEstimatesforOverallSurvival (ITT Population)

<!-- image -->

DatabaseCutoffDate:19FEB2020.

Source:[P177V01MK3475:adam-adsl;adtte]

Table 15 Piecewise Hazard Ratios for Overall Survival (ITT Population)

|                                | Pembrolizumab (N=153)          | Pembrolizumab (N=153)          | SOC (N=154)                    | SOC (N=154)                    |                                |
|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Month                          | Event                          | Rate                           | Event                          | Rate                           | Hazard Ratio                   |
| 4                              | 19                             | 0.033                          | 13                             | 0.022                          | 1.49                           |
| 4-8                            | 11                             | 0.022                          | 16                             | 0.031                          | 0.69                           |
| >8                             | 26                             | 0.010                          | 40                             | 0.017                          | 0.56                           |
| Database Cutoff Date:19FEB2020 | Database Cutoff Date:19FEB2020 | Database Cutoff Date:19FEB2020 | Database Cutoff Date:19FEB2020 | Database Cutoff Date:19FEB2020 | Database Cutoff Date:19FEB2020 |

Baseline characteristics of the 32 participants (19 in the pembrolizumab group and 13 in the SOC group) with early OS events within the first 4 months are provided in the table below:

Table: Subject Characteristics (ITT Population with Early OS Events)

|                        | Pembrolizumab   | Pembrolizumab   | SOC   | SOC    | Total   | Total   |
|------------------------|-----------------|-----------------|-------|--------|---------|---------|
|                        | n               | (%)             | n     | (%)    | n       | (%)     |
| Subjects in population | 19              |                 | 13    |        | 32      |         |
| Gender                 |                 |                 |       |        |         |         |
| Male                   | 9               | (47.4)          | 6     | (46.2) | 15      | (46.9)  |
| Female                 | 10              | (52.6)          | 7     | (53.8) | 17      | (53.1)  |
| Age (Years)            |                 |                 |       |        |         |         |
| <65                    | 6               | (31.6)          | 7     | (53.8) | 13      | (40.6)  |

32

15

17

13

<div style=\"page-break-after: always\"></div>

19

32

67.3

13.5

68.0

28 to 87

18

14

3

28

1

1

27

2

2

3

25

4

5

27

20

10

1

1

21

11

7

25

8

24

3

1

28

3

| >=65                         | 13       | (68.4)   | 6        | (46.2)   | 19       | (59.4)   |
|------------------------------|----------|----------|----------|----------|----------|----------|
| Subjects with data           | 19       |          | 13       |          | 32       |          |
| Mean                         | 68.5     |          | 65.6     |          | 67.3     |          |
| SD                           | 13.3     |          | 14.0     |          | 13.5     |          |
| Median                       | 71.0     |          | 63.0     |          | 68.0     |          |
| Range                        | 28 to 85 |          | 39 to 87 |          | 28 to 87 |          |
| Age (Years)                  |          |          |          |          |          |          |
| <=70                         | 9        | (47.4)   | 9        | (69.2)   | 18       | (56.3)   |
| >70                          | 10       | (52.6)   | 4        | (30.8)   | 14       | (43.8)   |
| Race                         |          |          |          |          |          |          |
| ASIAN                        | 2        | (10.5)   | 1        | (7.7)    | 3        | (9.4)    |
| WHITE                        | 16       | (84.2)   | 12       | (92.3)   | 28       | (87.5)   |
| Missing                      | 1        | (5.3)    | 0        | (0.0)    | 1        | (3.1)    |
| Ethnicity                    |          |          |          |          |          |          |
| HISPANIC OR LATINO           | 0        | (0.0)    | 1        | (7.7)    | 1        | (3.1)    |
| NOT HISPANIC OR LATINO       | 15       | (78.9)   | 12       | (92.3)   | 27       | (84.4)   |
| NOT REPORTED                 | 2        | (10.5)   | 0        | (0.0)    | 2        | (6.3)    |
| UNKNOWN                      | 2        | (10.5)   | 0        | (0.0)    | 2        | (6.3)    |
| Geographic Region            |          |          |          |          |          |          |
| Asia                         | 2        | (10.5)   | 1        | (7.7)    | 3        | (9.4)    |
| Western Europe/North America | 14       | (73.7)   | 11       | (84.6)   | 25       | (78.1)   |
| Rest of World                | 3        | (15.8)   | 1        | (7.7)    | 4        | (12.5)   |
| ECOG                         |          |          |          |          |          |          |
| 0                            | 2        | (10.5)   | 3        | (23.1)   | 5        | (15.6)   |
| 1                            | 17       | (89.5)   | 10       | (76.9)   | 27       | (84.4)   |
| Site of Primary Tumour *     |          |          |          |          |          |          |
| Right                        | 11       | (57.9)   | 9        | (69.2)   | 20       | (62.5)   |
| Left                         | 6        | (31.6)   | 4        | (30.8)   | 10       | (31.3)   |
| Other                        | 1        | (5.3)    | 0        | (0.0)    | 1        | (3.1)    |
| Missing                      | 1        | (5.3)    | 0        | (0.0)    | 1        | (3.1)    |
| Metastases Location          |          |          |          |          |          |          |
| Hepatic or pulmonary         | 16       | (84.2)   | 5        | (38.5)   | 21       | (65.6)   |
| Other Metastases             | 3        | (15.8)   | 8        | (61.5)   | 11       | (34.4)   |
| Metastases Location          |          |          |          |          |          |          |
| Pulmonary                    | 6        | (31.6)   | 1        | (7.7)    | 7        | (21.9)   |
| Other                        | 13       | (68.4)   | 12       | (92.3)   | 25       | (78.1)   |
| Diagnosed Stage              |          |          |          |          |          |          |
| Recurrent                    | 5        | (26.3)   | 3        | (23.1)   | 8        | (25.0)   |
| Newly diagnosed stage        | 14       | (73.7)   | 10       | (76.9)   | 24       | (75.0)   |
| Prior Systemic Therapy       |          |          |          |          |          |          |
| Adjuvant only                | 2        | (10.5)   | 1        | (7.7)    | 3        | (9.4)    |
| Neoadjuvant and adjuvant     | 0        | (0.0)    | 1        | (7.7)    | 1        | (3.1)    |
| None                         | 17       | (89.5)   | 11       | (84.6)   | 28       | (87.5)   |
| Mutation Status **           |          |          |          |          |          |          |
| BRAF/KRAS/NRAS all wild type | 1        | (5.3)    | 2        | (15.4)   | 3        | (9.4)    |

<div style=\"page-break-after: always\"></div>

5

10

2

12

32

32

1

31

8

24

8

21

3

| KRAS/NRAS mutant and BRAF V600E not mutant    | 3                                         | (15.8)   | 2   | (15.4)   | 5   | (15.6)   |
|-----------------------------------------------|-------------------------------------------|----------|-----|----------|-----|----------|
| BRAF V600E mutant and KRAS/NRAS not mutant    | 7                                         | (36.8)   | 3   | (23.1)   | 10  | (31.3)   |
| BRAF V600E and KRAS/NRAS mutant               | 0                                         | (0.0)    | 2   | (15.4)   | 2   | (6.3)    |
| Other                                         | 8                                         | (42.1)   | 4   | (30.8)   | 12  | (37.5)   |
| MSI-High Status #                             |                                           |          |     |          |     |          |
| Positive                                      | 19                                        | (100.0)  | 13  | (100.0)  | 32  | (100.0)  |
| Oncologic Surgery with Curative Intent ##     | Oncologic Surgery with Curative Intent ## |          |     |          |     |          |
| Did not receive surgery with curative- intent | 19                                        | (100.0)  | 13  | (100.0)  | 32  | (100.0)  |
| Prior Radiation Therapy                       |                                           |          |     |          |     |          |
| Yes                                           | 1                                         | (5.3)    | 0   | (0.0)    | 1   | (3.1)    |
| No                                            | 18                                        | (94.7)   | 13  | (100.0)  | 31  | (96.9)   |
| Sum of IRC Target Lesions at Baseline ###     |                                           |          |     |          |     |          |
| <= Median                                     | 4                                         | (21.1)   | 4   | (30.8)   | 8   | (25.0)   |
| > Median                                      | 15                                        | (78.9)   | 9   | (69.2)   | 24  | (75.0)   |
| Baseline CEA Group                            |                                           |          |     |          |     |          |
| N                                             | 3                                         | (15.8)   | 5   | (38.5)   | 8   | (25.0)   |
| H                                             | 15                                        | (78.9)   | 6   | (46.2)   | 21  | (65.6)   |
| Missing                                       | 1                                         | (5.3)    | 2   | (15.4)   | 3   | (9.4)    |

Database Cutoff Date: 19FEB2020.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 1. Summary of Efficacy for trial Keynote-177

| Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy I Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)   | Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy I Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)   | Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy I Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                 | EudraCT: 2015-002024-89; IND: 123,482                                                                                                                                                            | EudraCT: 2015-002024-89; IND: 123,482                                                                                                                                                            |
| Design                                                                                                                                                                                           | Phase 3, two-arm, multicenter, international, randomized, open-label, controlled study                                                                                                           | Phase 3, two-arm, multicenter, international, randomized, open-label, controlled study                                                                                                           |
|                                                                                                                                                                                                  | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                   | FPFV 30 Nov 2015. Study ongoing. NA NA                                                                                                                                                           |
| Hypothesis                                                                                                                                                                                       | Superiority                                                                                                                                                                                      | Superiority                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

Treatments groups

Endpoints and definitions

Data cut-off

Pembrolizumab (n=153)

SOC (Investigator's choice)

(n=154)

Dual Primary endpoint

Dual primary endpoint

Secondary endpoint

Exploratory endpoints

19 Feb 2020

Database lock

16 Mar 2020

## Results and Analysis

| Analysis description                            | Interim analysis 2 (i.e. final analysis for PFS, interim analysis for OS)                                                                                                                                                 | Interim analysis 2 (i.e. final analysis for PFS, interim analysis for OS)                                                                                                                                                 | Interim analysis 2 (i.e. final analysis for PFS, interim analysis for OS)                                                                                                                                                 |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | Intent to treat                                                                                                                                                                                                           | Intent to treat                                                                                                                                                                                                           | Intent to treat                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                           | Pembrolizumab                                                                                                                                                                                                             | SOC                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                                                         | 153                                                                                                                                                                                                                       | 154                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | PFS (median in months)                                                                                                                                                                                                    | 16.5                                                                                                                                                                                                                      | 8.2                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 95%CI                                                                                                                                                                                                                     | (5.4, 32.4)                                                                                                                                                                                                               | (6.1, 10.2)                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | OS (median in months)                                                                                                                                                                                                     | NR                                                                                                                                                                                                                        | 34.8                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95%CI                                                                                                                                                                                                                     | NR, NR                                                                                                                                                                                                                    | (26.3, NR)                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | ORR                                                                                                                                                                                                                       | 43.8%                                                                                                                                                                                                                     | 33.1%                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | 95%CI                                                                                                                                                                                                                     | (35.8, 52.0)                                                                                                                                                                                                              | (25.8, 41.1)                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | DOR (median in months)                                                                                                                                                                                                    | NR                                                                                                                                                                                                                        | 10.6                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | range                                                                                                                                                                                                                     | (2.3+ - 41.4+)                                                                                                                                                                                                            | (2.8 - 37.5+)                                                                                                                                                                                                             |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                     | Pembrolizumab vs SOC                                                                                                                                                                                                      | PFS                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                     | HR                                                                                                                                                                                                                        | 0.60                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                     | 95%CI                                                                                                                                                                                                                     | (0.45, 0.80)                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                   | 0.0002                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                     | Pembrolizumab vs SOC                                                                                                                                                                                                      | OS                                                                                                                                                                                                                        |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                     | HR                                                                                                                                                                                                                        | 0.77                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                     | 95%CI                                                                                                                                                                                                                     | (0.54, 1.09)                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                   | 0.0694                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | Key Secondary endpoint                                                                                                                                                                                                    | Pembrolizumab vs SOC                                                                                                                                                                                                      | ORR                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | Key Secondary endpoint                                                                                                                                                                                                    | Difference in%                                                                                                                                                                                                            | 10.7                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | Key Secondary endpoint                                                                                                                                                                                                    | 95%CI                                                                                                                                                                                                                     | (-0.2,21.3)                                                                                                                                                                                                               |
| Effect estimate per comparison                  | Key Secondary endpoint                                                                                                                                                                                                    | P-value                                                                                                                                                                                                                   | 0.0275                                                                                                                                                                                                                    |
| Notes                                           | Dual primary endpoints: at the IA2, PFS was statistically significant; OS did not reach statistical significance. Secondary endpoint (included in the multiplicity strategy): ORR did not reach statistical significance. | Dual primary endpoints: at the IA2, PFS was statistically significant; OS did not reach statistical significance. Secondary endpoint (included in the multiplicity strategy): ORR did not reach statistical significance. | Dual primary endpoints: at the IA2, PFS was statistically significant; OS did not reach statistical significance. Secondary endpoint (included in the multiplicity strategy): ORR did not reach statistical significance. |

PFS (per

RECIST 1.1 by

BICR)

OS

ORR

PFS2, DOR,

PRO (etc)

200 mg IV Q3W

mFOLFOX6

mFOLFOX6+bevacizumab mFOLFOX6+cetuximab

FOLFIRI

FOLFIRI+bevacizumab

FOLFIRI+cetuximab

Time from randomization to the first documented disease progression per RECIST

1.1 based on blinded central imaging vendor review or death due to any cause, whichever

occurs first.

Time from randomization to death due to any cause.

Per RECIST 1.1 by BICR (confirmed CR/PR)

<div style=\"page-break-after: always\"></div>

## Analysis performed across trials (pooled analyses and meta-analysis)

N/A

## Clinical studies in special populations

Age

## Table: Efficacy Results by Age Categories (ITT Population)

| Endpoint   | Age Category                                 | N (Pembrolizumab, SOC)    | Number of Events (OS and PFS) or Number of Objective Responses (ORR) (Pembrolizumab (%), SOC (%))   | Hazard Ratio (95% CI) â  (OS and PFS) or Difference in %(95% CI) â¡ (ORR) for Pembrolizumab vs. SOC   |
|------------|----------------------------------------------|---------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| PFS        | <65 years 65-74 years 75-84 years >=85 years | 80, 83 43, 40 22, 24 8, 7 | 35 (43.8), 59 (71.1) 27 (62.8), 32 (80.0) 15 (68.2), 18 (75.0) 5 (62.5), 4 (57.1)                   | 0.46 (0.30, 0.71) 0.63 (0.38, 1.06) 1.00 (0.50, 2.00) 0.91 (0.24, 3.40)                             |
| OS         | <65 years 65-74 years 75-84 years >=85 years | 80, 83 43, 40 22, 24 8, 7 | 20 (25.0), 34 (41.0) 20 (46.5), 17 (42.5) 12 (54.5), 14 (58.3) 4 (50.0), 4 (57.1)                   | 0.53 (0.31, 0.93) 1.19 (0.63, 2.28) 0.90 (0.41, 1.94) 0.78 (0.19, 3.11)                             |
| ORR        | <65 years 65-74 years 75-84 years >=85 years | 80, 83 43, 40 22, 24 8, 7 | 39 (48.8), 25 (30.1) 18 (41.9), 15 (37.5) 6 (27.3), 9 (37.5) 4 (50.0), 2 (28.6)                     | 18.63 (3.60, 32.90) 4.36 (-16.64, 24.88) -10.23 (-35.98, 17.21) 21.43 (-28.51, 61.77)               |

Database Cutoff Date: 19FEB2020

Table 24 Efficacy Results by Age Categories (ITT Population)

| Endpoint   | Age Category (years)   | N (Pembrolizumab,SOC)      | Number of Events (OS and PFS) or Number of Objective Responses (ORR) (Pembrolizumab (%), SOC (%)   | Hazard Ratio (95% CI)t (OS and PFS) Pembrolizumab vs.SOC                |
|------------|------------------------|----------------------------|----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| PFS        | â¤65 >65 â¤75 >75        | 80,88 73,66 130, 127 23,27 | 35 (43.8), 63 (71.6) 47 (64.4), 50 (75.8) 67 (51.5), 95 (74.8) 15 (65.2), 18 (66.7)                | 0.47 (0.30, 0.71) 0.73 (0.49, 1.10) 0.54 (0.39, 0.74) 1.01 (0.51, 2.02) |
| OS         | â¤65 >65 â¤75 >75        | 80,88 73,66 130, 127 23,27 | 20 (25.0), 36 (40.9) 36 (49.3), 33 (50.0) 43 (33.1), 54 (42.5) 13 (56.5), 15 (55.6)                | 0.54 (0.31, 0.93) 0.99 (0.62, 1.58) 0.73 (0.49, 1.08) 1.03 (0.49, 2.16) |
| ORR        | â¤65 >65 â¤75 >75        | 80,88 73,66 130,127 23,27  | 39 (48.8), 26 (29.5) 28 (38.4), 25 (37.9) 59 (45.4), 42 (33.1) 8 (34.8), 9 (33.3)                  | N/A N/A N/A N/A                                                         |

Source: [Appendix 49] through [Appendix 68]

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Supportive study(ies)

N/A

The MAH included in the dossier (but not presented as supportive) the CSR of KEYNOTE-164, a phase II single arm study of pembrolizumab in subjects with previously treated dMMR or MSI-H CRC, which included overall 124 adult, of whom 61 in Cohort A (patients previously treated with at least 2 lines of standard of care therapies), and 63 in Cohort B (patients previously treated with at least 1 line of systemic standard of care therapy). ORR per RECIST by IRC was the primary endpoint. Treatment with pembrolizumab resulted in an ORR of 32.8% (95%CI 21.3, 46) for Cohort A and 34.9% (95%CI 23.3, 48) for Cohort B, with 4.9% and 12.7% of complete responses in Cohort A and B, respectively With a median follow-up time of 31.4 months for Cohort A and 36.1 months for Cohort B, the median DOR was not reached in either cohort. 95% of responding patients have a response lasting â¥ 12 months.

Of note, although advanced unresectable disease was formally included in KEYNOTE-164, according to baseline characteristics 100% of the patients had Stage IV mCRC (Cohort A and B).

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical efficacy

The MAH is seeking an extension of indication for Keytruda (pembrolizumab) as monotherapy for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal carcinoma in adults, based on the results of the pivotal KEYNOTE-177 study , an ongoing phase 3 open-label randomized (1:1) study of pembrolizumab vs investigator's choice SOC chemotherapy. Patients in the SOC arm had the option to crossover to pembrolizumab at BICR-confirmed radiographic PD.

## Design and conduct of clinical studies

The randomized 1:1 active controlled design of KEYNOTE-177 study is acceptable. The open label design is acknowledged in view of the marked differences of the treatments in the two arms.

The inclusion/exclusion criteria are considered overall appropriate to define the target population, although mostly reflecting relatively fit patients (ECOG 0-1). Patients with ECOG 2/3 account for more than 30% of the mCRC patients. In MSI-H/dMMR this proportion seems to be even higher (AasebÃ¸ et al. 2019). Information that only patients with ECOG 0 or 1 were enrolled is however included in the SmPC.

The population proposed to be included in the initially sought indication was 'unresectable or metastatic', although only patients with stage IV disease (i.e. metastatic) were included in KEYNOTE-177. During the procedure,  the  indication  was  updated  to  include  'metastatic'  patients  only,  reflecting  the  population treated in the study.

Inclusion was based on locally determined MSI/MMR testing by PCR or ICH, respectively, which is considered acceptable in general, taking into account that testing is already recommended by international guidelines in routine clinical practice and the acceptable concordance between PCR and IHC. In KEYNOTE-177 only 16 MSI-H tumours were detected via PCR. IHC testing was used for the majority of participants (105 pembrolizumab, 97 SOC) with far fewer participants assessed using PCR (16 participants in each treatment group) or PCR and IHC (32 pembrolizumab, 40 SOC); therefore, considering the differences in the number of participants within each group, caution should be used when comparing across groups. Data provided for PCR detected (MSI-H) tumours are too limited to draw conclusions but given the reported data it could be that PCR-test with a 3 poly-A panel used in this study is not adequate in terms of specificity to detect MSI-H tumours. However, this is considered to be not clinically relevant in this specific indication due to the predominant use of IHC test in CRC.

The comparator arm consisted of an investigator's choice treatment (chosen before randomization) among 6 different polychemotherapy regimens, each acceptable as 1L regimen: 45% of the patients received mFOLFOX6+bevacizumab, followed by FOLFIRI+bevacizumab (25%), less than 20% of subjects received chemotherapy alone, and about 11% was treated with chemotherapy in combination with cetuximab. A consistent OS and PFS benefit of pembrolizumab vs each SOC (alone or grouped) was generally observed when analysed separately. Data for FOLFIRI/FOLFOX6 and cetuximab are too limited to draw any conclusion, nevertheless, contrary to worse OS, PFS was in favour of pembrolizumab. Further, due to the favourable safety profile of the pembrolizumab monotherapy, the use of several different regimen does not raise relevant concern of heterogeneity in the control arm.

The study had PFS per RECIST 1.1 by BICR and OS as dual primary endpoint, i.e. the study was considered to have met its primary objective if pembrolizumab is superior to SOC chemotherapies in either of the 2 primary endpoints. ORR was a secondary endpoint, and PFS2 and DOR among the exploratory endpoint. The use of central imaging review is endorsed in view of the open-label design.

A justification for the assumptions made for median PFS (10 months) and median OS (24 months) in the control arm, which the sample size calculation was based on, has not been found, although it seems

<div style=\"page-break-after: always\"></div>

congruent with the available historical data of chemotherapy in 1L CRC setting. Overall, statistical methods appeared standard and not controversial.

The timing of the interim analyses was postponed several times. The MAH explained that the reason for postponing interim analysis 2 in amendment 5 by 8 months was motivated by the slow number of PFS events observed after interim analysis 1. The results for the timing defined in Amendment 4 however are consistent with the results of the final Amendment 5, which is reassuring.

While in the original protocol PFS was the solely primary endpoint, OS was upgraded from key secondary to (dual) primary endpoint with Amendment 3 on 20.11.2017, which occurred before enrolment closure (on 19.02.2018) and before IA1 (on 19.10.2018). The MAH stated that revisions occurred to allow for more mature PFS and OS data to account for a potential delayed separation in survival curves observed in immuno-oncology studies, indeed all the study referenced were published before Amendment 3 was released. The argumentation that the changes were implemented solely based on emerging data from other immunotherapy trials outside of KEYNOTE-177 can be therefore followed.

The MAH explained the procedure of IA1, which is acceptable. There seem to be no association between IA1 and the motivation of protocol amendment 5. PFS results are significant for both approaches of pvalue boundaries, the expected and the observed event fraction.

Overall, the rate of protocol deviations was similar in both arms and no concern is raised over possible impact of protocol deviations on efficacy results.

## Efficacy data and additional analyses

A total of 307 patients were randomized to pembrolizumab (n=153) vs SOC arm (n=154). Compared to the  pembrolizumab  arm,  a  higher  number  of  patients  did  not  receive  the  SOC  treatment  assigned  at randomization (0 vs 11 patients) as well as discontinued SOC treatment for subject's or physician's decision (4 vs 23). In this regard, the MAH presented 2 worst-case scenarios for PFS and OS. 34 participants in the SOC arm who were not treated, or withdrawn by physician's decision, or withdrew by participant's choice follow the PFS/OS pattern in the pembrolizumab arm. The results show consistency with the primary PFS and OS analysis.

On  the  contrary,  it  is  noted  that,  apparently  unexpectedly,  a  higher  number  of  patients  in  the pembrolizumab than in the control arm discontinued treatment due to AEs (22 vs 17). However, based on the safety data, this could be related to a longer duration of exposure (see clinical safety).

The MAH presented the results of the 2 nd  interim analysis (i.e. final PFS and interim OS analysis) having data cut-off date of 19-FEB-2020 (24 months after the last subject was randomized), with a median survival follow-up duration of about 28 months.

The baseline characteristics appeared mostly balanced between the two treatment arms, with the exception (differences â¥ 5% between arms) of: gender (male 46.4% vs 54.2%), ECOG (ECOG 0 49% vs 54.5%), hepatic or pulmonary metastases (56.2% vs 47.4%), mutation status (KRAS/NRAS mutations 21.6% vs 26.6%, BRAF V600E 22.2% vs 27.9%), in pembrolizumab vs SOC arm, respectively. It is noted that no stratification factors at randomization were used. It is reassuring that the results of the multivariate cox regression analyses adjusted for unbalanced baseline factors were similar to the overall study results (PFS HR=0.60, OS HR=0.77).  BRAF/KRAS/NRAS mutations were mutually exclusive in almost all tested patients. Unfortunately,  about  30%  of  subjects  had  unknown  mutational  status,  as  this  was  not  mandatory  for enrolment. Tumour burden was more commonly higher than the median in the pembrolizumab arm, which is not expected to have favoured the pembrolizumab arm.

<div style=\"page-break-after: always\"></div>

Per protocol, tissue was not collected in KEYNOTE-177, and therefore, no data are available to permit assessment of PD-L1 expression and TMB scores. The MAH mentioned that expression of PD-L1 was not found to be significantly associated with survival in KEYNOTE-016 study, but the number of patients with PD-L1 data available in this phase II study was very limited (n=30). No data on smoking status have been collected.

Efficacy analyses were carried out in the ITT population. Pembrolizumab showed statistically significant and clinically meaningful improvement in PFS by BICR per RECIST 1.1 (final analysis) compared to SOC, with HR 0.60 (95%CI 0.45, 0.80), p=0.0002. Median PFS was 16.5 (95%CI 5.4, 32.4) vs 8.2 (95%CI 6.1, 10.2) months. PFS events occurred in 53.6% vs 73.5% of subjects in pembrolizumab vs SOC arm. The pembrolizumab PFS KM curve is slightly below/overlap the SOC one, but after month 6 the two curves demonstrate an increasingly pronounced separation (PFS rate at 12 months 55.3% vs 37.3%, PFS rate at 24 months 48.3% vs 18.6%). Censoring from month 22-24 preclude the interpretation of the tail of the curve. PFS sensitivity analyses were consistent with the primary analysis result. Overall, the PFS benefit of pembrolizumab over SOC can be considered clinically relevant.

On the contrary, OS (interim analysis) was not statistically significant, although a trend toward a survival advantage for pembrolizumab over SOC is noted: HR 0.77 (95%CI 0.54, 1.09), p=0.0694. Number of OS events were 36.6% vs 44.8% in pembrolizumab vs SOC arm, respectively, which is considered a reasonable maturity. Curves are however no more interpretable after 24 months due to high rate of censoring. Median OS was not reached in the pembrolizumab arm, vs 34.8 months (95%CI 26.3, NR) in the control arm, the latter being far higher compared to what originally expected with standard treatments (mOS 24 months). It is acknowledged that the high crossover rate to anti-PD(L)1 in the SOC arm (59%) could be implicated in this observation. Indeed, sensitivity analyses carried out to assess the impact of crossover on OS indicated possibly lower HRs compared to the primary OS analysis. However, no definitive conclusions can be drawn with respect to a possible effect on OS although pembrolizumab is not expected to be associated with a detrimental effect with respect to OS.

As repeatedly observed with anti-PD(L)1 vs chemotherapy, an initial crossing of KM overall survival curves up to month 8 is seen, after that point curves diverge (about 5-10% difference in favour of pembrolizumab arm). Hazard rates were greater in the pembrolizumab arm compared with the SOC arm for the first 4 months. Baseline characteristics of the 32 participants (19 in the pembrolizumab group and 13 in the SOC group) with early OS events within the first 4 months showed the largest difference between treatment groups included presence of hepatic or pulmonary metastases, age over 70 and high baseline CEA value, occurred in a higher proportion of participants in the pembrolizumab group. However, due to the limited number of patients, it is not possible to clearly define one or more characteristics as risk factors of early death with pembrolizumab. Text in the SmPC section 4.4 reporting that 'in KEYNOTE177, the hazard rates for overall survival events were greater for pembrolizumab compared with chemotherapy for the first 4 months of treatment, followed by a long-term survival benefit for pembrolizumab' has been added.

The MAH agreed to include interim OS analysis data in the SmPC and in the EPAR. Final OS analysis for KEYNOTE-177 will be submitted by the MAH (estimated Q3 2021) as Annex II condition to confirm interim OS data.

An advantage in PFS2 further support that pembrolizumab is not expected to be associated with a detrimental effect with respect to subsequent therapies (HR 0.63, 95%CI 0.45, 0.88).

ORR was a key secondary endpoint, adjusted for multiplicity. Statistical significance was not reached, however. ORR was also in favour of pembrolizumab compared to the standard chemotherapy: 43.8% (95% CI: 35.8, 52.0) vs 33.1% (95% CI: 25.8, 41.1), including higher CR rate (11.1% versus 3.9%). On the contrary, pembrolizumab more rarely induced disease stabilization, and progressive disease as best response were more than doubled with pembrolizumab than with chemotherapy (29.4% vs 12.3%).

<div style=\"page-break-after: always\"></div>

Withdrawal from study treatment was the main cause of the higher number of patients in the SOC compared to pembrolizumab arm not having the first radiological assessment.

By looking at the waterfall plot, it seems that the maximum target lesion change (both tumour increase and reduction) is more pronounced with pembrolizumab. Patients who responded to pembrolizumab have generally long duration of response (median DOR not reached in the pembrolizumab group vs 10.6 months in the SOC group), as also shown by a relevant proportion of patients who responded to pembrolizumab reaching DOR â¥ 12 months (85.1% vs 43.8%). As observed in other indications, pembrolizumab seems to induce prolonged and deep responses in patients who responded, but if patients did not respond the disease is rarely controlled and patient progress, which is also probably also linked to the early crossing of the KM OS/PFS curves.

Patients were allowed to undergo resection of primary tumour or metastases with curative intent if deemed eligible after responding to treatment. The possibility to be treated with curative intent after systemic treatment-induced response is considered clinically relevant as this can result in long term survival. The MAH clarified that a total of 13 patients underwent curative surgery in the SOC arm, vs 14 patients in the pembrolizumab arm. It is concluded that, despite a higher objective response rate and apparently deeper response achieved in the pembrolizumab arm compared to SOC, disappointingly the possibility to undergo curative surgery with pembrolizumab treatment did not seem to increase.

No significant deterioration in health status is observed with pembrolizumab, with a trend toward improvement in QoL and most of the functioning and symptoms score compared to SOC. Overall, PRO data are supporting the benefit of pembrolizumab over the chemotherapy regimens in KEYNOTE-177 study in terms of efficacy and safety. However, the open-label design of the study and the lack of multiplicity control does not allowt upholding formal superiority claims. PROs data have not been included in the SmPC.

Subgroup analyses showed overall consistent results with the exception of subgroups by metastatic sites and mutational status.

Based upon ad-hoc exploratory sub-group analyses, patients with hepatic and/or pulmonary metastases seem to achieve less benefit from pembrolizumab vs chemotherapy compared to a clearer advantage in patients with metastases other than hepatic and pulmonary. In particular, this seems to be observed in subjects with lung metastases: as the only site of metastases (15 vs 19, ca. 10% of the randomized patient population (PFS 1.02, OS 1.99), or with other sites (36 vs 34, ca. 23% of patients, PFS 1.13, OS 1.05, ORR 25% vs 41.2%). It is acknowledged that the concern regarding a reduced efficacy in patients with lung metastases is based on a limited dataset of only 34 patients and that conclusions based on this sample size are prone to uncertainties. In view of this, it can be considered acceptable that information on the uncertain benefit for patients with lung metastases are not to be included in the SmPC. Nevertheless, there is a common observation that patients with more advanced disease with high tumour burden may not have sufficient time to respond on immunotherapeutics (20% of the patients with lung metastases died in the first 4 month in KEYNOTE-177). The inclusion of OS KM curves in section 5.1 as well as text in section 4.4 of the SmPC (see above) are considered appropriate.

The benefit of pembrolizumab over SOC seems somewhat more limited in RAS mutant disease compared to wild type tumours. In the subgroup KRAS/NRAS mutant (n=74), no advantage of pembrolizumab over SOC was apparent in PFS (HR 1.19). For OS (HR 0.89) KM curves are overlapping until month 24 (after this point they seem to diverge in favour of pembrolizumab but there are too many censored patients), but no detriment is observed (HR 0.89), and ORR was also similar. Limitations in the interpretation of subgroup analyses are acknowledged, also related to small number of patients in some subgroups, and

<div style=\"page-break-after: always\"></div>

the lack of information on mutational status in 30% of subjects. Further, a multivariate Cox regression analysis of PFS suggested interaction between treatment and RAS status.

Higher tumour burden may confer worse prognosis in line with historical data in mCRC. Benefit of pembrolizumab over chemotherapy was seen regardless of tumour burden but much more pronounced in smaller tumours. Patients with prior radiation therapy seem not to benefit from pembrolizumab monotherapy treatment, but number of patients was too low (11 vs 13) to draw conclusion. Pembrolizumab improved PFS and OS over SOC regardless having or not received prior neoadjuvant treatment.

Heterogeneity has been suggested in MSI-H/dMMR CRC based on MSI aetiology. A benefit of pembrolizumab over SOC is however seen also in the small subgroup of patients with Lynch syndrome.

A trend toward more limited efficacy of pembrolizumab compared to SOC is seen in older patients compared to younger ones (â¤65 vs &gt;65, â¤75 vs &gt;75). For patients over 75 years of age (n=50), pembrolizumab and SOC seems to perform similarly in OS, PFS and ORR. The pembrolizumab safety profile could however represent an advantage over SOC in this aged population (lower incidence of drugrelated AEs, G3-5 AEs, drug-related G3-5 AEs, drug-related SAE and discontinuation due to drug-related SAE is reported in pembrolizumab compared to SOC arm in patients â¥75, see safety section). The MAH has reflected in the SmPC section 4.2 the fact that that a limited number of patients &gt;75 have been included in KN-177 study.

## 2.4.4. Conclusions on the clinical efficacy

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in PFS compared to SOC chemotherapies as first line treatment for patients with metastatic colorectal cancer MSI-H/dMMR in KEYNOTE-177 study. During the procedure, the MAH updated the indication to include 'metastatic' patients only to reflect the studied population. The benefit of pembrolizumab was supported by PFS sensitivity analyses. Although not statistically significant, a trend toward OS advantage in pembrolizumab treated patients, analysed at an interim analysis having a reasonable maturity level, is considered supportive of the PFS results, notwithstanding the crossing of the OS KM curves, as seen in several studies of anti-PD(L)1 antibodies. An advantage in PFS2 further support the data. Increased ORR is seen, although not statistically significant, but CR rate is higher and responses appear durable.

The MAH agreed to submit the final OS analysis for KEYNOTE-177 as part of the final CSR when available (estimated Q3 2021) as an Annex II condition in the Product Information in order to confirm interim OS data.

## 2.5. Clinical safety

## Introduction

Pembrolizumab monotherapy safety data presented in the current submission are from the randomized, controlled, open-label Phase 3 study KEYNOTE-177, which is the pivotal study supporting the intended use of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR CRC. Safety analyses are presented by the treatment group (pembrolizumab vs investigator's choice of SOC chemotherapy, consisting in either mFOLFOX6 or FOLFIRI or respective combinations with bevacizumab or cetuximab) in participant who received treatment (ASaT population, n=153 in pembrolizumab and n=143 in SOC arm,) up to the data cutoff date of 19-FEB-2020. Adverse events were graded according to the NCI CTCAE, version 4.03. AEs were coded using MedDRA Version 22.1.

<div style=\"page-break-after: always\"></div>

In addition, the new pembrolizumab safety data from KEYNOTE-177 have been compared to the established safety profile for pembrolizumab monotherapy from the Reference Safety Dataset. Thus, the following 4 datasets are presented side by side:

1. KEYNOTE-177 Dataset - Pembrolizumab (N=153): Participants with unresectable or metastatic MSIH/dMMR CRC, who received pembrolizumab in KEYNOTE-177.
2. KEYNOTE-177 Dataset - SOC (N=143): Participants with unresectable or metastatic MSI-H/dMMR CRC who received SOC therapy in KEYNOTE-177.
3. Pembrolizumab Monotherapy Reference Safety Dataset (N = 5884): includes participants who received pembrolizumab in the following populations and studies: melanoma (n=2076) in KEYNOTE001, KEYNOTE-002, KEYNOTE-006 and KEYNOTE-054; NSCLC (n=2022) in KEYNOTE-001, KEYNOTE002, KEYNOTE-006, KEYNOTE-010, KEYNOTE-024 and KEYNOTE-42; HNSCC (n=909) in KEYNOTE012, KEYNOTE-040, KEYNOTE-048 and KEYNOTE-055; HL (n=241) in KEYNOTE-013 and KEYNOTE087; Bladder (n=636) in KEYNOTE-045 and KEYNOTE-052. This dataset represents the established safety profile for pembrolizumab.
4. Cumulative Running Pembrolizumab Monotherapy Safety Dataset (N=8098): Cumulative pembrolizumab safety data from all studies reported to a regulatory authority for which a submission occurred at least 6 weeks prior to the database lock date for KEYNOTE-177. Participants from KEYNOTE-177 (pembrolizumab arm), the RSD, and participants treated with pembrolizumab in KEYNOTE-012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial Tract Cancer) and Cohort D (Gastric Cancer), KEYNOTE-013 Cohort 3 (Hodgkin Lymphoma), KEYNOTE-013 Cohort 4A (PMBCL), KEYNOTE017, KEYNOTE-024, KEYNOTE-028 Cohort A4 (Esophageal Cancer), Cohort B4 (Cervical Cancer) and Cohort C1 (SCLC), KEYNOTE-040, KEYNOTE-042, KEYNOTE-045, KEYNOTE-048, KEYNOTE-052, KEYNOTE-054, KEYNOTE-055, KEYNOTE-057, KEYNOTE-059 Cohort 1 (Gastric Cancer), KEYNOTE062, KEYNOTE-087, KEYNOTE-158 Cohort E (Cervical Cancer) and Cohort G (SCLC), KEYNOTE-158 with TMB-H, KEYNOTE-164 Cohort A (CRC), KEYNOTE-170, KEYNOTE-180, KEYNOTE-181, KEYNOTE224, and KEYNOTE-427.

Statistical Methods for Key Safety Analyses: The analysis of safety results followed a tiered approach. 'Tier 1' safety endpoints were subject to inferential testing for statistical significance with p-values and 95% CI provided for between-group comparisons. Other safety parameters were considered Tier 2 or Tier 3. Tier 2 parameters were assessed via point estimates with 95% CI for between-group comparisons; only point estimates by treatment group are provided for Tier 3 safety parameters. There are no Tier 1 events in KEYNOTE-177 study. The between-treatment difference were analyzed using the Miettinen and Nurminen method.

## Patient exposure

## Table: Summary of Drug Exposure (ASaT Population)

|                             | KN177 Data for Pembrolizumab â â  (N=153)   | KN177 Data for SOC Â¶Â¶ (N=143)   | Reference Safety Dataset for Pembrolizumab â¡â¡ (N=5884)   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§ (N=8098)   |
|-----------------------------|-------------------------------------------|---------------------------------|----------------------------------------------------------|-------------------------------------------------------------------|
| Duration on therapy (month) |                                           |                                 |                                                          |                                                                   |
| Mean                        | 13.3                                      | 8.3                             | 7.1                                                      | 7.0                                                               |
| Median                      | 11.1                                      | 5.7                             | 4.9                                                      | 4.2                                                               |
| SD                          | 10.25                                     | 8.01                            | 6.55                                                     | 7.10                                                              |
| Range                       | 0.0 to 30.6                               | 0.1 to 39.6                     | 0.0 to 32.5                                              | 0.0 to 53.4                                                       |
| Number of Administration    | Number of Administration                  | Number of Administration        | Number of Administration                                 | Number of Administration                                          |

7.0

4.2

7.10

0.0 to 53.4

<div style=\"page-break-after: always\"></div>

11.2

7.0

10.52

1.0 to 72.0

| Mean   | 19.0        | 68.7         | 11.4        | 11.2        |
|--------|-------------|--------------|-------------|-------------|
| Median | 16.0        | 50.0         | 8.0         | 7.0         |
| SD     | 14.08       | 62.09        | 9.87        | 10.52       |
| Range  | 1.0 to 35.0 | 4.0 to 296.0 | 1.0 to 59.0 | 1.0 to 72.0 |

Each subject is counted once on each applicable duration category row.

Duration of Exposure is calculated as last dose date - first dose date + 1.

â â  Includes all subjects who received at least one dose of pembrolizumab in KN177.

Â¶Â¶ Includes all subjects who received at least one dose of SOC in KN177.

â¡â¡ Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Â§Â§ Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3; KN002 (original phase); KN006; KN010; KN012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial Tract Cancer) and Cohort D (Gastric Cancer); KN013 Cohort 3 (cHL) and KN013 Cohort 4A (PMBCL); KN024; KN028 Cohort A4 (Esophageal), Cohort B4 (Cervical) and Cohort C1 (SCLC); KN040; KN042; KN045; KN048; KN052; KN054; KN055; KN057; KN059 Cohort 1; KN062; KN087; KN158 Cohort E (Cervical), Cohort G (SCLC) and TMB-H; KN164 Cohort A; KN170; KN177; KN180; KN181; KN224; KN427; P017.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Cohort D: 26APR2016, KN059-Cohort 1: 08AUG2018, KN062: 26MAR2019)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Cohort C: 01SEP2015, KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN164-Cohort A: 03AUG2016, KN177: 19FEB2020)

Database cutoff date for PMBCL (KN013-Cohort 4A: 04AUG2017. KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158-Cohort E: 27JUN2019)

Database cutoff date for HCC (KN224: 15MAY2018)

Database Cutoff Date for Merkel Cell (P017: 06FEB2018)

Database cutoff date for Esophageal (KN028: 31JAN2018, KN180: 30JUL2018, KN181: 15OCT2018)

Database cutoff date for RCC (KN427: 07SEP2018)

Database cutoff date for TMB-H (KN158: 27JUN2019)

Database cutoff date for SCLC (KN028-Cohort C1: 31JUL2018, KN158-Cohort G: 27JUN2019)

Database cutoff date for NMIBC (KN057: 24MAY2019)

Table: Drug Exposure by Duration (ASaT Population)

|                                                                                                                                                    | KN177 Data for Pembrolizumab â â  (N=153)                                                                                                            | KN177 Data for Pembrolizumab â â  (N=153)                                                                                                            | KN177 Data for Pembrolizumab â â  (N=153)                                                                                                            | KN177 Data for SOC Â¶Â¶ (N=143)                                                                                                                      | KN177 Data for SOC Â¶Â¶ (N=143)                                                                                                                      | KN177 Data for SOC Â¶Â¶ (N=143)                                                                                                                      | Reference Safety Dataset for Pembrolizumab â¡â¡ (N=5884)                                                                                             | Reference Safety Dataset for Pembrolizumab â¡â¡ (N=5884)                                                                                             | Reference Safety Dataset for Pembrolizumab â¡â¡ (N=5884)                                                                                             | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§ (N=8098)                                                                                    | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§ (N=8098)                                                                                    | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§ (N=8098)                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                    | n                                                                                                                                                  | (%)                                                                                                                                                | Person- years                                                                                                                                      | n                                                                                                                                                  | (%)                                                                                                                                                | Person- years                                                                                                                                      | n                                                                                                                                                  | (%)                                                                                                                                                | Person- years                                                                                                                                      | n                                                                                                                                                  | (%)                                                                                                                                                | Person- years                                                                                                                                      |
| Duration of exposure                                                                                                                               |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |                                                                                                                                                    |
| >0m                                                                                                                                                | 153                                                                                                                                                | (100.0)                                                                                                                                            | (169.0)                                                                                                                                            | 143                                                                                                                                                | (100.0)                                                                                                                                            | (98.6)                                                                                                                                             | 5,884                                                                                                                                              | (100.0)                                                                                                                                            | (3,465.2)                                                                                                                                          | 8,098                                                                                                                                              | (100.0)                                                                                                                                            | (4,622.0)                                                                                                                                          |
| >=1m                                                                                                                                               | 134                                                                                                                                                | (87.6)                                                                                                                                             | (168.5)                                                                                                                                            | 133                                                                                                                                                | (93.0)                                                                                                                                             | (98.3)                                                                                                                                             | 5,033                                                                                                                                              | (85.5)                                                                                                                                             | (3,437.0)                                                                                                                                          | 6,808                                                                                                                                              | (84.1)                                                                                                                                             | (4,577.7)                                                                                                                                          |
| >=3m                                                                                                                                               | 112                                                                                                                                                | (73.2)                                                                                                                                             | (165.0)                                                                                                                                            | 104                                                                                                                                                | (72.7)                                                                                                                                             | (93.4)                                                                                                                                             | 3,620                                                                                                                                              | (61.5)                                                                                                                                             | (3,201.8)                                                                                                                                          | 4,768                                                                                                                                              | (58.9)                                                                                                                                             | (4,241.1)                                                                                                                                          |
| >=6m                                                                                                                                               | 96                                                                                                                                                 | (62.7)                                                                                                                                             | (158.7)                                                                                                                                            | 65                                                                                                                                                 | (45.5)                                                                                                                                             | (78.8)                                                                                                                                             | 2,610                                                                                                                                              | (44.4)                                                                                                                                             | (2,835.0)                                                                                                                                          | 3,332                                                                                                                                              | (41.1)                                                                                                                                             | (3,722.4)                                                                                                                                          |
| >=12m                                                                                                                                              | 73                                                                                                                                                 | (47.7)                                                                                                                                             | (141.7)                                                                                                                                            | 32                                                                                                                                                 | (22.4)                                                                                                                                             | (54.7)                                                                                                                                             | 1,196                                                                                                                                              | (20.3)                                                                                                                                             | (1,760.2)                                                                                                                                          | 1,595                                                                                                                                              | (19.7)                                                                                                                                             | (2,418.7)                                                                                                                                          |
| Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. | Each subject is counted once on each applicable duration category row. Duration of Exposure is calculated as last dose date - first dose date + 1. |

(4,622.0)

(4,577.7)

(4,241.1)

(3,722.4)

(2,418.7)

Safety populations: distribution of gender, race, and ECOG performance status were generally similar across the KEYNOTE-177 pembrolizumab safety dataset and the SOC Safety Dataset. Compared with the RSD, the KEYNOTE-177 pembrolizumab safety dataset had a lower proportion of male participants and a greater proportion of EU participants.

<div style=\"page-break-after: always\"></div>

## Adverse events

## Table: Adverse Event Summary (ASaT Population)

|                                                               | KN177 Data for Pembrolizuma b â â    | KN177 Data for Pembrolizuma b â â    | KN177 Data for SOC Â¶Â¶   | KN177 Data for SOC Â¶Â¶   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   |
|---------------------------------------------------------------|------------------------------------|------------------------------------|-------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                               | n                                  | (%)                                | n                       | (%)                     | n                                               | (%)                                             | n                                                        | (%)                                                      |
| Subjects in population                                        | 153                                |                                    | 143                     |                         | 5,884                                           |                                                 | 8,098                                                    |                                                          |
| with one or more adverse events                               | 149                                | (97.4)                             | 142                     | (99.3)                  | 5,687                                           | (96.7)                                          | 7,812                                                    | (96.5)                                                   |
| with no adverse event                                         | 4                                  | (2.6)                              | 1                       | (0.7)                   | 197                                             | (3.3)                                           | 286                                                      | (3.5)                                                    |
| with drug-related â  adverse events                            | 122                                | (79.7)                             | 141                     | (98.6)                  | 4,123                                           | (70.1)                                          | 5,581                                                    | (68.9)                                                   |
| with toxicity grade 3-5 adverse events                        | 86                                 | (56.2)                             | 111                     | (77.6)                  | 2,813                                           | (47.8)                                          | 3,941                                                    | (48.7)                                                   |
| with toxicity grade 3-5 drug-related adverse events           | 33                                 | (21.6)                             | 94                      | (65.7)                  | 909                                             | (15.4)                                          | 1,297                                                    | (16.0)                                                   |
| with serious adverse events                                   | 62                                 | (40.5)                             | 75                      | (52.4)                  | 2,252                                           | (38.3)                                          | 3,094                                                    | (38.2)                                                   |
| with serious drug-related adverse events                      | 25                                 | (16.3)                             | 41                      | (28.7)                  | 650                                             | (11.0)                                          | 912                                                      | (11.3)                                                   |
| who died                                                      | 6                                  | (3.9)                              | 7                       | (4.9)                   | 311                                             | (5.3)                                           | 446                                                      | (5.5)                                                    |
| who died due to a drug-related adverse event                  | 0                                  | (0.0)                              | 1                       | (0.7)                   | 39                                              | (0.7)                                           | 60                                                       | (0.7)                                                    |
| discontinued drug due to an adverse event                     | 21                                 | (13.7)                             | 17                      | (11.9)                  | 783                                             | (13.3)                                          | 1,041                                                    | (12.9)                                                   |
| discontinued drug due to a drug-related adverse event         | 15                                 | (9.8)                              | 8                       | (5.6)                   | 405                                             | (6.9)                                           | 542                                                      | (6.7)                                                    |
| discontinued drug due to a serious adverse event              | 12                                 | (7.8)                              | 13                      | (9.1)                   | 570                                             | (9.7)                                           | 756                                                      | (9.3)                                                    |
| discontinued drug due to a serious drug-related adverse event | 7                                  | (4.6)                              | 5                       | (3.5)                   | 244                                             | (4.1)                                           | 327                                                      | (4.0)                                                    |

â  Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

## Table: Exposure-Adjusted Adverse Event Summary (Including Multiple Occurrences of Events) (ASaT Population)

81335 (1556.67)

24615 (471.11)

8765 (167.75)

1959 (37.49)

5523 (105.70)

1261 (24.13)

455 (8.71)

60 (1.15)

1122 (21.47)

583 (11.16)

796 (15.23)

343 (6.56)

|                                                                       | Event Count and Rate (Events/100 person-years) â    | Event Count and Rate (Events/100 person-years) â    | Event Count and Rate (Events/100 person-years) â    | Event Count and Rate (Events/100 person-years) â        |
|-----------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|--------------------------------------------------------|
|                                                                       | KN177 Data for Pembrolizumab â â                     | KN177 Data for SOC Â¶Â¶                              | Reference Safety Dataset for Pembrolizumab â¡â¡      | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§ |
| Number of subjects exposed                                            | 153                                                | 143                                                | 5884                                               | 8098                                                   |
| Total exposure â¡ in person-years                                      | 181.34                                             | 109.95                                             | 3894.24                                            | 5224.94                                                |
| Total events (rate)                                                   |                                                    |                                                    |                                                    |                                                        |
| adverse events                                                        | 2298 (1267.26)                                     | 3308 (3008.65)                                     | 60934 (1564.72)                                    | 81335 (1556.67)                                        |
| drug-related Â§ adverse events                                         | 671 (370.03)                                       | 2021 (1838.11)                                     | 19159 (491.98)                                     | 24615 (471.11)                                         |
| toxicity grade 3-5 adverse events                                     | 227 (125.18)                                       | 380 (345.61)                                       | 6129 (157.39)                                      | 8765 (167.75)                                          |
| toxicity grade 3-5 drug-related adverse events                        | 50 (27.57)                                         | 219 (199.18)                                       | 1370 (35.18)                                       | 1959 (37.49)                                           |
| serious adverse events                                                | 115 (63.42)                                        | 148 (134.61)                                       | 4071 (104.54)                                      | 5523 (105.70)                                          |
| serious drug-related adverse events                                   | 30 (16.54)                                         | 55 (50.02)                                         | 911 (23.39)                                        | 1261 (24.13)                                           |
| adverse events leading to death                                       | 6 (3.31)                                           | 7 (6.37)                                           | 318 (8.17)                                         | 455 (8.71)                                             |
| drug-related adverse events leading to death                          | 0 (0.00)                                           | 1 (0.91)                                           | 39 (1.00)                                          | 60 (1.15)                                              |
| adverse events resulting in drug discontinuation                      | 21 (11.58)                                         | 18 (16.37)                                         | 855 (21.96)                                        | 1122 (21.47)                                           |
| drug-related adverse events resulting in drug discontinuation         | 15 (8.27)                                          | 9 (8.19)                                           | 442 (11.35)                                        | 583 (11.16)                                            |
| serious adverse events resulting in drug discontinuation              | 12 (6.62)                                          | 13 (11.82)                                         | 606 (15.56)                                        | 796 (15.23)                                            |
| serious drug-related adverse events resulting in drug discontinuation | 7 (3.86)                                           | 5 (4.55)                                           | 257 (6.60)                                         | 343 (6.56)                                             |

â  Event rate per 100 person-years of exposure=event count *100/person-years of exposure.

â¡ Drug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date + 30 or the database cutoff date.

Â§ Determined by the investigator to be related to the drug.

For subjects who received second course treatment, adverse events which occurred in second course phase are excluded.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms 'Neoplasm progression', 'Malignant neoplasm progression' and 'Disease progression' not related to the drug are excluded.

8,098

(96.5)

(3.5)

(68.9)

(48.7)

(16.0)

(38.2)

(11.3)

446

(5.5)

(0.7)

(12.9)

(6.7)

(9.3)

(4.0)

<div style=\"page-break-after: always\"></div>

## Table: Exposure-Adjusted AE by Observation Period (Including Multiple Occurrences of Events) (Incidence â¥ 10% in One or More Treatment Groups) (Excerpt)

|                                  | Event Count and Rate(Events/100 person-months)i   | Event Count and Rate(Events/100 person-months)i   | Event Count and Rate(Events/100 person-months)i   | Event Count and Rate(Events/100 person-months)i   | Event Count and Rate(Events/100 person-months)i   | Event Count and Rate(Events/100 person-months)i   | Event Count and Rate(Events/100 person-months)i   | Event Count and Rate(Events/100 person-months)i   |
|----------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                  | Pembrolizumab                                     | Pembrolizumab                                     | Pembrolizumab                                     | Pembrolizumab                                     | SOC                                               | SOC                                               | SOC                                               | SOC                                               |
| Observationperiodofdrug exposure | 0-3months                                         | 3-6months                                         | 6-12months                                        | Beyond12 months                                   | 0-3months                                         | 3-6months                                         | 6-12months                                        | Beyond12 months                                   |
| Number of Subjects exposed       | 153                                               | 122                                               | 103                                               | 77                                                | 143                                               | 114                                               | 80                                                | 36                                                |
| Totalexposure*person- months     | 419.19                                            | 333.15                                            | 527.28                                            | 896.40                                            | 407.25                                            | 288.80                                            | 322.08                                            | 301.26                                            |
| Totalevents(rate)                | 796 (189.9)                                       | 366 (109.9)                                       | 525 (99.6)                                        | 611 (68.2)                                        | 1704 (418.4)                                      | 687 (237.9)                                       | 557 (172.9)                                       | 360 (119.5)                                       |

Adverse events (all grades)

## Table: Subjects With Adverse Events (Incidence â¥ 10% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

7,812

(96.5)

286

(3.5)

1,628

(20.1)

2,491

(30.8)

1,653

(20.4)

786

(9.7)

1,587

(19.6)

1,030

(12.7)

1,083

(13.4)

1,008

(12.4)

1,231

(15.2)

895

(11.1)

1,373

(17.0)

1,484

(18.3)

1,371

(16.9)

604

(7.5)

559

(6.9)

567

(7.0)

385

(4.8)

1,232

(15.2)

871

(10.8)

331

(4.1)

459

(5.7)

1,116

(13.8)

922

(11.4)

403

(5.0)

393

(4.9)

860

(10.6)

716

(8.8)

489

(6.0)

386

(4.8)

490

(6.1)

515

(6.4)

387

(4.8)

(1.4)

204

(2.5)

227

(2.8)

(1.5)

747

(9.2)

(1.0)

(1.1)

|                                      | KN177 Data for Pembrolizumab â â    | KN177 Data for Pembrolizumab â â    | KN177 Data for SOC Â¶Â¶   | KN177 Data for SOC Â¶Â¶   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   |
|--------------------------------------|-----------------------------------|-----------------------------------|-------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                      | n                                 | (%)                               | n                       | (%)                     | n (%)                                           | n (%)                                           | n (%)                                                    | n (%)                                                    |
| Subjects in population               | 153                               |                                   | 143                     |                         | 5,884                                           |                                                 | 8,098                                                    |                                                          |
| with one or more adverse events      | 149                               | (97.4)                            | 142                     | (99.3)                  | 5,687                                           | (96.7)                                          | 7,812                                                    | (96.5)                                                   |
| with no adverse events               | 4                                 | (2.6)                             | 1                       | (0.7)                   | 197                                             | (3.3)                                           | 286                                                      | (3.5)                                                    |
| Diarrhoea                            | 68                                | (44.4)                            | 89                      | (62.2)                  | 1,193                                           | (20.3)                                          | 1,628                                                    | (20.1)                                                   |
| Fatigue                              | 58                                | (37.9)                            | 72                      | (50.3)                  | 1,878                                           | (31.9)                                          | 2,491                                                    | (30.8)                                                   |
| Nausea                               | 47                                | (30.7)                            | 85                      | (59.4)                  | 1,203                                           | (20.4)                                          | 1,653                                                    | (20.4)                                                   |
| Abdominal pain                       | 37                                | (24.2)                            | 42                      | (29.4)                  | 477                                             | (8.1)                                           | 786                                                      | (9.7)                                                    |
| Decreased appetite                   | 36                                | (23.5)                            | 58                      | (40.6)                  | 1,132                                           | (19.2)                                          | 1,587                                                    | (19.6)                                                   |
| Vomiting                             | 33                                | (21.6)                            | 53                      | (37.1)                  | 726                                             | (12.3)                                          | 1,030                                                    | (12.7)                                                   |
| Arthralgia                           | 28                                | (18.3)                            | 7                       | (4.9)                   | 846                                             | (14.4)                                          | 1,083                                                    | (13.4)                                                   |
| Pyrexia                              | 28                                | (18.3)                            | 20                      | (14.0)                  | 734                                             | (12.5)                                          | 1,008                                                    | (12.4)                                                   |
| Anaemia                              | 27                                | (17.6)                            | 32                      | (22.4)                  | 834                                             | (14.2)                                          | 1,231                                                    | (15.2)                                                   |
| Back pain                            | 26                                | (17.0)                            | 24                      | (16.8)                  | 654                                             | (11.1)                                          | 895                                                      | (11.1)                                                   |
| Constipation                         | 26                                | (17.0)                            | 45                      | (31.5)                  | 992                                             | (16.9)                                          | 1,373                                                    | (17.0)                                                   |
| Cough                                | 26                                | (17.0)                            | 23                      | (16.1)                  | 1,138                                           | (19.3)                                          | 1,484                                                    | (18.3)                                                   |
| Pruritus                             | 25                                | (16.3)                            | 12                      | (8.4)                   | 1,053                                           | (17.9)                                          | 1,371                                                    | (16.9)                                                   |
| Aspartate aminotransferase increased | 24                                | (15.7)                            | 12                      | (8.4)                   | 380                                             | (6.5)                                           | 604                                                      | (7.5)                                                    |
| Dizziness                            | 24                                | (15.7)                            | 27                      | (18.9)                  | 428                                             | (7.3)                                           | 559                                                      | (6.9)                                                    |
| Alanine aminotransferase increased   | 22                                | (14.4)                            | 16                      | (11.2)                  | 388                                             | (6.6)                                           | 567                                                      | (7.0)                                                    |
| Blood alkaline phosphatase increased | 22                                | (14.4)                            | 6                       | (4.2)                   | 238                                             | (4.0)                                           | 385                                                      | (4.8)                                                    |
| Dyspnoea                             | 21                                | (13.7)                            | 15                      | (10.5)                  | 984                                             | (16.7)                                          | 1,232                                                    | (15.2)                                                   |
| Headache                             | 21                                | (13.7)                            | 22                      | (15.4)                  | 706                                             | (12.0)                                          | 871                                                      | (10.8)                                                   |
| Abdominal pain upper                 | 20                                | (13.1)                            | 11                      | (7.7)                   | 211                                             | (3.6)                                           | 331                                                      | (4.1)                                                    |
| Nasopharyngitis                      | 20                                | (13.1)                            | 10                      | (7.0)                   | 344                                             | (5.8)                                           | 459                                                      | (5.7)                                                    |
| Rash                                 | 20                                | (13.1)                            | 16                      | (11.2)                  | 896                                             | (15.2)                                          | 1,116                                                    | (13.8)                                                   |
| Asthenia                             | 19                                | (12.4)                            | 31                      | (21.7)                  | 663                                             | (11.3)                                          | 922                                                      | (11.4)                                                   |
| Dry skin                             | 19                                | (12.4)                            | 13                      | (9.1)                   | 302                                             | (5.1)                                           | 403                                                      | (5.0)                                                    |
| Hypertension                         | 19                                | (12.4)                            | 16                      | (11.2)                  | 294                                             | (5.0)                                           | 393                                                      | (4.9)                                                    |
| Hypothyroidism                       | 19                                | (12.4)                            | 3                       | (2.1)                   | 647                                             | (11.0)                                          | 860                                                      | (10.6)                                                   |
| Oedema peripheral                    | 18                                | (11.8)                            | 12                      | (8.4)                   | 510                                             | (8.7)                                           | 716                                                      | (8.8)                                                    |
| Pain in extremity                    | 18                                | (11.8)                            | 11                      | (7.7)                   | 389                                             | (6.6)                                           | 489                                                      | (6.0)                                                    |
| Dry mouth                            | 17                                | (11.1)                            | 9                       | (6.3)                   | 283                                             | (4.8)                                           | 386                                                      | (4.8)                                                    |
| Upper respiratory tract infection    | 16                                | (10.5)                            | 8                       | (5.6)                   | 371                                             | (6.3)                                           | 490                                                      | (6.1)                                                    |
| Urinary tract infection              | 14                                | (9.2)                             | 16                      | (11.2)                  | 382                                             | (6.5)                                           | 515                                                      | (6.4)                                                    |
| Hypokalaemia                         | 13                                | (8.5)                             | 24                      | (16.8)                  | 270                                             | (4.6)                                           | 387                                                      | (4.8)                                                    |
| Alopecia                             | 11                                | (7.2)                             | 29                      | (20.3)                  | 85                                              | (1.4)                                           | 114                                                      | (1.4)                                                    |
| Stomatitis                           | 10                                | (6.5)                             | 43                      | (30.1)                  | 144                                             | (2.4)                                           | 204                                                      | (2.5)                                                    |
| Dyspepsia                            | 9                                 | (5.9)                             | 16                      | (11.2)                  | 148                                             | (2.5)                                           | 227                                                      | (2.8)                                                    |
| Mucosal inflammation                 |                                   |                                   | 27                      |                         |                                                 | (1.6)                                           | 121                                                      |                                                          |
| Weight decreased                     | 7                                 | (4.6)                             |                         | (18.9)                  | 92                                              |                                                 |                                                          | (1.5)                                                    |
| Neutropenia                          | 7 3                               | (4.6) (2.0)                       | 17 30                   | (11.9) (21.0)           | 560 49                                          | (9.5) (0.8)                                     | 747 79                                                   | (9.2) (1.0)                                              |
| Peripheral sensory neuropathy        | 3                                 | (2.0)                             | 31                      | (21.7)                  | 62                                              | (1.1)                                           | 87                                                       | (1.1)                                                    |

<div style=\"page-break-after: always\"></div>

(1.2)

(0.7)

149

(1.8)

(0.3)

(1.0)

| Epistaxis                                   | 2 (1.3)   |   23 | (16.1)   |   82 | (1.4)   |   99 | (1.2)   |
|---------------------------------------------|-----------|------|----------|------|---------|------|---------|
| Neutrophil count decreased                  | 2 (1.3)   |   33 | (23.1)   |   37 | (0.6)   |   55 | (0.7)   |
| Neuropathy peripheral                       | 1 (0.7)   |   27 | (18.9)   |  114 | (1.9)   |  149 | (1.8)   |
| Palmar-plantar erythrodysaesthesia syndrome | 1 (0.7)   |   25 | (17.5)   |   19 | (0.3)   |   24 | (0.3)   |
| White blood cell count decreased            | 1 (0.7)   |   17 | (11.9)   |   56 | (1.0)   |   81 | (1.0)   |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Figure: Between-Treatment Comparisons in AEs (Incidence &gt;= 10% in One or More Treatment Groups)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table: Subjects With Grade 3-5 Adverse Events (Incidence â¥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

3,941

(48.7)

4,157

(51.3)

132

(1.6)

(1.4)

(1.1)

376

(4.6)

221

(2.7)

(0.8)

199

(2.5)

314

(3.9)

(1.2)

(1.6)

(1.1)

(0.9)

(1.2)

(1.0)

(1.2)

(0.2)

(1.5)

(0.6)

(0.2)

(0.9)

(0.3)

(0.0)

(1.1)

(1.1)

(0.2)

(0.3)

(1.0)

(0.3)

(0.1)

(0.2)

(0.0)

(0.8)

(0.2)

(0.3)

171

(2.1)

(0.1)

(0.7)

(0.2)

(0.1)

(0.0)

(1.2)

(1.2)

(0.3)

(0.0)

(1.3)

(0.1)

(0.3)

(0.0)

(0.7)

(0.0)

(0.3)

|                                                        | KN177 Data for Pembrolizumab â â    | KN177 Data for Pembrolizumab â â    | KN177 Data for SOC Â¶Â¶   | KN177 Data for SOC Â¶Â¶   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   |
|--------------------------------------------------------|-----------------------------------|-----------------------------------|-------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                        | n (%)                             | n (%)                             | n (%)                   | n (%)                   | (%)                                             | (%)                                             | (%)                                                      | (%)                                                      |
| Subjects in population                                 | 153                               |                                   | 143                     |                         | n 5,884                                         |                                                 | n 8,098                                                  |                                                          |
| with one or more adverse events with no adverse events | 86 67                             | (56.2) (43.8)                     | 111 32                  | (77.6) (22.4)           | 2,813 3,071                                     | (47.8) (52.2)                                   | 3,941 4,157                                              | (48.7) (51.3)                                            |
| Hypertension                                           | 11                                | (7.2)                             | 7                       | (4.9)                   | 101                                             | (1.7)                                           | 132                                                      | (1.6)                                                    |
| Diarrhoea                                              | 9                                 | (5.9)                             | 16                      | (11.2)                  | 78                                              | (1.3)                                           | 112                                                      | (1.4)                                                    |
| Abdominal pain                                         | 8                                 | (5.2)                             | 8                       | (5.6)                   | 42                                              | (0.7)                                           | 87                                                       | (1.1)                                                    |
| Anaemia                                                | 8                                 | (5.2)                             | 15                      | (10.5)                  | 234                                             | (4.0)                                           | 376                                                      | (4.6)                                                    |
| Hyponatraemia                                          | 8                                 | (5.2)                             | 4                       | (2.8)                   | 153                                             | (2.6)                                           | 221                                                      | (2.7)                                                    |
| Gamma-glutamyltransferase increased                    | 7                                 | (4.6)                             | 1                       | (0.7)                   | 35                                              | (0.6)                                           | 62                                                       | (0.8)                                                    |
| Fatigue                                                | 6                                 | (3.9)                             | 13                      | (9.1)                   | 144                                             | (2.4)                                           | 199                                                      | (2.5)                                                    |
| Pneumonia                                              | 5                                 | (3.3)                             | 3                       | (2.1)                   | 238                                             | (4.0)                                           | 314                                                      | (3.9)                                                    |
| Alanine aminotransferase increased                     | 4                                 | (2.6)                             | 3                       | (2.1)                   | 60                                              | (1.0)                                           | 99                                                       | (1.2)                                                    |
| Aspartate aminotransferase increased                   | 4                                 | (2.6)                             | 3                       | (2.1)                   | 65                                              | (1.1)                                           | 126                                                      | (1.6)                                                    |
| Blood alkaline phosphatase increased                   | 4                                 | (2.6)                             | 2                       | (1.4)                   | 48                                              | (0.8)                                           | 86                                                       | (1.1)                                                    |
| Nausea                                                 | 4                                 | (2.6)                             | 6                       | (4.2)                   | 50                                              | (0.8)                                           | 72                                                       | (0.9)                                                    |
| Asthenia                                               | 3                                 | (2.0)                             | 6                       | (4.2)                   | 58                                              | (1.0)                                           | 100                                                      | (1.2)                                                    |
| Colitis                                                | 3                                 | (2.0)                             | 0                       | (0.0)                   | 60                                              | (1.0)                                           | 85                                                       | (1.0)                                                    |
| Hyperglycaemia                                         | 3                                 | (2.0)                             | 1                       | (0.7)                   | 63                                              | (1.1)                                           | 97                                                       | (1.2)                                                    |
| Infection                                              | 3                                 | (2.0)                             | 0                       | (0.0)                   | 10                                              | (0.2)                                           | 15                                                       | (0.2)                                                    |
| Pulmonary embolism                                     | 3                                 | (2.0)                             | 5                       | (3.5)                   | 91                                              | (1.5)                                           | 124                                                      | (1.5)                                                    |
| Syncope                                                | 3                                 | (2.0)                             | 0                       | (0.0)                   | 34                                              | (0.6)                                           | 49                                                       | (0.6)                                                    |
| Abdominal pain upper                                   | 2                                 | (1.3)                             | 1                       | (0.7)                   | 9                                               | (0.2)                                           | 20                                                       | (0.2)                                                    |
| Acute kidney injury                                    | 2                                 | (1.3)                             | 2                       | (1.4)                   | 51                                              | (0.9)                                           | 74                                                       | (0.9)                                                    |
| Adrenal insufficiency                                  | 2                                 | (1.3)                             | 0                       | (0.0)                   | 18                                              | (0.3)                                           | 25                                                       | (0.3)                                                    |
| Autoimmune colitis                                     | 2                                 | (1.3)                             | 0                       | (0.0)                   | 1                                               | (0.0)                                           | 3                                                        | (0.0)                                                    |
| Back pain                                              | 2                                 | (1.3)                             | 1                       | (0.7)                   | 63                                              | (1.1)                                           | 90                                                       | (1.1)                                                    |
| Dehydration                                            | 2                                 | (1.3)                             | 5                       | (3.5)                   | 62                                              | (1.1)                                           | 93                                                       | (1.1)                                                    |
|                                                        |                                   |                                   | 0                       | (0.0)                   | 7                                               | (0.1)                                           | 16                                                       | (0.2)                                                    |
| Delirium Hepatitis                                     | 2                                 | (1.3) (1.3)                       | 0                       | (0.0)                   | 17                                              | (0.3)                                           | 26                                                       | (0.3)                                                    |
| Hypokalaemia                                           | 2 2                               | (1.3)                             | 9                       | (6.3)                   | 58                                              | (1.0)                                           | 83                                                       | (1.0)                                                    |
| Intestinal obstruction                                 | 2                                 | (1.3)                             | 2                       | (1.4)                   | 12                                              | (0.2)                                           | 25                                                       | (0.3)                                                    |
| Psoriasis                                              | 2                                 | (1.3)                             | 0                       | (0.0)                   | 4                                               | (0.1)                                           | 6                                                        | (0.1)                                                    |
| Small intestinal obstruction                           | 2                                 | (1.3)                             | 5                       | (3.5)                   | 9                                               | (0.2)                                           | 19                                                       | (0.2)                                                    |
| Subileus                                               | 2                                 | (1.3)                             | 0                       | (0.0)                   | 0                                               | (0.0)                                           | 2                                                        | (0.0)                                                    |
| Vomiting                                               | 2                                 | (1.3)                             | 7                       | (4.9)                   | 42                                              | (0.7)                                           | 68                                                       | (0.8)                                                    |
| Weight increased thrombosis                            | 2                                 | (1.3)                             | 0                       | (0.0)                   | 6                                               | (0.1) (0.3)                                     | 13                                                       | (0.2)                                                    |
| Deep vein                                              | 1                                 | (0.7)                             | 2                       | (1.4)                   | 16                                              |                                                 | 26                                                       | (0.3)                                                    |
| Dyspnoea                                               | 1                                 | (0.7)                             | 0                       | (0.0)                   | 133                                             | (2.3)                                           | 171                                                      | (2.1)                                                    |
| Febrile neutropenia                                    | 1                                 | (0.7)                             | 7                       | (4.9)                   | 7                                               | (0.1)                                           | 11                                                       | (0.1)                                                    |
| Hypophosphataemia                                      | 1                                 | (0.7)                             | 2                       | (1.4)                   | 39                                              | (0.7)                                           | 59                                                       | (0.7)                                                    |
| Ileus                                                  | 1                                 | (0.7)                             | 3                       | (2.1)                   | 9                                               | (0.2)                                           | 19                                                       | (0.2)                                                    |
| Influenza                                              | 1                                 | (0.7)                             | 2                       | (1.4)                   | 7                                               | (0.1)                                           | 10                                                       | (0.1)                                                    |
| Large intestinal obstruction                           | 1                                 | (0.7)                             | 2                       | (1.4)                   | 3                                               | (0.1)                                           | 4                                                        | (0.0)                                                    |
| Pleural effusion                                       | 1                                 | (0.7)                             | 0                       | (0.0)                   | 68                                              | (1.2)                                           | 95                                                       | (1.2) (1.2)                                              |
| Urinary tract infection Blood creatinine increased     | 1 0                               | (0.7) (0.0)                       | 4 2                     | (2.8) (1.4)             | 73 11                                           | (1.2) (0.2)                                     | 98 23                                                    | (0.3)                                                    |
| Cholangitis                                            | 0                                 | (0.0)                             | 2                       | (1.4)                   | 1                                               | (0.0)                                           | 4                                                        | (0.0)                                                    |
|                                                        | 0                                 |                                   | 7                       | (4.9)                   |                                                 | (1.3)                                           | 107                                                      | (1.3)                                                    |
| Decreased appetite                                     |                                   | (0.0)                             |                         |                         | 74                                              |                                                 |                                                          | (0.1)                                                    |
| Device related infection                               | 0                                 | (0.0)                             | 2                       | (1.4)                   | 8                                               | (0.1)                                           | 10 22                                                    | (0.3)                                                    |
| Embolism Intestinal                                    | 0                                 | (0.0)                             | 7 2                     | (4.9)                   | 14                                              | (0.2)                                           | 3                                                        | (0.0)                                                    |
| perforation                                            | 0                                 | (0.0)                             |                         | (1.4)                   | 3                                               | (0.1)                                           |                                                          |                                                          |
| Lymphocyte count decreased                             | 0                                 | (0.0)                             | 2                       | (1.4)                   | 30                                              | (0.5)                                           | 53                                                       | (0.7) (0.0)                                              |
| Neurotoxicity                                          | 0                                 | (0.0)                             | 3                       | (2.1)                   | 0                                               | (0.0)                                           | 0                                                        |                                                          |
| Neutropenia                                            | 0                                 | (0.0)                             | 22                      | (15.4)                  | 15                                              | (0.3)                                           | 28                                                       | (0.3)                                                    |

<div style=\"page-break-after: always\"></div>

(0.2)

(0.3)

(0.0)

(1.2)

(0.0)

(0.0)

(0.1)

(0.3)

(0.1)

| Neutrophil count decreased       |   0 | (0.0)   |   24 | (16.8)   |   8 | (0.1)   |   17 | (0.2)   |
|----------------------------------|-----|---------|------|----------|-----|---------|------|---------|
| Oedema peripheral                |   0 | (0.0)   |    2 | (1.4)    |  19 | (0.3)   |   26 | (0.3)   |
| Peripheral sensory neuropathy    |   0 | (0.0)   |    3 | (2.1)    |   1 | (0.0)   |    2 | (0.0)   |
| Pneumonitis                      |   0 | (0.0)   |    0 | (0.0)    |  82 | (1.4)   |   97 | (1.2)   |
| Proteinuria                      |   0 | (0.0)   |    2 | (1.4)    |   1 | (0.0)   |    3 | (0.0)   |
| Skin ulcer                       |   0 | (0.0)   |    2 | (1.4)    |   3 | (0.1)   |    3 | (0.0)   |
| Stomatitis                       |   0 | (0.0)   |    6 | (4.2)    |   9 | (0.2)   |    9 | (0.1)   |
| Urosepsis                        |   0 | (0.0)   |    2 | (1.4)    |  22 | (0.4)   |   25 | (0.3)   |
| White blood cell count decreased |   0 | (0.0)   |    6 | (4.2)    |   4 | (0.1)   |    5 | (0.1)   |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Drug-related adverse events (all grades)

## Table: Subjects With Drug-Related Adverse Events (Incidence â¥ 5% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

5,581

(68.9)

2,517

(31.1)

832

(10.3)

1,503

(18.6)

1,063

(13.1)

672

(8.3)

337

(4.2)

829

(10.2)

567

(7.0)

748

(9.2)

333

(4.1)

(1.6)

604

(7.5)

483

(6.0)

182

(2.2)

342

(4.2)

278

(3.4)

(1.5)

(1.3)

232

(2.9)

156

(1.9)

(0.8)

259

(3.2)

(1.3)

(0.8)

(0.6)

164

(2.0)

201

(2.5)

(1.0)

(0.6)

(0.3)

(0.6)

(0.7)

(0.4)

(0.0)

|                                      | KN177 Data for Pembrolizumab â â    | KN177 Data for Pembrolizumab â â    | KN177 Data for SOC Â¶Â¶   | KN177 Data for SOC Â¶Â¶   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   |
|--------------------------------------|-----------------------------------|-----------------------------------|-------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                      | n                                 | (%)                               | n                       | (%)                     | n                                               | (%)                                             | n                                                        | (%)                                                      |
| Subjects in population               | 153                               |                                   | 143                     |                         | 5,884                                           |                                                 | 8,098                                                    |                                                          |
| with one or more adverse events      | 122                               | (79.7)                            | 141                     | (98.6)                  | 4,123                                           | (70.1)                                          | 5,581                                                    | (68.9)                                                   |
| with no adverse events               | 31                                | (20.3)                            | 2                       | (1.4)                   | 1,761                                           | (29.9)                                          | 2,517                                                    | (31.1)                                                   |
| Diarrhoea                            | 38                                | (24.8)                            | 75                      | (52.4)                  | 628                                             | (10.7)                                          | 832                                                      | (10.3)                                                   |
| Fatigue                              | 32                                | (20.9)                            | 63                      | (44.1)                  | 1,166                                           | (19.8)                                          | 1,503                                                    | (18.6)                                                   |
| Pruritus                             | 21                                | (13.7)                            | 7                       | (4.9)                   | 831                                             | (14.1)                                          | 1,063                                                    | (13.1)                                                   |
| Nausea                               | 19                                | (12.4)                            | 79                      | (55.2)                  | 532                                             | (9.0)                                           | 672                                                      | (8.3)                                                    |
| Aspartate aminotransferase increased | 17                                | (11.1)                            | 7                       | (4.9)                   | 217                                             | (3.7)                                           | 337                                                      | (4.2)                                                    |
| Rash                                 | 17                                | (11.1)                            | 11                      | (7.7)                   | 669                                             | (11.4)                                          | 829                                                      | (10.2)                                                   |
| Arthralgia                           | 16                                | (10.5)                            | 2                       | (1.4)                   | 434                                             | (7.4)                                           | 567                                                      | (7.0)                                                    |
| Hypothyroidism                       | 16                                | (10.5)                            | 0                       | (0.0)                   | 561                                             | (9.5)                                           | 748                                                      | (9.2)                                                    |
| Alanine aminotransferase increased   | 15                                | (9.8)                             | 10                      | (7.0)                   | 232                                             | (3.9)                                           | 333                                                      | (4.1)                                                    |
| Blood alkaline phosphatase increased | 12                                | (7.8)                             | 3                       | (2.1)                   | 84                                              | (1.4)                                           | 130                                                      | (1.6)                                                    |
| Decreased appetite                   | 12                                | (7.8)                             | 49                      | (34.3)                  | 461                                             | (7.8)                                           | 604                                                      | (7.5)                                                    |
| Asthenia                             | 11                                | (7.2)                             | 25                      | (17.5)                  | 363                                             | (6.2)                                           | 483                                                      | (6.0)                                                    |
| Dry mouth                            | 11                                | (7.2)                             | 6                       | (4.2)                   | 142                                             | (2.4)                                           | 182                                                      | (2.2)                                                    |
| Pyrexia                              | 11                                | (7.2)                             | 7                       | (4.9)                   | 256                                             | (4.4)                                           | 342                                                      | (4.2)                                                    |
| Anaemia                              | 9                                 | (5.9)                             | 17                      | (11.9)                  | 202                                             | (3.4)                                           | 278                                                      | (3.4)                                                    |
| Colitis                              | 8                                 | (5.2)                             | 0                       | (0.0)                   | 84                                              | (1.4)                                           | 123                                                      | (1.5)                                                    |
| Stomatitis                           | 8                                 | (5.2)                             | 43                      | (30.1)                  | 71                                              | (1.2)                                           | 103                                                      | (1.3)                                                    |
| Dry skin                             | 7                                 | (4.6)                             | 10                      | (7.0)                   | 174                                             | (3.0)                                           | 232                                                      | (2.9)                                                    |
| Abdominal pain                       | 6                                 | (3.9)                             | 10                      | (7.0)                   | 113                                             | (1.9)                                           | 156                                                      | (1.9)                                                    |
| Alopecia                             | 5                                 | (3.3)                             | 28                      | (19.6)                  | 44                                              | (0.7)                                           | 61                                                       | (0.8)                                                    |
| Vomiting                             | 5                                 | (3.3)                             | 40                      | (28.0)                  | 196                                             | (3.3)                                           | 259                                                      | (3.2)                                                    |
| Dizziness                            | 4                                 | (2.6)                             | 15                      | (10.5)                  | 83                                              | (1.4)                                           | 102                                                      | (1.3)                                                    |
| Mucosal inflammation                 | 4                                 | (2.6)                             | 25                      | (17.5)                  | 48                                              | (0.8)                                           | 64                                                       | (0.8)                                                    |
| Hypokalaemia                         | 3                                 | (2.0)                             | 8                       | (5.6)                   | 36                                              | (0.6)                                           | 45                                                       | (0.6)                                                    |
| Weight decreased                     | 3                                 | (2.0)                             | 8                       | (5.6)                   | 138                                             | (2.3)                                           | 164                                                      | (2.0)                                                    |
| Constipation                         | 2                                 | (1.3)                             | 10                      | (7.0)                   | 156                                             | (2.7)                                           | 201                                                      | (2.5)                                                    |
| Dysgeusia                            | 2                                 | (1.3)                             | 13                      | (9.1)                   | 60                                              | (1.0)                                           | 80                                                       | (1.0)                                                    |
| Platelet count decreased             | 2                                 | (1.3)                             | 9                       | (6.3)                   | 32                                              | (0.5)                                           | 47                                                       | (0.6)                                                    |
| Proteinuria                          | 2                                 | (1.3)                             | 10                      | (7.0)                   | 14                                              | (0.2)                                           | 26                                                       | (0.3)                                                    |
| Hypertension                         | 1                                 | (0.7)                             | 9                       | (6.3)                   | 32                                              | (0.5)                                           | 45                                                       | (0.6)                                                    |
| Neuropathy peripheral                | 1                                 | (0.7)                             | 25                      | (17.5)                  | 40                                              | (0.7)                                           | 53                                                       |                                                          |
|                                      |                                   |                                   |                         |                         |                                                 |                                                 | 34                                                       | (0.7)                                                    |
| Neutrophil count decreased           | 1                                 | (0.7) (0.7)                       | 33                      | (23.1)                  | 26                                              | (0.4)                                           |                                                          | (0.4)                                                    |
| Paronychia                           | 1                                 |                                   | 8                       | (5.6)                   | 2                                               | (0.0)                                           | 3                                                        | (0.0)                                                    |

<div style=\"page-break-after: always\"></div>

(0.5)

(0.1)

(0.6)

(0.2)

(0.4)

(0.1)

| White blood cell count decreased            |   1 (0.7) | 17    | (11.9)    | 28        | (0.5)   |   38 | (0.5)   |
|---------------------------------------------|-----------|-------|-----------|-----------|---------|------|---------|
| Epistaxis                                   |         0 | (0.0) | 20        | (14.0) 6  | (0.1)   |    8 | (0.1)   |
| Neutropenia                                 |         0 | (0.0) | 30        | (21.0) 30 | (0.5)   |   49 | (0.6)   |
| Palmar-plantar erythrodysaesthesia syndrome |         0 | (0.0) | 25 (17.5) | 15        | (0.3)   |   18 | (0.2)   |
| Peripheral sensory neuropathy               |         0 | (0.0) | 29 (20.3) | 28        | (0.5)   |   36 | (0.4)   |
| Temperature intolerance                     |         0 | (0.0) | 8 (5.6)   | 4         | (0.1)   |    5 | (0.1)   |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Drug-related adverse events (grade 3-5)

Table: Subjects With Grade 3-5 Drug-Related Adverse Events (Incidence â¥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

1,297

(16.0)

6,801

(84.0)

(0.7)

(0.9)

(0.9)

(1.1)

(0.6)

(0.7)

(0.0)

(0.3)

(0.3)

(0.6)

(0.1)

(0.2)

(0.2)

(0.1)

(0.4)

(0.3)

(0.2)

(0.0)

(0.0)

(0.2)

(0.2)

(0.0)

(0.2)

(0.1)

(0.0)

(1.1)

(0.0)

(0.2)

(0.1)

(0.1)

(0.0)

|                                      | KN177 Data for Pembrolizumab â â    | KN177 Data for Pembrolizumab â â    | KN177 Data for SOC Â¶Â¶   | KN177 Data for SOC Â¶Â¶   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   |
|--------------------------------------|-----------------------------------|-----------------------------------|-------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                      | n                                 | (%)                               | n                       | (%)                     | n                                               | (%)                                             | n                                                        | (%)                                                      |
| Subjects in population               | 153                               |                                   | 143                     |                         | 5,884                                           |                                                 | 8,098                                                    |                                                          |
| with one or more adverse events      | 33                                | (21.6)                            | 94                      | (65.7)                  | 909                                             | (15.4)                                          | 1,297                                                    | (16.0)                                                   |
| with no adverse events               | 120                               | (78.4)                            | 49                      | (34.3)                  | 4,975                                           | (84.6)                                          | 6,801                                                    | (84.0)                                                   |
| Alanine aminotransferase increased   | 3                                 | (2.0)                             | 1                       | (0.7)                   | 34                                              | (0.6)                                           | 54                                                       | (0.7)                                                    |
| Colitis                              | 3                                 | (2.0)                             | 0                       | (0.0)                   | 53                                              | (0.9)                                           | 75                                                       | (0.9)                                                    |
| Diarrhoea                            | 3                                 | (2.0)                             | 14                      | (9.8)                   | 55                                              | (0.9)                                           | 75                                                       | (0.9)                                                    |
| Fatigue                              | 3                                 | (2.0)                             | 13                      | (9.1)                   | 63                                              | (1.1)                                           | 88                                                       | (1.1)                                                    |
| Anaemia                              | 2                                 | (1.3)                             | 7                       | (4.9)                   | 29                                              | (0.5)                                           | 50                                                       | (0.6)                                                    |
| Aspartate aminotransferase increased | 2                                 | (1.3)                             | 1                       | (0.7)                   | 35                                              | (0.6)                                           | 60                                                       | (0.7)                                                    |
| Autoimmune colitis                   | 2                                 | (1.3)                             | 0                       | (0.0)                   | 1                                               | (0.0)                                           | 3                                                        | (0.0)                                                    |
| Gamma-glutamyltransferase increased  | 2                                 | (1.3)                             | 0                       | (0.0)                   | 15                                              | (0.3)                                           | 21                                                       | (0.3)                                                    |
| Hepatitis                            | 2                                 | (1.3)                             | 0                       | (0.0)                   | 14                                              | (0.2)                                           | 22                                                       | (0.3)                                                    |
| Hyponatraemia                        | 2                                 | (1.3)                             | 1                       | (0.7)                   | 29                                              | (0.5)                                           | 45                                                       | (0.6)                                                    |
| Psoriasis                            | 2                                 | (1.3)                             | 0                       | (0.0)                   | 4                                               | (0.1)                                           | 6                                                        | (0.1)                                                    |
| Acute kidney injury                  | 1                                 | (0.7)                             | 2                       | (1.4)                   | 8                                               | (0.1)                                           | 14                                                       | (0.2)                                                    |
| Hypertension                         | 1                                 | (0.7)                             | 6                       | (4.2)                   | 10                                              | (0.2)                                           | 13                                                       | (0.2)                                                    |
| Hypokalaemia                         | 1                                 | (0.7)                             | 4                       | (2.8)                   | 10                                              | (0.2)                                           | 11                                                       | (0.1)                                                    |
| Asthenia                             | 0                                 | (0.0)                             | 5                       | (3.5)                   | 22                                              | (0.4)                                           | 35                                                       | (0.4)                                                    |
| Decreased appetite                   | 0                                 | (0.0)                             | 3                       | (2.1)                   | 21                                              | (0.4)                                           | 28                                                       | (0.3)                                                    |
| Dehydration                          | 0                                 | (0.0)                             | 2                       | (1.4)                   | 8                                               | (0.1)                                           | 14                                                       | (0.2)                                                    |
| Febrile neutropenia                  | 0                                 | (0.0)                             | 6                       | (4.2)                   | 0                                               | (0.0)                                           | 1                                                        | (0.0)                                                    |
| Intestinal perforation               | 0                                 | (0.0)                             | 2                       | (1.4)                   | 0                                               | (0.0)                                           | 0                                                        | (0.0)                                                    |
| Lymphocyte count decreased           | 0                                 | (0.0)                             | 2                       | (1.4)                   | 7                                               | (0.1)                                           | 14                                                       | (0.2)                                                    |
| Nausea                               | 0                                 | (0.0)                             | 3                       | (2.1)                   | 13                                              | (0.2)                                           | 16                                                       | (0.2)                                                    |
| Neurotoxicity                        | 0                                 | (0.0)                             | 3                       | (2.1)                   | 0                                               | (0.0)                                           | 0                                                        | (0.0)                                                    |
| Neutropenia                          | 0                                 | (0.0)                             | 22                      | (15.4)                  | 9                                               | (0.2)                                           | 20                                                       | (0.2)                                                    |
| Neutrophil count decreased           | 0                                 | (0.0)                             | 24                      | (16.8)                  | 4                                               | (0.1)                                           | 8                                                        | (0.1)                                                    |
| Peripheral sensory neuropathy        | 0                                 | (0.0)                             | 3                       | (2.1)                   | 1                                               | (0.0)                                           | 2                                                        | (0.0)                                                    |
| Pneumonitis                          | 0                                 | (0.0)                             | 0                       | (0.0)                   | 77                                              | (1.3)                                           | 91                                                       | (1.1)                                                    |
| Proteinuria                          | 0                                 | (0.0)                             | 2                       | (1.4)                   | 0                                               | (0.0)                                           | 1                                                        | (0.0)                                                    |
| Pulmonary embolism                   | 0                                 | (0.0)                             | 2                       | (1.4)                   | 9                                               | (0.2)                                           | 13                                                       | (0.2)                                                    |
| Stomatitis                           | 0                                 | (0.0)                             | 6                       | (4.2)                   |                                                 | (0.1)                                           | 5                                                        | (0.1)                                                    |
| Vomiting                             | 0                                 |                                   |                         |                         | 5                                               |                                                 |                                                          | (0.1)                                                    |
| White blood cell count decreased     | 0                                 | (0.0) (0.0)                       | 5 6                     | (3.5) (4.2)             | 10 1                                            | (0.2) (0.0)                                     | 11 1                                                     | (0.0)                                                    |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

<div style=\"page-break-after: always\"></div>

## Adverse Drug Reactions (ADR) in section 4.8 of the SmPC

## Table: Adverse Reactions in Patients Treated with Pembrolizumab

|                                      |                                       | Monotherapy                          | Monotherapy                          |
|--------------------------------------|---------------------------------------|--------------------------------------|--------------------------------------|
|                                      |                                       | All AEs %(n)                         | Gr 3-5 AEs n                         |
| Infections and infestations          | Infections and infestations           | Infections and infestations          | Infections and infestations          |
| Common                               | Pneumonia                             | 7.3% (451)                           | 255                                  |
| Blood and lymphatic system disorders | Blood and lymphatic system disorders  | Blood and lymphatic system disorders | Blood and lymphatic system disorders |
| Very common                          | Anaemia                               | 14.1% (872)                          | 247                                  |
| Common                               | Thrombocytopenia                      | 1.6% (100)                           | 21                                   |
| Common                               | Neutropenia                           | 1.0% (62)                            | 19                                   |
| Common                               | Lymphopenia                           | 1.2% (72)                            | 17                                   |
| Uncommon                             | Leukopenia                            | 0.7% (46)                            | 7                                    |
| Uncommon                             | Eosinophilia                          | 0.6% (40)                            | 0                                    |
| Rare                                 | Immune thrombocytopenia               | 0.097% (6)                           | 5                                    |
| Rare                                 | Haemolytic anaemia                    | 0.02% (1)                            | 1                                    |
| Rare                                 | Haemophagocytic lymphohistiocytosis # | (0)                                  | 0                                    |
| Rare                                 | Pure red cell aplasia #               | (0)                                  | 0                                    |
| Immune system disorders              | Immune system disorders               | Immune system disorders              | Immune system disorders              |
| Common                               | Infusion Reactions a                  | 2.4% (149)                           | 14                                   |
| Uncommon                             | Sarcoidosis                           | 0.2% (10)                            | 0                                    |
| Not known                            | solid organ transplant rejection *    | Not Calculated                       |                                      |
| Endocrine disorders                  | Endocrine disorders                   | Endocrine disorders                  | Endocrine disorders                  |
| Very common                          | hypothyroidism b                      | 11.3% (699)                          | 7                                    |
| Common                               | Hyperthyroidism                       | 4.2% (261)                           | 7                                    |
| Common                               | Thyroiditis c                         | 1.0% (62)                            | 1                                    |
| Uncommon                             | Adrenal Insufficiency d               | 0.8% (52)                            | 25                                   |
| Uncommon                             | Hypophysitis e                        | 0.6% (38)                            | 20                                   |
| Metabolism and nutrition disorders   | Metabolism and nutrition disorders    | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   |
| Very common                          | Decreased appetite                    | 19.1% (1181)                         | 74                                   |
| Common                               | Hyponatraemia                         | 5.8% (356)                           | 161                                  |
| Common                               | Hypokalaemia                          | 4.6% (286)                           | 61                                   |
| Common                               | Hypocalcaemia                         | 1.9% (120)                           | 9                                    |
| Uncommon                             | Type 1 Diabetes Mellitus f            | 0.3% (21)                            | 20                                   |
| Psychiatric disorders                | Psychiatric disorders                 | Psychiatric disorders                | Psychiatric disorders                |
| Common                               | Insomnia                              | 7.2% (448)                           | 8                                    |
| Nervous system disorders             | Nervous system disorders              | Nervous system disorders             | Nervous system disorders             |
| Very common                          | Headache                              | 12.1% (747)                          | 18                                   |
| Common                               | Dizziness                             | 7.4% (460)                           | 11                                   |
| Common                               | Neuropathy peripheral                 | 2.0% (123)                           | 4                                    |
| Common                               | Lethargy                              | 1.2% (74)                            | 3                                    |
| Common                               | Dysgeusia                             | 1.9% (116)                           | 1                                    |
| Uncommon                             | Epilepsy                              | 0.2% (11)                            | 7                                    |
| Rare                                 | Encephalitis g                        | 0.06% (4)                            | 3                                    |
| Rare                                 | Guillain-Barre Syndrome h             | 0.06% (4)                            | 2                                    |
| Rare                                 | Myelitis i                            | 0.03% (2)                            | 2                                    |
| Rare                                 | Myasthenic Syndrome j                 | 0.05% (3)                            | 1                                    |
| Rare                                 | meningitis (aseptic) k                | 0.05% (3)                            | 3                                    |

0

0

Not Calculated

<div style=\"page-break-after: always\"></div>

0

0

| Eye disorders                                   | Dry eye                                              | 1.7% (108)                                      | 0                                               |
|-------------------------------------------------|------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Common Uncommon                                 | Uveitis l                                            | 0.4% (23)                                       | 2                                               |
|                                                 | Vogt-Koyanagi-Harada syndrome #                      |                                                 |                                                 |
| Rare                                            |                                                      | (0)                                             | 0                                               |
| Cardiac disorders                               | Cardiac disorders                                    | Cardiac disorders                               | Cardiac disorders                               |
| Common                                          | cardiac arrhythmia (including atrial fibrillation) m | 3.3% (204)                                      | 46                                              |
| Uncommon                                        | Myocarditis                                          | 0.1% (7)                                        | 6                                               |
| Uncommon                                        | Pericardial effusion                                 | 0.8% (52)                                       | 25                                              |
| Uncommon                                        | Pericarditis                                         | 0.1% (9)                                        | 5                                               |
| Vascular disorders                              | Vascular disorders                                   | Vascular disorders                              | Vascular disorders                              |
| Common                                          | Hypertension                                         | 5.1% (316)                                      | 113                                             |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders |
| Very common                                     | Dyspnoea                                             | 16.5% (1021)                                    | 133                                             |
| Very common                                     | Cough                                                | 19.4% (1199)                                    | 10                                              |
| Common                                          | Pneumonitis n                                        | 4.6% (286)                                      | 99                                              |
| Gastrointestinal disorders                      | Gastrointestinal disorders                           | Gastrointestinal disorders                      | Gastrointestinal disorders                      |
| Very common                                     | Diarrhoea                                            | 21.0% (1297)                                    | 91                                              |
| Very common                                     | abdominal pain o                                     | 13.0% (807)                                     | 67                                              |
| Very common                                     | Nausea                                               | 20.7% (1281)                                    | 54                                              |
| Very common                                     | Vomiting                                             | 12.7% (785)                                     | 46                                              |
| Very common                                     | Constipation                                         | 16.7% (1032)                                    | 24                                              |
| Common                                          | Colitis p                                            | 2.0% (121)                                      | 72                                              |
| Common                                          | Dry mouth                                            | 4.9% (304)                                      | 1                                               |
| Uncommon                                        | Pancreatitis q                                       | 0.3% (21)                                       | 12                                              |
| Uncommon                                        | gastrointestinal ulceration r                        | 0.1% (8)                                        | 5                                               |
| Rare                                            | Small intestinal perforation                         | 0.03% (2)                                       | 1                                               |
| Hepatobiliary disorders                         | Hepatobiliary disorders                              | Hepatobiliary disorders                         | Hepatobiliary disorders                         |
| Uncommon                                        | Hepatitis s                                          | 0.99% (61)                                      | 49                                              |
| Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders               | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          |
| Very common                                     | rash t                                               | 19.5% (1209)                                    | 2                                               |
| Very common                                     | pruritus u                                           | 18.5% (1146)                                    | 2                                               |
| Common                                          | Severe Skin Reactions v                              | 1.6% (102)                                      | 78                                              |
| Common                                          | Erythema                                             | 2.9% (177)                                      | 2                                               |
| Common                                          | Dermatitis                                           | 1.0% (62)                                       | 1                                               |
| Common                                          | Dry skin                                             | 5.3% (327)                                      | 0                                               |
| Common                                          | vitiligo w                                           | 4.0% (245)                                      | 0                                               |
| Common                                          | Alopecia                                             | 1.6% (99)                                       | 0                                               |
| Common                                          | Eczema                                               | 1.6% (97)                                       | 0                                               |
| Common                                          | Dermatitis acneiform                                 | 1.3% (78)                                       | 0                                               |
| Uncommon                                        | Psoriasis                                            | 0.7% (43)                                       | 7                                               |
| Uncommon                                        | lichenoid keratosis x                                | 0.4% (23)                                       | 4                                               |
| Uncommon                                        | Papule                                               | 0.4% (27)                                       | 1                                               |
| Uncommon                                        | Hair colour changes                                  | 0.3% (20)                                       | 0                                               |
|                                                 | stevens-johnson syndrome                             | 0.05% (3)                                       | 2                                               |
| Rare Rare                                       | Erythema nodosum                                     | 0.05% (3)                                       | 0                                               |
| Rare                                            | Toxic epidermal necrolysis #                         | (0)                                             | 0                                               |
| Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders |
| Very common                                     | musculoskeletal pain y                               | 19.1% (1182)                                    | 100                                             |
| Very common                                     | Arthralgia                                           | 14.4% (892)                                     | 39                                              |
| Common                                          | myositis z                                           | 7.6% (467)                                      | 18                                              |
| Common                                          | Pain in extremity                                    | 6.8% (422)                                      | 18                                              |
| Common                                          | arthritis aa                                         | 2.3% (143)                                      | 9                                               |

<div style=\"page-break-after: always\"></div>

| Uncommon                                             | tenosynovitis bb                                     | 0.5% (32)    | 1   |
|------------------------------------------------------|------------------------------------------------------|--------------|-----|
| Rare                                                 | Sjogren's syndrome                                   | 0.05% (3)    | 1   |
| Renal and urinary disorders                          | Renal and urinary disorders                          |              |     |
| Uncommon                                             | Nephritis cc                                         | 0.4% (25)    | 17  |
| General disorders and administration site conditions | General disorders and administration site conditions |              |     |
| Very common                                          | Fatigue                                              | 31.8% (1965) | 150 |
| Very common                                          | Asthenia                                             | 11.2% (693)  | 61  |
| Very common                                          | oedema dd                                            | 11.6% (719)  | 42  |
| Very common                                          | Pyrexia                                              | 13.0% (803)  | 29  |
| Common                                               | Influenza like illness                               | 3.9% (244)   | 1   |
| Common                                               | Chills                                               | 4.2% (260)   | 0   |
| Investigations                                       | Investigations                                       |              |     |
| Common                                               | Aspartate aminotransferase increased                 | 6.8% (420)   | 70  |
| Common                                               | Alanine aminotransferase increased                   | 6.9% (428)   | 67  |
| Common                                               | Blood alkaline phosphatase increased                 | 4.3% (266)   | 52  |
| Common                                               | Hypercalcaemia                                       | 3.0% (185)   | 51  |
| Common                                               | Blood bilirubin increased                            | 2.2% (134)   | 23  |
| Common                                               | Blood creatinine increased                           | 4.3% (268)   | 12  |
| Uncommon                                             | Amylase increased                                    | 0.3% (20)    | 10  |

Every subject is counted a single time for each applicable row.

*  Adverse reaction frequencies presented may not be fully attributable to pembrolizumab alone but may contain contributions from the underlying disease or from other medicinal products used in a combination.
- # The 'rule of 3' has been applied in calculation.
- a. Infusion Reactions (anaphylactic reaction, anaphylactoid reaction, cytokine release syndrome, drug hypersensitivity, hypersensitivity, infusion related reaction)
- b. hypothyroidism (hypothyroidism, myxoedema)
- c. Thyroiditis (autoimmune thyroiditis, thyroid disorder, thyroiditis)
- d. Adrenal Insufficiency (addison's disease, adrenal insufficiency, adrenocortical insufficiency acute, secondary adrenocortical insufficiency)
- e. Hypophysitis (hypophysitis, hypopituitarism)
- f. Type 1 Diabetes Mellitus (diabetic ketoacidosis, type 1 diabetes mellitus)
- g. Encephalitis (encephalitis, encephalitis autoimmune)
- h. Guillain-Barre Syndrome (axonal neuropathy, demyelinating polyneuropathy, guillain-barre syndrome)
- i. Myelitis (myelitis, myelitis transverse)
- j. Myasthenic Syndrome (myasthenia gravis, myasthenic syndrome)
- k. meningitis (aseptic) (meningitis, meningitis noninfective)
- l. Uveitis (chorioretinitis, iridocyclitis, iritis, uveitis)
- m. cardiac arrhythmia (including atrial fibrillation) (adams-stokes syndrome, arrhythmia, arrhythmia supraventricular, atrial fibrillation, atrial flutter, atrial tachycardia, atrioventricular block, atrioventricular block complete, atrioventricular block first degree, bundle branch block left, bundle branch block right, electrocardiogram qt prolonged, electrocardiogram repolarisation abnormality, heart rate irregular, paroxysmal arrhythmia, sinus bradycardia, sinus tachycardia, supraventricular extrasystoles, supraventricular tachycardia, tachyarrhythmia, ventricular extrasystoles, ventricular fibrillation, ventricular tachycardia, wolff-parkinson-white syndrome)
- n. Pneumonitis (interstitial lung disease, organising pneumonia, pneumonitis)
- o. abdominal pain (abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper)
- p. Colitis (autoimmune colitis, colitis, colitis microscopic, enterocolitis, immune-mediated enterocolitis)
- q. Pancreatitis (autoimmune pancreatitis, pancreatitis, pancreatitis acute)
- r. gastrointestinal ulceration (duodenal ulcer, gastric ulcer)
- s. Hepatitis (autoimmune hepatitis, drug-induced liver injury, hepatitis, hepatitis acute, immune-mediated hepatitis)
- t. rash (genital rash, rash, rash erythematous, rash follicular, rash macular, rash maculo-papular, rash papular, rash pruritic, rash vesicular)
- u. pruritus (pruritus, pruritus genital, urticaria, urticaria papular)
- v. Severe Skin Reactions (dermatitis bullous, dermatitis exfoliative, dermatitis exfoliative generalised, erythema

<div style=\"page-break-after: always\"></div>

multiforme, exfoliative rash, lichen planus, oral lichen planus, pemphigoid, pemphigus, pruritus, pruritus genital, rash, rash erythematous, rash maculo-papular, rash pruritic, rash pustular, skin necrosis, stevens-johnson syndrome, toxic skin eruption)

- w. vitiligo (hypopigmentation of eyelid, skin depigmentation, skin hypopigmentation, vitiligo)
- x. lichenoid keratosis (lichen planus, lichen sclerosus, lichenoid keratosis)
- y. musculoskeletal pain (back pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal stiffness, torticollis)
- z. myositis (myalgia, myopathy, myositis, necrotising myositis, polymyalgia rheumatica, rhabdomyolysis)
5. aa. arthritis (arthritis, joint effusion, joint swelling, polyarthritis)
6. bb. tenosynovitis (synovitis, tendon pain, tendonitis, tenosynovitis)
- cc. Nephritis (acute kidney injury, autoimmune nephritis, glomerulonephritis, glomerulonephritis membranous, nephritis, nephrotic syndrome, renal failure, tubulointerstitial nephritis)
- dd. oedema (eyelid oedema, face oedema, fluid overload, fluid retention, generalised oedema, lip oedema, localised oedema, oedema, oedema peripheral, periorbital oedema)
9. Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177 and KN204.
10. Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)
11. Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)
12. Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)
13. Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 21MAR2019, KM204: 16JAN2020)
14. Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)
15. Database cutoff date for CRC (KN177: 19FEB2020)

## Serious adverse event/deaths/other significant events

## Serious Adverse Events

## Table: Subjects With Serious Adverse Events Up to 90 Days of Last Dose (Incidence â¥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

3,093

(38.2)

5,005

(61.8)

(0.6)

(1.0)

(1.1)

(1.0)

(1.0)

315

(3.9)

(0.3)

(0.0)

(0.2)

(0.1)

(0.3)

(0.2)

(0.3)

(0.0)

(1.1)

(1.2)

|                                 | KN177 Data for Pembrolizumab â â    | KN177 Data for Pembrolizumab â â    | KN177 Data for SOC Â¶Â¶   | KN177 Data for SOC Â¶Â¶   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   |
|---------------------------------|-----------------------------------|-----------------------------------|-------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                 | n                                 | (%)                               | n                       | (%)                     | n                                               | (%)                                             | n                                                        | (%)                                                      |
| Subjects in population          | 153                               |                                   | 143                     |                         | 5,884                                           |                                                 | 8,098                                                    |                                                          |
| with one or more adverse events | 62                                | (40.5)                            | 75                      | (52.4)                  | 2,251                                           | (38.3)                                          | 3,093                                                    | (38.2)                                                   |
| with no adverse events          | 91                                | (59.5)                            | 68                      | (47.6)                  | 3,633                                           | (61.7)                                          | 5,005                                                    | (61.8)                                                   |
| Abdominal pain                  | 7                                 | (4.6)                             | 2                       | (1.4)                   | 27                                              | (0.5)                                           | 51                                                       | (0.6)                                                    |
| Diarrhoea                       | 4                                 | (2.6)                             | 9                       | (6.3)                   | 58                                              | (1.0)                                           | 81                                                       | (1.0)                                                    |
| Pyrexia                         | 4                                 | (2.6)                             | 0                       | (0.0)                   | 66                                              | (1.1)                                           | 91                                                       | (1.1)                                                    |
| Acute kidney injury             | 3                                 | (2.0)                             | 2                       | (1.4)                   | 50                                              | (0.8)                                           | 82                                                       | (1.0)                                                    |
| Colitis                         | 3                                 | (2.0)                             | 0                       | (0.0)                   | 59                                              | (1.0)                                           | 79                                                       | (1.0)                                                    |
| Pneumonia                       | 3                                 | (2.0)                             | 2                       | (1.4)                   | 243                                             | (4.1)                                           | 315                                                      | (3.9)                                                    |
| Adrenal insufficiency           | 2                                 | (1.3)                             | 0                       | (0.0)                   | 18                                              | (0.3)                                           | 25                                                       | (0.3)                                                    |
| Autoimmune colitis              | 2                                 | (1.3)                             | 0                       | (0.0)                   | 0                                               | (0.0)                                           | 3                                                        | (0.0)                                                    |
| Hepatitis                       | 2                                 | (1.3)                             | 0                       | (0.0)                   | 9                                               | (0.2)                                           | 18                                                       | (0.2)                                                    |
| Infection                       | 2                                 | (1.3)                             | 0                       | (0.0)                   | 5                                               | (0.1)                                           | 9                                                        | (0.1)                                                    |
| Intestinal obstruction          | 2                                 | (1.3)                             | 2                       | (1.4)                   | 12                                              | (0.2)                                           | 25                                                       | (0.3)                                                    |
| Small intestinal obstruction    | 2                                 | (1.3)                             | 5                       | (3.5)                   | 10                                              | (0.2)                                           | 20                                                       | (0.2)                                                    |
| Squamous cell carcinoma         | 2                                 | (1.3)                             | 0                       | (0.0)                   | 24                                              | (0.4)                                           | 28                                                       | (0.3)                                                    |
| Subileus                        | 2                                 | (1.3)                             | 0                       | (0.0)                   | 0                                               | (0.0)                                           | 3                                                        | (0.0)                                                    |
| Anaemia                         | 1                                 | (0.7)                             | 2                       | (1.4)                   | 59                                              | (1.0)                                           | 86                                                       | (1.1)                                                    |
| Dyspnoea                        | 1                                 | (0.7)                             | 0                       | (0.0)                   | 83                                              | (1.4)                                           | 96                                                       | (1.2)                                                    |

<div style=\"page-break-after: always\"></div>

(0.1)

(0.2)

(0.2)

(0.1)

140

(1.7)

(1.2)

(0.5)

(0.0)

(0.3)

(0.7)

(0.1)

(0.4)

(0.1)

(0.0)

(0.0)

(1.3)

(0.0)

(1.0)

(0.3)

| Febrile neutropenia          |   1 | (0.7)   |   6 | (4.2)   |   4 | (0.1)   |   8 | (0.1)   |
|------------------------------|-----|---------|-----|---------|-----|---------|-----|---------|
| Ileus                        |   1 | (0.7)   |   3 | (2.1)   |  10 | (0.2)   |  19 | (0.2)   |
| Influenza                    |   1 | (0.7)   |   2 | (1.4)   |  11 | (0.2)   |  15 | (0.2)   |
| Large intestinal obstruction |   1 | (0.7)   |   2 | (1.4)   |   3 | (0.1)   |   5 | (0.1)   |
| Pneumonitis                  |   1 | (0.7)   |   0 | (0.0)   | 116 | (2.0)   | 140 | (1.7)   |
| Pulmonary embolism           |   1 | (0.7)   |   4 | (2.8)   |  71 | (1.2)   |  94 | (1.2)   |
| Vomiting                     |   1 | (0.7)   |   4 | (2.8)   |  28 | (0.5)   |  42 | (0.5)   |
| Cholangitis                  |   0 | (0.0)   |   2 | (1.4)   |   1 | (0.0)   |   4 | (0.0)   |
| Decreased appetite           |   0 | (0.0)   |   3 | (2.1)   |  18 | (0.3)   |  28 | (0.3)   |
| Dehydration                  |   0 | (0.0)   |   4 | (2.8)   |  42 | (0.7)   |  59 | (0.7)   |
| Device related infection     |   0 | (0.0)   |   2 | (1.4)   |   5 | (0.1)   |   7 | (0.1)   |
| Fatigue                      |   0 | (0.0)   |   3 | (2.1)   |  23 | (0.4)   |  30 | (0.4)   |
| Hypokalaemia                 |   0 | (0.0)   |   2 | (1.4)   |   8 | (0.1)   |  11 | (0.1)   |
| Intestinal perforation       |   0 | (0.0)   |   2 | (1.4)   |   4 | (0.1)   |   4 | (0.0)   |
| Neutropenia                  |   0 | (0.0)   |   3 | (2.1)   |   3 | (0.1)   |   4 | (0.0)   |
| Pleural effusion             |   0 | (0.0)   |   0 | (0.0)   |  83 | (1.4)   | 107 | (1.3)   |
| Tumour associated fever      |   0 | (0.0)   |   2 | (1.4)   |   2 | (0.0)   |   3 | (0.0)   |
| Urinary tract infection      |   0 | (0.0)   |   1 | (0.7)   |  59 | (1.0)   |  79 | (1.0)   |
| Urosepsis                    |   0 | (0.0)   |   2 | (1.4)   |  24 | (0.4)   |  26 | (0.3)   |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

## Table: Subjects With Drug-related Serious Adverse Events Up to 90 Days of Last Dose (Incidence â¥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

912

(11.3)

7,186

(88.7)

(0.9)

(0.2)

(0.0)

(0.6)

(0.2)

(0.3)

133

(1.6)

(0.1)

(0.1)

(0.0)

(0.0)

(0.0)

(0.1)

|                                 | KN177 Data for Pembrolizumab â â    | KN177 Data for Pembrolizumab â â    | KN177 Data for SOC Â¶Â¶   | KN177 Data for SOC Â¶Â¶   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   |
|---------------------------------|-----------------------------------|-----------------------------------|-------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                 | n                                 | (%)                               | n                       | (%)                     | n                                               | (%)                                             | n                                                        | (%)                                                      |
| Subjects in population          | 153                               |                                   | 143                     |                         | 5,884                                           |                                                 | 8,098                                                    |                                                          |
| with one or more adverse events | 25                                | (16.3)                            | 41                      | (28.7)                  | 650                                             | (11.0)                                          | 912                                                      | (11.3)                                                   |
| with no adverse events          | 128                               | (83.7)                            | 102                     | (71.3)                  | 5,234                                           | (89.0)                                          | 7,186                                                    | (88.7)                                                   |
| Colitis                         | 3                                 | (2.0)                             | 0                       | (0.0)                   | 51                                              | (0.9)                                           | 69                                                       | (0.9)                                                    |
| Acute kidney injury             | 2                                 | (1.3)                             | 2                       | (1.4)                   | 10                                              | (0.2)                                           | 18                                                       | (0.2)                                                    |
| Autoimmune colitis              | 2                                 | (1.3)                             | 0                       | (0.0)                   | 0                                               | (0.0)                                           | 3                                                        | (0.0)                                                    |
| Diarrhoea                       | 2                                 | (1.3)                             | 9                       | (6.3)                   | 38                                              | (0.6)                                           | 52                                                       | (0.6)                                                    |
| Hepatitis                       | 2                                 | (1.3)                             | 0                       | (0.0)                   | 8                                               | (0.1)                                           | 15                                                       | (0.2)                                                    |
| Pyrexia                         | 2                                 | (1.3)                             | 0                       | (0.0)                   | 17                                              | (0.3)                                           | 28                                                       | (0.3)                                                    |
| Pneumonitis                     | 1                                 | (0.7)                             | 0                       | (0.0)                   | 110                                             | (1.9)                                           | 133                                                      | (1.6)                                                    |
| Decreased appetite              | 0                                 | (0.0)                             | 3                       | (2.1)                   | 5                                               | (0.1)                                           | 10                                                       | (0.1)                                                    |
| Fatigue                         | 0                                 | (0.0)                             | 3                       | (2.1)                   | 8                                               | (0.1)                                           | 12                                                       | (0.1)                                                    |
| Febrile neutropenia             | 0                                 | (0.0)                             | 5                       | (3.5)                   | 0                                               | (0.0)                                           | 1                                                        | (0.0)                                                    |
| Intestinal perforation          | 0                                 | (0.0)                             | 2                       | (1.4)                   | 0                                               | (0.0)                                           | 0                                                        | (0.0)                                                    |
| Neutropenia                     | 0                                 | (0.0)                             | 3                       | (2.1)                   | 1                                               | (0.0)                                           | 2                                                        | (0.0)                                                    |
| Vomiting                        | 0                                 | (0.0)                             | 2                       | (1.4)                   | 9                                               | (0.2)                                           | 10                                                       | (0.1)                                                    |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

## Deaths Due to Adverse Events

The proportion of participants with AEs resulting in death was similar in the KEYNOTE-177 pembrolizumab and SOC safety datasets (6 participants [3.9%] vs 7 participants [4.9%]).

<div style=\"page-break-after: always\"></div>

All AEs leading to a fatal outcome were reported in a single participant. In the pembrolizumab arm: abdominal sepsis, death, diarrhoea, duodenal perforation, failure to thrive, pseudobulbar palsy; in the SOC arm: aortic dissection, aspiration, cardiac arrest, cholangitis, intestinal perforation, pulmonary embolism, upper gastrointestinal haemorrhage. None of the deaths were attributed to a drug-related AEs by investigator, vs one death considered due to a drug-related AE in the SOC arm.

Additionally, 3 subjects in the pembrolizumab crossover phase experienced AEs leading to death: recurrent lung carcinoma, pulmonary embolism, respiratory failure. All AEs leading to death were considered not related to pembrolizumab by the investigator.

## Adverse Events of Special Interest (AEOSI)

The analysis of AEOSIs is the primary method of assessing immune-related AEs (irAEs) and infusionrelated reactions for this study. The frequency and maximum severity of AEOSI analyses are based on a predefined list of preferred AE terms deemed clinically consistent with the identified risks of pembrolizumab (AEOSIs) and potentially associated with an immune etiology. This list was developed by the Sponsor and includes AEOSI terms identified to allow consistent assessment of AEOSIs across pembrolizumab studies. The list of terms is updated periodically based on emerging pembrolizumab safety data.

## Table: Adverse Event Summary AEOSI (ASaT Population)

|                                                               | KN177 Data for Pembrolizumab â â    | KN177 Data for Pembrolizumab â â    | KN177 Data for SOC Â¶Â¶   | KN177 Data for SOC Â¶Â¶   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   |
|---------------------------------------------------------------|-----------------------------------|-----------------------------------|-------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                               | n                                 | (%)                               | n                       | (%)                     | n                                               | (%)                                             | n                                                        | (%)                                                      |
| Subjects in population                                        | 153                               |                                   | 143                     |                         | 5,884                                           |                                                 | 8,098                                                    |                                                          |
| with one or more adverse events                               | 47                                | (30.7)                            | 18                      | (12.6)                  | 1,464                                           | (24.9)                                          | 1,957                                                    | (24.2)                                                   |
| with no adverse event                                         | 106                               | (69.3)                            | 125                     | (87.4)                  | 4,420                                           | (75.1)                                          | 6,141                                                    | (75.8)                                                   |
| with drug-related â  adverse events                            | 42                                | (27.5)                            | 15                      | (10.5)                  | 1,272                                           | (21.6)                                          | 1,708                                                    | (21.1)                                                   |
| with toxicity grade 3-5 adverse events                        | 14                                | (9.2)                             | 3                       | (2.1)                   | 377                                             | (6.4)                                           | 516                                                      | (6.4)                                                    |
| with toxicity grade 3-5 drug-related adverse events           | 12                                | (7.8)                             | 3                       | (2.1)                   | 329                                             | (5.6)                                           | 455                                                      | (5.6)                                                    |
| with serious adverse events                                   | 16                                | (10.5)                            | 1                       | (0.7)                   | 378                                             | (6.4)                                           | 502                                                      | (6.2)                                                    |
| with serious drug-related adverse events                      | 14                                | (9.2)                             | 1                       | (0.7)                   | 335                                             | (5.7)                                           | 449                                                      | (5.5)                                                    |
| who died                                                      | 0                                 | (0.0)                             | 0                       | (0.0)                   | 11                                              | (0.2)                                           | 17                                                       | (0.2)                                                    |
| who died due to a drug-related adverse event                  | 0                                 | (0.0)                             | 0                       | (0.0)                   | 11                                              | (0.2)                                           | 17                                                       | (0.2)                                                    |
| discontinued drug due to an adverse event                     | 10                                | (6.5)                             | 0                       | (0.0)                   | 227                                             | (3.9)                                           | 303                                                      | (3.7)                                                    |
| discontinued drug due to a drug-related adverse event         | 10                                | (6.5)                             | 0                       | (0.0)                   | 224                                             | (3.8)                                           | 300                                                      | (3.7)                                                    |
| discontinued drug due to a serious adverse event              | 6                                 | (3.9)                             | 0                       | (0.0)                   | 155                                             | (2.6)                                           | 199                                                      | (2.5)                                                    |
| discontinued drug due to a serious drug-related adverse event | 6                                 | (3.9)                             | 0                       | (0.0)                   | 153                                             | (2.6)                                           | 197                                                      | (2.4)                                                    |

## Table: Exposure-adjusted AEOSI

|                            | Event Count and Rate (Events/100 person-YEARS)f   | Event Count and Rate (Events/100 person-YEARS)f   | Event Count and Rate (Events/100 person-YEARS)f   | Event Count and Rate (Events/100 person-YEARS)f        |
|----------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------------|
|                            | KN177Data for Pembrolizuma btt                    | KN177 Data for SOCH                               | Reference Safety Dataset for Pembrolizuma b##     | Cumulative Running Safety Dataset for Pembrolizuma bss |
| Number of subjects exposed | 153                                               | 143                                               | 5884                                              | 8098                                                   |
| Totalexposure+person-YEARS | 181.33                                            | 109.95                                            | 3894.13                                           | 5224.80                                                |
| Total events (rate)        | 65 (35.85)                                        | 29 (26.38)                                        | 2127 (54.62)                                      | 2800 (53.59)                                           |

1,957

(24.2)

6,141

(75.8)

1,708

(21.1)

516

(6.4)

455

(5.6)

502

(6.2)

449

(5.5)

(0.2)

(0.2)

303

(3.7)

300

(3.7)

199

(2.5)

197

(2.4)

<div style=\"page-break-after: always\"></div>

## Table: AEOSI by grade

|                                 | KN177 Data for Pembrolizumabtt   | KN177 Data for Pembrolizumabtt   | KN177 Data for SOCI   | KN177 Data for SOCI   | Reference Safety Dataset for Pembrolizumab+t   | Reference Safety Dataset for Pembrolizumab+t   | Cumulative Running Safety Dataset for Pembrolizumabs$   | Cumulative Running Safety Dataset for Pembrolizumabs$   |
|---------------------------------|----------------------------------|----------------------------------|-----------------------|-----------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                 | n1                               | (%)                              | n                     | (%)                   | n                                              | (%)                                            | n                                                       | (%)                                                     |
| Subjects in population          | 153                              |                                  | 143                   |                       | 5,884                                          |                                                | 8,098                                                   |                                                         |
| with one or more adverse events | 47                               | (30.7)                           | 18                    | (12.6)                | 1,464                                          | (24.9)                                         | 1,957                                                   | (24.2)                                                  |
| Grade 1                         | 12                               | (7.8)                            | 4                     | (2.8)                 | 364                                            | (6.2)                                          | 470                                                     | (5.8)                                                   |
| Grade 2                         | 21                               | (13.7)                           | 11                    | (7.7)                 | 723                                            | (12.3)                                         | 971                                                     | (12.0)                                                  |
| Grade 3                         | 12                               | (7.8)                            | 3                     | (2.1)                 | 321                                            | (5.5)                                          | 442                                                     | (5.5)                                                   |
| Grade 4                         | 2                                | (1.3)                            | 0                     | (0.0)                 | 45                                             | (0.8)                                          | 57                                                      | (0.7)                                                   |
| Grade 5                         | 0                                | (0.0)                            | 0                     | (0.0)                 | 11                                             | (0.2)                                          | 17                                                      | (0.2)                                                   |
| with no adverse events          | 106                              | (69.3)                           | 125                   | (87.4)                | 4,420                                          | (75.1)                                         | 6,141                                                   | (75.8)                                                  |

## Table: Subjects With Adverse Events of Special Interest (Incidence &gt; 0% in One or More Treatment Groups) By AEOSI Category (ASaT Population)

1,957

(24.2)

6,141

(75.8)

|                                                                               | KN177 Data for Pembrolizumab â â    | KN177 Data for Pembrolizumab â â    | KN177 Data for SOC Â¶Â¶   | KN177 Data for SOC Â¶Â¶   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Reference Safety Dataset for Pembrolizumab â¡â¡   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   | Cumulative Running Safety Dataset for Pembrolizumab Â§Â§   |
|-------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|-------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                                               | n                                 | (%)                               | n                       | (%)                     | n                                               | (%)                                             | n                                                        | (%)                                                      |
| Subjects in population with one or more adverse events with no adverse events | 153 47                            | (30.7) (69.3)                     | 143 18 125              | (12.6) (87.4)           | 5,884 1,464 4,420                               | (24.9) (75.1)                                   | 8,098 1,957 6,141                                        | (24.2) (75.8)                                            |
| Adrenal Insufficiency                                                         | 106 4                             | (2.6)                             | 0                       | (0.0)                   | 47                                              | (0.8)                                           | 66                                                       | (0.8)                                                    |
| Colitis                                                                       | 10                                | (6.5)                             | 0                       | (0.0)                   | 110                                             | (1.9)                                           | 163                                                      | (2.0)                                                    |
| Encephalitis                                                                  | 0                                 | (0.0)                             | 0                       | (0.0)                   | 2                                               | (0.0)                                           | 4                                                        | (0.0)                                                    |
| Guillain-Barre Syndrome                                                       | 0                                 | (0.0)                             | 0                       | (0.0)                   | 4                                               | (0.1)                                           | 6                                                        | (0.1)                                                    |
| Hepatitis                                                                     | 4                                 | (2.6)                             | 0                       | (0.0)                   | 55                                              | (0.9)                                           | 82                                                       | (1.0)                                                    |
| Hyperthyroidism                                                               | 6                                 | (3.9)                             | 0                       | (0.0)                   | 245                                             | (4.2)                                           | 348                                                      | (4.3)                                                    |
| Hypophysitis                                                                  | 2                                 | (1.3)                             | 0                       | (0.0)                   | 36                                              | (0.6)                                           | 44                                                       | (0.5)                                                    |
| Hypothyroidism                                                                | 19                                | (12.4)                            | 3                       | (2.1)                   | 648                                             | (11.0)                                          | 864                                                      | (10.7)                                                   |
| Infusion Reactions                                                            | 3                                 | (2.0)                             | 11                      | (7.7)                   | 135                                             | (2.3)                                           | 165                                                      | (2.0)                                                    |
| Myasthenic Syndrome                                                           | 0                                 | (0.0)                             | 0                       | (0.0)                   | 3                                               | (0.1)                                           | 4                                                        | (0.0)                                                    |
| Myelitis                                                                      | 0                                 | (0.0)                             | 0                       | (0.0)                   | 2                                               | (0.0)                                           | 2                                                        | (0.0)                                                    |
| Myocarditis                                                                   | 0                                 | (0.0)                             | 1                       | (0.7)                   | 5                                               | (0.1)                                           | 7                                                        | (0.1)                                                    |
| Myositis                                                                      | 1                                 | (0.7)                             | 0                       | (0.0)                   | 19                                              | (0.3)                                           | 32                                                       | (0.4)                                                    |
| Nephritis                                                                     | 1                                 | (0.7)                             | 0                       | (0.0)                   | 23                                              | (0.4)                                           | 36                                                       | (0.4)                                                    |
| Pancreatitis                                                                  | 1                                 | (0.7)                             | 0                       | (0.0)                   | 18                                              | (0.3)                                           | 31                                                       | (0.4)                                                    |
| Pneumonitis                                                                   | 6                                 | (3.9)                             | 1                       | (0.7)                   | 259                                             | (4.4)                                           | 326                                                      | (4.0)                                                    |
| Sarcoidosis                                                                   | 0                                 | (0.0)                             | 0                       | (0.0)                   | 10                                              | (0.2)                                           | 11                                                       | (0.1)                                                    |
| Severe Skin Reactions                                                         | 2                                 | (1.3)                             | 2                       | (1.4)                   | 95                                              | (1.6)                                           | 125                                                      | (1.5)                                                    |
| Thyroiditis                                                                   | 2                                 | (1.3)                             | 0                       | (0.0)                   | 57                                              | (1.0)                                           | 75                                                       | (0.9)                                                    |
| Uveitis                                                                       | 0                                 | (0.0)                             | 0                       | (0.0)                   | 20                                              | (0.3) (0.3)                                     | 25                                                       | (0.3)                                                    |
| Type 1 Diabetes Mellitus                                                      | 1                                 | (0.7)                             | 0                       | (0.0)                   | 20                                              |                                                 | 29                                                       | (0.4)                                                    |

<div style=\"page-break-after: always\"></div>

## Table: summary of outcome for AEOSI (excerpt)

Colitis

|                        |              |   KN177 Data for Pembrolizumabit | KN177 Data for Pembrolizumabit   | KN177 Data for SOCW   | KN177 Data for SOCW   | Reference Safety Dataset for Pembrolizumab!t   | Reference Safety Dataset for Pembrolizumab!t   |   Cumulative Rumning Safety Dataset for Pembrolizumab | Cumulative Rumning Safety Dataset for Pembrolizumab   |
|------------------------|--------------|----------------------------------|----------------------------------|-----------------------|-----------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                        | Outcome      |                               11 | (%)                              |                       | (%)                   | n                                              | (%)                                            |                                                    11 | (%)                                                   |
| Subjects in population |              |                              153 |                                  | 143                   |                       | 5884                                           |                                                |                                                  8098 |                                                       |
| Withoneormore AEOSI    | Overall      |                               47 | (30.7)                           | 18                    | (12.0)                | 1464                                           | (24.9)                                         |                                                  1957 | (24.2)                                                |
|                        | Fatal        |                                0 | (0.0)                            | 0                     | (0.0)                 | 11                                             | (0.8)                                          |                                                    17 | (0.9)                                                 |
|                        | Not Resolved |                               23 | (48.9)                           | 2                     | (11.1)                | 689                                            | (47.1)                                         |                                                   912 | (46.6)                                                |
|                        | Resolving    |                                2 | (4.3)                            | 1                     | (5.6)                 | 99                                             | (6.8)                                          |                                                   153 | (7.8)                                                 |
|                        | Unknown      |                                0 | (0.0)                            | 0                     | (0.0)                 | 27                                             | (1.8)                                          |                                                    29 | (1.5)                                                 |
|                        | Sequelae     |                                2 | (4.3)                            | 0                     | (0.0)                 | 31                                             | (2.1)                                          |                                                    42 | (2.1)                                                 |
|                        | Resolved     |                               20 | (42.6)                           | 15                    | (83.3)                | 607                                            | (41.5)                                         |                                                   804 | (41.1)                                                |

## Table: Adverse Event Summary AEOSI - Colitis (ASaT Population)

|                                                       | KN177 Data for Pembrolizumabtt   | KN177 Data for Pembrolizumabtt   | KN177 Data for SOCff   | KN177 Data for SOCff   | Reference Safety Dataset for Pembrolizumabtt   | Reference Safety Dataset for Pembrolizumabtt   | Cumulative Running Safety Dataset for Pembrolizumabss   | Cumulative Running Safety Dataset for Pembrolizumabss   |
|-------------------------------------------------------|----------------------------------|----------------------------------|------------------------|------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                       | 1n1                              | (%)                              | n                      | (%)                    | n                                              | (%)                                            | 1n1                                                     | (%)                                                     |
| Subjects in population                                | 153                              |                                  | 143                    |                        | 5,884                                          |                                                | 8,098                                                   |                                                         |
| with one or more adverse events                       | 10                               | (6.5)                            | 0                      | (0.0)                  | 110                                            | (1.9)                                          | 163                                                     | (2.0)                                                   |
| with no adverse event                                 | 143                              | (93.5)                           | 143                    | (100.0)                | 5,774                                          | (98.1)                                         | 7,935                                                   | (98.0)                                                  |
| with drug-relatedf adverse events                     | 10                               | (6.5)                            | 0                      | (0.0)                  | 97                                             | (1.6)                                          | 141                                                     | (1.7)                                                   |
| with toxicity grade 3-5 adverse events                | 5                                | (3.3)                            | 0                      | (0.0)                  | 67                                             | (1.1)                                          | 95                                                      | (1.2)                                                   |
| with toxicity grade 3-5 drug-related adverse events   | 5                                | (3.3)                            | 0                      | (0.0)                  | 60                                             | (1.0)                                          | 85                                                      | (1.0)                                                   |
| with serious adverse events                           | 5                                | (3.3)                            | 0                      | (0.0)                  | 66                                             | (1.1)                                          | 93                                                      | (1.1)                                                   |
| with serious drug-related adverse events              | 5                                | (3.3)                            | 0                      | (0.0)                  | 58                                             | (1.0)                                          | 81                                                      | (1.0)                                                   |
| who died                                              | 0                                | (0.0)                            | 0                      | (0.0)                  | 0                                              | (0.0)                                          | 0                                                       | (0.0)                                                   |
| who died due to a drug-related adverse event          | 0                                | (0.0)                            | 0                      | (0.0)                  | 0                                              | (0.0)                                          | 0                                                       | (0.0)                                                   |
| discontinued drug due to an adverse event             | 4                                | (2.6)                            | 0                      | (0.0)                  | 30                                             | (0.5)                                          | 42                                                      | (0.5)                                                   |
| discontinued drug due to a drug-related adverse event | 4                                | (2.6)                            | 0                      | (0.0)                  | 30                                             | (0.5)                                          | 42                                                      | (0.5)                                                   |
| discontinued drug due to a serious adverse event      | 2                                | (1.3)                            | 0                      | (0.0)                  | 18                                             | (0.3)                                          | 26                                                      | (0.3)                                                   |

Of the 5 patients who had Grade 3-5 colitis (3.3%), 3 cases were grade 3 (2%) and 2 cases grade 4 (1.3%), vs 1.1% and 0.1% Grade 3 and grade 4, respectively, in the RSD.

## Table: exposure adjusted event rates (events/100 person-years) (include PTs of colitis and autoimmune colitis) table made by assessor

|                        |   KN177 Pembro |   RSD Pembro |   KN177 SOC |
|------------------------|----------------|--------------|-------------|
| Colitis, all grade     |            6.4 |          4.1 |           0 |
| Colitis, Grade 3-5 AEs |            2.8 |          1.7 |           0 |

<div style=\"page-break-after: always\"></div>

## Table: Colitis by grade (excerpt)

| Colitis   | 10 (6.5)   | 0 (0.0)   |   110 | (1.9)   |   163 | (2.0)   |
|-----------|------------|-----------|-------|---------|-------|---------|
| Grade 1   | 3 (2.0)    | 0 (0.0)   |    11 | (0.2)   |    20 | (0.2)   |
| Grade 2   | 2 (1.3)    | 0 (0.0)   |    32 | (0.5)   |    48 | (0.6)   |
| Grade 3   | 3 (2.0)    | 0 (0.0)   |    64 | (1.1)   |    89 | (1.1)   |
| Grade 4   | 2 (1.3)    | 0 (0.0)   |     3 | (0.1)   |     6 | (0.1)   |

## Table: time to onset and duration of AEOSI colitis

|                                                                         | KN177 Data for Pembrolizumabtt 1n (%)   | KN177Datafor SOCM n (%)   | Reference Safety Dataset for Pembrolizumabtt 1n (%)   | Cumulative Running Safety Dataset for Pembrolizumabs$ 1n (%)   |
|-------------------------------------------------------------------------|-----------------------------------------|---------------------------|-------------------------------------------------------|----------------------------------------------------------------|
| Subjects in population                                                  | 153                                     | 143 0                     | 5884 110                                              | 8098 163                                                       |
| Subjects with Colitis Time to Onset of First Colitis (days)â Mean (Std) | 10 (6.5)                                | 0                         | (1.9) 187.5 (160.8) 132.0                             | (2.0) 187.9 (166.9)                                            |
| Median Range Total episodes of Colitis Average Episodes per patient     | 256.9 (172.1) 186.0 95 to 560           | 0.0 Oto0 0                | 7to 739                                               | 125.0 7to 739                                                  |
|                                                                         | 11                                      | 0                         | 155                                                   | 211 1.29                                                       |
| Episode duration (days) Median                                          | 1.10 71.0                               | 0                         | 1.41 27.0                                             | 32.0                                                           |
| Range                                                                   | 15 to 378                               | Oto0                      | 1 to 266+                                             | 1 to 642                                                       |

Out of the 10 participants with colitis events in the KEYNOTE-177 pembrolizumab safety dataset, 8 were treated with systemic corticosteroids (vs 58% in the RSD).

As of the data cutoff date, 9 of 10 participants with colitis AEOSIs had resolved events. One participant had an unresolved Grade 1 event; however, this participant experienced disease progression resulting in the participant's death.

## Laboratory findings

In KEYNOTE-177, the only laboratory test that was &gt;10% points higher in the pembrolizumab group relative to the SOC group was blood bilirubin increased, with most of the toxicities being Grade 1 or 2.

The incidence of laboratory abnormalities with clinically meaningful (Grade 3 to 4 events) worsening from baseline was similar in the pembrolizumab safety dataset compared with the SOC safety dataset, except for lower rates ( â¥ 10% lower incidence) of neutrophils decreased reported in the pembrolizumab safety dataset compared with the SOC safety dataset (2.7% vs 34.5%), known to be associated with cytotoxic chemotherapies.

The incidences of laboratory abnormalities with clinically meaningful worsening from baseline in the KEYNOTE-177 pembrolizumab safety dataset were generally consistent with the RSD.

None of the participants in KEYNOTE-177 (in either arm) had laboratory values that satisfied the protocolspecified criteria for potential drug-induced liver injury.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Age

## Table: Adverse Event Summary by Age Category (ASaT Population)

## - Keynote 177 - Pembrolizumab vs SOC

|                                                               |       | KN177 Data for Pembrolizumabit   | KN177 Data for Pembrolizumabit   | KN177 Data for Pembrolizumabit   | KN177 Data for Pembrolizumabit   | KN177 Data for Pembrolizumabit   | KN177 Data for SOcl   | KN177 Data for SOcl   | KN177 Data for SOcl   | KN177 Data for SOcl   | KN177 Data for SOcl   | KN177 Data for SOcl   | KN177 Data for SOcl   |
|---------------------------------------------------------------|-------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                                                               |       | <65                              | <65                              | 65-74                            | 75-84                            |                                  | >=85 <65              | >=85 <65              | 65-74                 | 65-74                 | 75-84                 | 75-84                 | >=85                  |
|                                                               | n     | (%)                              | (%)                              | n (%)                            | n (%)                            | n                                | (%) n                 | (%)                   | n (%)                 | n (%)                 | n (%)                 | n (%)                 | n (%)                 |
| Subjects in population                                        | 80    |                                  | 43                               |                                  | 22                               | 8                                | 76                    |                       | 38                    |                       | 23                    | 6                     |                       |
| with one or more adverse events                               | 79    | (98.8)                           | 41                               | (95.3)                           | 21 (95.5)                        | 8 (100.0)                        | 76                    | (100.0)               | 37                    | (97.4)                | 23 (100.0)            |                       | 6 (100.0)             |
| with no adverse event                                         | 1     | (1.3)                            | 2                                | (4.7)                            | 1 (4.5)                          | 0 (0.0)                          | 0                     | (0.0)                 | 1                     | (2.6)                 | 0 (0.0)               |                       | 0 (0.0)               |
| withdrug-relatedadverse events                                | 66    | (82.5)                           | 33                               | (76.7)                           | 16 (72.7)                        | 7 (87.5)                         | 76                    | (100.0)               | 36                    | (94.7)                | 23 21                 | (100.0)               | 6 (100.0)             |
| with toxicity grade 3-5 adverse events                        | 39    | (48.8)                           | 27                               | (62.8)                           | 12 (54.5)                        | 8 (100.0)                        | 53                    | (69.7)                | 31                    | (81.6)                | (91.3)                |                       | 6 (100.0)             |
| with toxicity grade 3-5 drug-related adverse events           | 16    | (20.0)                           | 6                                | (14.0)                           | 5 (22.7)                         | 6 (75.0)                         | 41                    | (53.9)                | 28                    | (73.7)                | 20                    | (87.0)                | 5 (83.3)              |
| with serious adverse events                                   |       | (31.3)                           | 22                               | (51.2)                           | 8 (36.4)                         | 7 (87.5)                         | 34                    | (44.7)                | 24                    | (63.2)                | 14 (60.9)             | 3                     | (50.0)                |
| with serious drug-related adverse events                      | 25 12 | (15.0)                           | 5                                | (11.6)                           | 3 (13.6)                         | 5 (62.5)                         | 12                    | (15.8)                | 14                    | (36.8)                | 13                    | (56.5)                | 2 (33.3)              |
| who died                                                      | 1     | (1.3)                            | 3                                | (0'L)                            | 1                                | 1 (12.5)                         | 3                     | (3.9)                 | 2                     | (5.3)                 | 1 (4.3)               | 1                     | (16.7)                |
| who died due to a drug-related adverse event                  | 0     | (0.0)                            | 0                                | (0.0)                            | (4.5) 0 (0.0)                    | 0 (0.0)                          | 1                     | (1.3)                 | 0                     | (0.0)                 | 0 5                   | 0                     | (0.0)                 |
| discontinued drug due to an adverse event                     | 9     | (11.3)                           | 5                                | (11.6)                           | 5 (22.7)                         | 2 (25.0)                         | 8                     | (10.5)                | 3                     | (6L)                  | (0.0) (21.7)          | 1                     | (16.7)                |
| discontinued drug due to adrug-related adverse event          |       | 8 (10.0)                         | 3                                | (0L)                             | 3 (13.6)                         | 1 (12.5)                         | 3                     | (3.9)                 | 0                     | (0.0)                 | 4 (17.4)              | 1                     | (16.7)                |
| discontinued drug due to a serious adverse event              |       | 4 (5.0)                          | 4                                | (9.3)                            | 2 (9.1)                          | 2 (25.0)                         | 6                     | (7.9)                 | 2                     | (5.3)                 | 4 (17.4)              | 1                     | (16.7)                |
| discontinued drug due to a serious drug-related adverse event |       | 3 (3.8)                          | 2                                | (4.7)                            | 1 (4.5)                          | 1 (12.5)                         | 1                     | (1.3)                 | 0                     | (0.0)                 | 3 (13.0)              |                       | (16.7)                |
| CNS (confusion/extrapyramidal)                                | 7     | (8.8)                            | 4 (9.3)                          | 3                                | (13.6)                           | 3 (37.5)                         | 11                    | (14.5)                | 7                     | (18.4)                | 2 (8.7)               |                       | 0 (0.0)               |
| AE related to falling                                         | 7     | (8.8)                            | 8 (18.6)                         | 4                                | (18.2)                           | 2 (25.0)                         | 7                     | (9.2)                 | 3                     | (6L)                  | 8 (34.8)              | 1                     | (16.7)                |
| CV events                                                     | 16    | (20.0)                           | 8 (18.6)                         | 6                                | (27.3)                           | 5 (62.5)                         | 23                    | (30.3)                | 14                    | (36.8)                | 13 (56.5)             |                       | 2 (33.3)              |
| Cerebrovascularevents                                         | 1     | (1.3)                            | 2 (4.7)                          | 1                                | (4.5)                            | 0 (0.0)                          | 2                     | (2.6)                 | 0                     | (0.0)                 | 2 (8.7)               | 0                     | (0.0)                 |
| Infections                                                    | 52    | (65.0)                           | 28 (65.1)                        | 10                               | (45.5)                           | 4 (50.0)                         | 48                    | (63.2)                | 21                    | (55.3)                | 12                    | (52.2)                | 2 (33.3)              |

## - Pembrolizumab monotherapy RSD and CSD

|                                                               |       | Reference Safety Dataset for Pembrolizumab##   | Reference Safety Dataset for Pembrolizumab##   | Reference Safety Dataset for Pembrolizumab##   | Reference Safety Dataset for Pembrolizumab##   | Reference Safety Dataset for Pembrolizumab##   | Reference Safety Dataset for Pembrolizumab##   | Reference Safety Dataset for Pembrolizumab##   | Reference Safety Dataset for Pembrolizumab##   | Cumulative Running Safety Dataset for Pembrolizumabs5   | Cumulative Running Safety Dataset for Pembrolizumabs5   | Cumulative Running Safety Dataset for Pembrolizumabs5   | Cumulative Running Safety Dataset for Pembrolizumabs5   | Cumulative Running Safety Dataset for Pembrolizumabs5   | Cumulative Running Safety Dataset for Pembrolizumabs5   | Cumulative Running Safety Dataset for Pembrolizumabs5   | Cumulative Running Safety Dataset for Pembrolizumabs5   |
|---------------------------------------------------------------|-------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                               |       |                                                | <65                                            | <65                                            | 65-74                                          | 65-74                                          |                                                |                                                | >=85 <65                                       | >=85 <65                                                |                                                         |                                                         | 75-84                                                   | 75-84                                                   | >=85                                                    | >=85                                                    | >=85                                                    |
|                                                               |       | n                                              | (%)                                            | n                                              | (%)                                            | n                                              | 75-84 (%)                                      | n                                              | (%)                                            | n                                                       | (%)                                                     | n                                                       | 65-74 (%)                                               | n                                                       | (%)                                                     | n                                                       | (%)                                                     |
| Subjects in population                                        | 3,385 |                                                |                                                | 1,737                                          |                                                | 663                                            |                                                | 66                                             |                                                | 4,598                                                   |                                                         | 2,445                                                   |                                                         | 918                                                     |                                                         | 137                                                     |                                                         |
| with one or more adverse events                               | 3,266 | (96.5)                                         | 1,677                                          |                                                | (96.5)                                         | 646                                            | (97.4)                                         | 98                                             | (99.0)                                         | 4,434                                                   | (96.4)                                                  | 2,351                                                   | (96.2)                                                  | 891                                                     | (97.1)                                                  | 136                                                     | (99.3)                                                  |
| with no adverse event                                         | 119   | (3.5)                                          |                                                | 60                                             | (3.5)                                          | 17                                             | (2.6)                                          | 1                                              | (1.0)                                          | 164                                                     | (3.6)                                                   | 94                                                      | (3.8)                                                   | 27                                                      | (2.9)                                                   | 1                                                       | (0.7)                                                   |
| with drug-related adverse events                              | 2,358 | (69.7)                                         |                                                | 1,223                                          | (70.4)                                         | 467                                            | (70.4)                                         | 75                                             | (75.8)                                         | 3,132                                                   | (68.1)                                                  | 1,711                                                   | (70.0)                                                  | 635                                                     | (69.2)                                                  | 103                                                     | (75.2)                                                  |
| with toxicity grade3-5adverse events                          | 1,489 | (44.0)                                         |                                                | 891                                            | (51.3)                                         | 373                                            | (56.3)                                         | 60                                             | (60.6)                                         | 2,112                                                   | (45.9)                                                  | 1,241                                                   | (50.8)                                                  | 507                                                     | (55.2)                                                  | 81                                                      | (59.1)                                                  |
| with toxicity grade 3-5 drug-related adverse events           | 452   | (13.4)                                         |                                                | 311                                            | (17.9)                                         | 128                                            | (19.3)                                         | 18                                             | (18.2)                                         | 646                                                     | (14.0)                                                  | 440                                                     | (18.0)                                                  | 181                                                     | (19.7)                                                  | 30                                                      | (21.9)                                                  |
| with serious adverse events                                   | 1,168 | (34.5)                                         |                                                | 719                                            | (41.4)                                         | 315                                            | (47.5)                                         | 50                                             | (50.5)                                         | 1,615                                                   | (35.1)                                                  | 988                                                     | (40.4)                                                  | 425                                                     | (46.3)                                                  | 66                                                      | (48.2)                                                  |
| with serious drug-related adverse events                      |       | 339                                            | (10.0)                                         | 214                                            | (12.3)                                         | 85                                             | (12.8)                                         | 12                                             | (12.1)                                         | 464                                                     | (10.1)                                                  | 310                                                     | (12.7)                                                  | 119                                                     | (13.0)                                                  | 19                                                      | (13.9)                                                  |
| who died                                                      |       | 143                                            | (4.2)                                          | 103                                            | (5.9)                                          | 54                                             | (8.1)                                          | 11                                             | (11.1)                                         | 201                                                     | (4.4)                                                   | 153                                                     | (6.3)                                                   | 79                                                      | (8.6)                                                   | 13                                                      | (9.5)                                                   |
| who died due to a drug-related adverse event                  |       | 21                                             | (0.6)                                          | 12                                             | (0.7)                                          | 5                                              | (0.8)                                          | 1                                              | (1.0)                                          | 27                                                      | (0.6)                                                   | 22                                                      | (0.9)                                                   | 10                                                      | (1.1)                                                   | 1                                                       | (0.7)                                                   |
| discontinueddrug due toan adverse event                       |       | 392                                            | (11.6)                                         | 246                                            | (14.2)                                         | 131                                            | (19.8)                                         | 14                                             | (14.1)                                         | 511                                                     | (11.1)                                                  | 336                                                     | (13.7)                                                  | 173                                                     | (18.8)                                                  | 21                                                      | (15.3)                                                  |
| discontinued drug due toa drug-related adverse event          |       | 202                                            | (6.0)                                          | 135                                            | (7.8)                                          | 62                                             | (9.4)                                          | 6                                              | (6.1)                                          | 260                                                     | (5.7)                                                   | 185                                                     | (7.6)                                                   | 86                                                      | (9.4)                                                   | 11                                                      | (8.0)                                                   |
| discontinueddrug due toa serious adverse event                |       | 285                                            | (8.4)                                          | 174                                            | (10.0)                                         | 100                                            | (15.1)                                         | 11                                             | (11.1)                                         | 375                                                     | (8.2)                                                   | 237                                                     | (9.7)                                                   | 129                                                     | (14.1)                                                  | 15                                                      | (10.9)                                                  |
| discontinued drug due to a serious drug-related adverse event |       | 122                                            | (3.6)                                          | 81                                             | (4.7)                                          | 38                                             | (5.7)                                          | 3                                              | (3.0)                                          | 159                                                     | (3.5)                                                   | 111                                                     | (4.5)                                                   | 52                                                      | (5.7)                                                   | 5                                                       | (3.6)                                                   |
| CNS (confusion/extrapyramidal)                                | 247   | (7.3)                                          | 157                                            | (9.0)                                          | 46                                             |                                                | (6.9)                                          | 16                                             | (16.2)                                         | 335                                                     | (7.3)                                                   | 215                                                     | (8.8)                                                   | 62                                                      | (6.8)                                                   | 22                                                      | (16.1)                                                  |
| AErelated tofalling                                           | 225   | (6.6)                                          | 152                                            | (8.8)                                          | 70                                             |                                                | (10.6)                                         | 20                                             | (20.2)                                         | 295                                                     | (6.4)                                                   | 206                                                     | (8.4)                                                   | 99                                                      | (10.8)                                                  | 26                                                      | (19.0)                                                  |
| CVevents                                                      | 649   | (19.2)                                         | 395                                            | (22.7)                                         | 160                                            |                                                | (24.1)                                         | 25                                             | (25.3)                                         | 869                                                     | (18.9)                                                  | 516                                                     | (21.1)                                                  | 208                                                     | (22.7)                                                  | 34                                                      | (24.8)                                                  |
| Cerebrovascular events                                        | 61    | (1.8)                                          | 40                                             | (2.3)                                          | 20                                             |                                                | (3.0)                                          | 3                                              | (3.0)                                          | 76                                                      | (1.7)                                                   | 53                                                      | (2.2)                                                   | 29                                                      | (3.2)                                                   | 3                                                       | (2.2)                                                   |
|                                                               | 1434  | (42.4)                                         |                                                | (44.5)                                         |                                                |                                                |                                                | 44                                             |                                                |                                                         |                                                         | 1048                                                    | (42.9)                                                  |                                                         |                                                         | 63                                                      |                                                         |
| Infections                                                    |       |                                                | 773                                            |                                                | 308                                            |                                                | (46.5)                                         |                                                | (44.4)                                         | 1866                                                    | (40.6)                                                  |                                                         |                                                         | 404                                                     | (44.0)                                                  |                                                         | (46.0)                                                  |

<div style=\"page-break-after: always\"></div>

Sex

Table: Adverse Event Summary by Gender (Male, Female) (ASaT Population)

|                                                  | KN177DataforPembrolizumabtt   | KN177DataforPembrolizumabtt   | KN177DataforPembrolizumabtt   | KN177DataforPembrolizumabtt   | KN177Data forSOc   | KN177Data forSOc   | KN177Data forSOc   | KN177Data forSOc   | ReferenceSafetyDatasetfor Pembrolizumabt   | ReferenceSafetyDatasetfor Pembrolizumabt   | ReferenceSafetyDatasetfor Pembrolizumabt   | ReferenceSafetyDatasetfor Pembrolizumabt   | CumulativeRunningSafetyDataset forPembrolizumabs5   | CumulativeRunningSafetyDataset forPembrolizumabs5   | CumulativeRunningSafetyDataset forPembrolizumabs5   | CumulativeRunningSafetyDataset forPembrolizumabs5   |
|--------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|--------------------|--------------------|--------------------|--------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                  | M                             | M                             | F                             | F                             | M                  | M                  | F                  | F                  | M                                          | M                                          | F                                          | F                                          | M                                                   | M                                                   | F                                                   | F                                                   |
|                                                  | n                             | (%)                           | n                             | (%)                           |                    | (%)                | n                  | (%)                |                                            | (%)                                        | n                                          | (%)                                        |                                                     | (%)                                                 | 11                                                  | (%)                                                 |
| Subjects in population                           | 71                            |                               | 82                            |                               | 75                 |                    | 68                 |                    | 3,887                                      |                                            | 1,997                                      |                                            | 5,406                                               |                                                     | 2,692                                               |                                                     |
| with one or more adverse events                  | 69                            | (97.2)                        | 80                            | (97.6)                        | 74                 | (98.7)             | 68                 | (100.0)            | 3,754                                      | (96.6)                                     | 1,933                                      | (96.8)                                     | 5,203                                               | (96.2)                                              | 2,609                                               | (96.9)                                              |
| with no adverse event                            | 2                             | (2.8)                         | 2                             | (2.4)                         | 1                  | (1.3)              | 0                  | (0.0)              | 133                                        | (3.4)                                      | 64                                         | (3.2)                                      | 203                                                 | (3.8)                                               | 83                                                  | (3.1)                                               |
| withdrug-relatedadverse events                   | 55                            | (77.5)                        | 67                            | (81.7)                        | 73                 | (97.3)             | 68                 | (100.0)            | 2,703                                      | (69.5)                                     | 1,420                                      | (71.1)                                     | 3,680                                               | (68.1)                                              | 1,901                                               | (70.6)                                              |
| with toxicitygrade3-5adverse events              | 34                            | (47.9)                        | 52                            | (63.4)                        | 55                 | (73.3)             | 56                 | (82.4)             | 1,884                                      | (48.5)                                     | 929                                        | (46.5)                                     | 2,649                                               | (49.0)                                              | 1,292                                               | (48.0)                                              |
| with toxicitygrade3-5drug-related adverse events | 17                            | (23.9)                        | 16                            | (19.5)                        | 46                 | (61.3)             | 48                 | (70.6)             | 626                                        | (16.1)                                     | 283                                        | (14.2)                                     | 908                                                 | (16.8)                                              | 389                                                 | (14.5)                                              |
| withserious adverse events                       | 25                            | (35.2)                        | 37                            | (45.1)                        | 37                 | (49.3)             | 38                 | (55.9)             | 1,525                                      | (39.2)                                     | 727                                        | (36.4)                                     | 2,100                                               | (38.8)                                              | 994                                                 | (36.9)                                              |
| withseriousdrug-relatedadverseevents             | 13                            | (18.3)                        | 12                            | (14.6)                        | 16                 | (21.3)             | 25                 | (36.8)             | 443                                        | (11.4)                                     | 207                                        | (10.4)                                     | 638                                                 | (11.8)                                              | 274                                                 | (10.2)                                              |
| who died                                         | 2                             | (2.8)                         | 4                             | (4.9)                         | 4                  | (5.3)              | 3                  | (4.4)              | 220                                        | (5.7)                                      | 91                                         | (4.6)                                      | 326                                                 | (6.0)                                               | 120                                                 | (4.5)                                               |
| whodiedduetoadrug-relatedadverse event           | 0                             | (0.0)                         | 0                             | (0.0)                         | 1                  | (1.3)              | 0                  | (0.0)              | 25                                         | (0.6)                                      | 14                                         | (0.7)                                      | 40                                                  | (0.7)                                               | 20                                                  | (0.7)                                               |
| discontinueddrugduetoan adverseevent             | 7                             | (9.9)                         | 14                            | (17.1)                        | 7                  | (9.3)              | 10                 | (14.7)             | 526                                        | (13.5)                                     | 257                                        | (12.9)                                     | 713                                                 | (13.2)                                              | 328                                                 | (12.2)                                              |
| discontinueddrugduetoadrug-related adverseevent  | 6                             | (8.5)                         | 9                             | (11.0)                        | 4                  | (5.3)              | 4                  | (5.9)              | 276                                        | (7.1)                                      | 129                                        | (6.5)                                      | 376                                                 | (7.0)                                               | 166                                                 | (6.2)                                               |
| discontinueddrugduetoaserious adverse event      | 5                             | (7.0)                         | 7                             | (8.5)                         | 5                  | (6.7)              | 8                  | (11.8)             | 385                                        | (9.9)                                      | 185                                        | (9.3)                                      | 521                                                 | (9.6)                                               | 235                                                 | (8.7)                                               |

## Region

Table: Adverse Event Summary by Region (EU, Ex-EU) (ASaT Population)

|                                                  | KN177Data forPembrolizumabit   | KN177Data forPembrolizumabit   | KN177Data forPembrolizumabit   | KN177Data forPembrolizumabit   | KN177Data forSOc   | KN177Data forSOc   | KN177Data forSOc   | KN177Data forSOc   | ReferenceSafetyDatasetfor Pembrolizumabt+   | ReferenceSafetyDatasetfor Pembrolizumabt+   | ReferenceSafetyDatasetfor Pembrolizumabt+   | ReferenceSafetyDatasetfor Pembrolizumabt+   | CumulativeRunningSafetyDataset for Pembrolizumab3s   | CumulativeRunningSafetyDataset for Pembrolizumab3s   | CumulativeRunningSafetyDataset for Pembrolizumab3s   | CumulativeRunningSafetyDataset for Pembrolizumab3s   |
|--------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------|--------------------|--------------------|--------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                  | EU                             | EU                             | Ex-EU                          | Ex-EU                          | EU                 | EU                 | Ex-EU              | Ex-EU              | EU                                          | EU                                          | Ex-EU                                       | Ex-EU                                       | EU                                                   | EU                                                   | Ex-EU                                                | Ex-EU                                                |
|                                                  | n                              | (%)                            | n                              | (%)                            |                    | (%)                | n                  | (%)                | n                                           | (%)                                         | n                                           | (%)                                         | n                                                    | (%)                                                  | n                                                    | (%)                                                  |
| Subjects in population                           | 78                             |                                | 75                             |                                | 81                 |                    | 62                 |                    | 2,091                                       |                                             | 3,793                                       |                                             | 2,831                                                |                                                      | 5,267                                                |                                                      |
| with one ormore adverse events                   | 75                             | (96.2)                         | 74                             | (98.7)                         | 81                 | (100.0)            | 61                 | (98.4)             | 2,012                                       | (96.2)                                      | 3,675                                       | (96.9)                                      | 2,720                                                | (96.1)                                               | 5,092                                                | (96.7)                                               |
| withnoadverse event                              | 3                              | (3.8)                          | 1                              | (1.3)                          | 0                  | (0.0)              | 1                  | (1.6)              | 79                                          | (3.8)                                       | 118                                         | (3.1)                                       | 111                                                  | (3.9)                                                | 175                                                  | (3.3)                                                |
| withdrug-relatedfadverseevents                   | 64                             | (82.1)                         | 58                             | (77.3)                         | 80                 | (98.8)             | 61                 | (98.4)             | 1,426                                       | (68.2)                                      | 2,697                                       | (71.1)                                      | 1,901                                                | (67.1)                                               | 3,680                                                | (69.9)                                               |
| withtoxicitygrade3-5adverseevents                | 44                             | (56.4)                         | 42                             | (56.0)                         | 58                 | (71.6)             | 53                 | (85.5)             | 952                                         | (45.5)                                      | 1,861                                       | (49.1)                                      | 1,346                                                | (47.5)                                               | 2,595                                                | (49.3)                                               |
| with toxicitygrade3-5drug-related adverse events | 21                             | (26.9)                         | 12                             | (16.0)                         | 46                 | (56.8)             | 48                 | (77.4)             | 312                                         | (14.9)                                      | 597                                         | (15.7)                                      | 439                                                  | (15.5)                                               | 858                                                  | (16.3)                                               |
| withserious adverseevents                        | 36                             | (46.2)                         | 26                             | (34.7)                         | 43                 | (53.1)             | 32                 | (51.6)             | 786                                         | (37.6)                                      | 1,466                                       | (38.7)                                      | 1,096                                                | (38.7)                                               | 1,998                                                | (37.9)                                               |
| withserious drug-related adverse events          | 18                             | (23.1)                         | 7                              | (9.3)                          | 22                 | (27.2)             | 19                 | (30.6)             | 235                                         | (11.2)                                      | 415                                         | (10.9)                                      | 321                                                  | (11.3)                                               | 591                                                  | (11.2)                                               |
| whodied                                          | 4                              | (5.1)                          | 2                              | (2.7)                          | 3                  | (3.7)              | 4                  | (6.5)              | 108                                         | (5.2)                                       | 203                                         | (5.4)                                       | 158                                                  | (5.6)                                                | 288                                                  | (5.5)                                                |
| whodiedduetoadrug-related adverse event          | 0                              | (0.0)                          | 0                              | (0.0)                          | 1                  | (1.2)              | 0                  | (0.0)              | 12                                          | (0.6)                                       | 27                                          | (0.7)                                       | 18                                                   | (0.6)                                                | 42                                                   | (0.8)                                                |
| discontinueddrugdueto anadverseevent             | 13                             | (16.7)                         | 8                              | (10.7)                         | 12                 | (14.8)             | 5                  | (8.1)              | 263                                         | (12.6)                                      | 520                                         | (13.7)                                      | 356                                                  | (12.6)                                               | 685                                                  | (13.0)                                               |
| discontinueddrugduetoadrug-related adverseevent  | 9                              | (11.5)                         | 6                              | (8.0)                          | 5                  | (6.2)              | 3                  | (4.8)              | 148                                         | (7.1)                                       | 257                                         | (6.8)                                       | 190                                                  | (6.7)                                                | 352                                                  | (6.7)                                                |
| discontinueddrugduetoaseriousadverse event       | 10                             | (12.8)                         | 2                              | (2.7)                          | 8                  | (9.9)              | 5                  | (8.1)              | 191                                         | (9.1)                                       | 379                                         | (10.0)                                      | 259                                                  | (9.1)                                                | 497                                                  | (9.4)                                                |

## Immunogenicity

No new immunogenicity data are available.

## Safety related to drug-drug interactions and other interactions

As pembrolizumab is an IgG antibody that is administered parenterally and cleared by catabolism, food and DDI are not anticipated to influence exposure. Drugs that affect the cytochrome P450 and other metabolizing enzymes, are not expected to interfere with the metabolism of an IgG antibody.

Studies evaluating PD drug interactions with pembrolizumab have not been conducted. No relationship was observed between prolonged use of systemic corticosteroids and pembrolizumab exposure. Nevertheless, given the study design, exclusion criteria, and immunomodulatory mechanism of action, the use of systemic corticosteroids (at doses greater than physiologic replacement), or other immunosuppressants before the start of pembrolizumab treatment, is not recommended, but can be used to treat immune-related adverse reactions.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

## Treatment discontinuation

In the KEYNOTE-177 safety dataset, discontinuation due to AE (all causality) occurred in 21 (13.7%) vs 17 (11.9%) patients in pembrolizumab vs SOC arm, respectively. After adjustment for exposure, the incidence of AEs leading to discontinuation remained consistent in the KEYNOTE-177 pembrolizumab safety dataset relative to the SOC safety dataset (11.58 vs 16.37 events/100 person-years).

The proportion of participants who experienced AEs leading to pembrolizumab discontinuation in the KEYNOTE-177 pembrolizumab safety dataset (13.7%) was consistent with the RSD (13.3%)

The incidence of drug-related AEs leading to treatment discontinuation 9.8% (15 patients) in the KEYNOTE-177 pembrolizumab safety dataset and 5.6% (8 patients) in the SOC safety dataset. After adjustment for exposure, the incidence of drug-related AEs leading to treatment discontinuation was similar in the pembrolizumab safety dataset relative to the SOC safety dataset (8.27 vs 8.19 events/100 person-years). The drug-related AEs leading to treatment discontinuation in the pembrolizumab arm were: Autoimmune colitis, Colitis, Hepatitis, Alanine aminotransferase increased (2 patients each), Autoimmune hepatitis, Immune-mediated hepatitis, Aspartate aminotransferase increased, Hypophysitis, Acute kidney injury, Pneumonitis, Psoriasis (1 patient each).

The proportion of participants who experienced drug-related AEs leading to pembrolizumab discontinuation in the KEYNOTE-177 pembrolizumab safety dataset (9.8%) was generally consistent with the RSD (6.9%). Compared to the RSD, a higher frequency of discontinuation due to gastrointestinal and hepatic events was observed. After adjustment for exposure, the incidence of drug-related AEs leading to discontinuation remained similar in the KEYNOTE-177 pembrolizumab safety dataset relative to the RSD (8.27 vs 11.35 events/100 person-years).

## Treatment interruption

A lower proportion of participants in the KEYNOTE-177 pembrolizumab safety dataset experienced an AE as well as drug-related AEs resulting in treatment interruption than in the SOC safety dataset (AEs: 37.9% vs 69.2%; drug-related AEs 22.9% vs 58.7%).

Compared to the RSD, the proportion of participants who experienced AEs and drug-related AEs leading to treatment interruption in the KEYNOTE-177 pembrolizumab safety dataset was higher than the RSD (AEs: 37.9% vs 25.2%; drug-related AEs: 22.9% vs 14.2%).

Drug-related AEs leading to treatment interruption that occurred more frequently ( â¥ 2% difference) in the KEYNOTE-177 pembrolizumab safety dataset versus the RSD were aspartate aminotransferase increased (3.3% vs 0.7%), diarrhea (3.3% vs 1.4%), and colitis (2.6% vs 0.5%).

## Safety in Participants Who Crossed Over to Pembrolizumab Monotherapy

There were 56 participants from the SOC group who crossed over to pembrolizumab monotherapy within the study. Of the 56 participants who crossed over to pembrolizumab, 94.6% experienced at least 1 AE after initiating crossover treatment. The incidences of drug-related AEs, drug-related Grade 3 to 5 AEs, SAEs, and drug-related SAEs were similar to those in the pembrolizumab group in the initial treatment phase.

Review of listings of events in participants who crossed over to pembrolizumab did not identify any new safety  concerns.  The  summary  safety  data  observed  for  participants  who  crossed  over  from  SOC  to

<div style=\"page-break-after: always\"></div>

pembrolizumab treatment were generally consistent with the summary AE data in the pembrolizumab group in the initial treatment phase.

Table: AE Summary Cross-over Phase (ASaT Population Who Crossed Over From Standard of Care to Pembrolizumab)

|                                                             | Pembrolizumab   | Pembrolizumab   |
|-------------------------------------------------------------|-----------------|-----------------|
|                                                             | n               | (%)             |
| Subjects in population*                                     | 56              |                 |
| with one or more adverse events                             | 53              | (94.6)          |
| with no adverse event                                       | 3               | (5.4)           |
| with drug-relatedt adverse events                           | 41              | (73.2)          |
| with toxicity grade 3-5 adverse events                      | 33              | (58.9)          |
| with toxicity grade 3-5 drug-related adverse events         | 9               | (16.1)          |
| with serious adverse events                                 | 26              | (46.4)          |
| with serious drug-related adverse events                    | 7               | (12.5)          |
| who died                                                    | 3               | (5.4)           |
| who died due to a drug-related adverseevent                 | 0               | (0.0)           |
| discontinued+ drug due to an adverse event                  | 10              | (17.9)          |
| discontinuedt drug due to a drug-related adverse event      | 5               | (8.9)           |
| discontinued+ drug due to a serious adverse event           | 8               | (14.3)          |
| discontinued+drug duetoa serious drug-related adverse event | 3               | (5.4)           |

Database Cutoff Date: 19FEB2020.

## Post marketing experience

The safety profile of pembrolizumab was summarized in the PSUR (period from 04-SEP-2018-03 to SEP2019). There are no records of any pembrolizumab registration being revoked or withdrawn for safety reasons in any country.

## 2.5.1. Discussion on clinical safety

The evaluation of the safety profile of pembrolizumab in the sought extension of indication for Keytruda as first line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer is based on the pivotal phase III study KEYNOTE-177 IA2 results (n=153 patients in the pembrolizumab group vs n=143 patients in the SOC chemotherapy mFOLFOX6 or FOLFIRI or respective combinations with bevacizumab or cetuximab). Data have been presented side by side with the Reference Safety Dataset (RSD, n=5884) and the Cumulative Running Pembrolizumab Monotherapy Safety Dataset (N=8098), in order to assess the consistency of the pembrolizumab monotherapy safety in the intended indication with its already established safety profile in the other indications.

Median exposure to treatment was longer for the pembrolizumab group than for the SOC group (11.1 vs 5.7 months). It was also longer compared to the RSD (11.1 vs 4.9 months), with more than twice the median number of administrations in KN177 (median 16 vs 8). Patients exposed to pembrolizumab â¥12 months were 47.7% in KN177, vs 20.3% in the RSD.

Regarding the summary of adverse events , pembrolizumab treatment was generally well-tolerated when compared to SOC treatment.

<div style=\"page-break-after: always\"></div>

The overall incidence of AEs was similar in pembrolizumab (97.4%) and SOC safety datasets (99.3%), as well as in the RSD (96.5%). The most frequent (&gt;20% incidence) AEs in the KN177 pembrolizumab arm were diarrhoea, fatigue, nausea, abdominal pain, decreased appetite and vomiting. Diarrhoea, nausea and fatigue were also the most common ARs in the SOC arm, although at higher frequency (&gt;50%). On the contrary, AEs with a â¥10% point difference in KN177 pembrolizumab compared with the SOC group were arthralgia, hypothyroidism, and blood alkaline phosphatase increased. When compared to the established pembrolizumab safety profile of the RSD, AEs more frequently ( â¥ 10% point difference) reported in the KN177 pembrolizumab safety dataset than RSD were diarrhoea (44.4% vs 20.3%), abdominal pain (24.2% vs 8.1%), and nausea (30.7% vs 20.4%). Higher rates of diarrhoea and abdominal pain compared to RSD are still observed after adjusting for exposure. Overall, the above events appear more commonly reported in both arms of KN177 study; they can be considered expected in patients with colon cancer.

The incidence of grade 3-5 AEs was lower in the KEYNOTE-177 pembrolizumab compared with the SOC safety dataset (56.2% vs 77.6%), which was driven by the higher incidences of haematological toxicities in the chemotherapy arm. But it was higher when compared to the RSD (48.7%). However, the difference between pembrolizumab in KN177 and in RSD is no more evident after adjusting for exposure. The most common G3-5 AEs was hypertension (7.2%, vs 4.9% in the SOC and 1.7% in the RSD). The MAH stated that all participants with a reported event of G3-5 hypertension had a medical history of hypertension at the time of enrolment. In addition, the frequency of hypertension is markedly lower at 0.7%, lower than the SOC (4.2%) and in line with the RSD (0.2%) when treatment-related G3-5 AEs are considered. This is reassuring.

The most frequently (&gt;10%) reported drug-related AEs in KN177 pembrolizumab arm were diarrhoea, fatigue, pruritus, nausea, AST increased, rash, arthralgia and hypothyroidism. Among them, diarrhoea, fatigue and nausea were detected at higher incidence in the SOC arm. Diarrhoea was the drug-related AR reported more frequently (&gt;10% point difference) in the KN177 pembrolizumab safety dataset vs the RSD (24.8% vs 10.7%). Diarrhoea, colitis, ALT increase and fatigue were the most commonly reported G3-5 drug-related AEs (2% each) in the KN177 pembrolizumab arm; all were more common in KN177 than in the RSD, and colitis and ALT increase were also more frequent than in the SOC arm (0% and 0.7% respectively).

Incidence of SAE was lower in the pembrolizumab than in the SOC arm of KN177 study (40.5% vs 52.4%) and in line with the RSD (38.3%). The most frequently reported (&gt;2%) SAEs in the KN177 pembrolizumab safety dataset were abdominal pain, diarrhoea, and pyrexia. Abdominal pain was higher in the KN177 pembrolizumab safety dataset (4.6%) compared to SOC (1.4%) as well as to pembrolizumab RSD (0.6%). The MAH stated that medical review of abdominal pain events indicate that these AEs were associated with the underlying colon cancer disease. Diarrhoea was on the contrary less common in the pembrolizumab than in the SOC arm (2.6% vs 6.3%), but higher compared to the RSD (0.6%).

The overall incidence of drug-related SAE in the KN177 pembrolizumab safety dataset was lower compared with the SOC safety dataset (16.3% vs 28.7%). On the contrary, when compared to RSD the incidence in KN177 was slightly higher (16.3% vs 11.3%), but this trend reversed when adjusted for exposure (rate 16.34 vs 24.13). The most common drug-related SAE was colitis (2%, in 3 patients), followed by acute kidney injury, autoimmune colitis, diarrhoea, hepatitis and pyrexia (1.3%, 2 patients each). Colitis was not reported in the SOC, and it was reported at higher incidence than in the RSD (2% vs 0.9% for colitis, 1.3% vs 0% for autoimmune colitis).

As expected, the overall incidence of AEOSI was higher in the KN177 pembrolizumab compared with the SOC safety dataset (30.7% vs 12.6%), the most common ( â¥ 2% incidence) being hypothyroidism, colitis, hyperthyroidism, pneumonitis, adrenal insufficiency, hepatitis, and infusion reactions. The frequency of

<div style=\"page-break-after: always\"></div>

AEOSI was higher for pembrolizumab-treated patients in KN177 compared to RSD (30.7% vs 24.9%), but it is reassuring that this trend reverted when adjusted for exposure (rate 35.85 vs 53.39). While the most common AEOSI was hypothyroidism in both pembrolizumab KN177 arm and RSD at a similar frequency (12.4% vs 10.7%), it can be observed an higher incidence of colitis (6.5% vs 2%), adrenal insufficiency (2.6% vs 0.8%) and hepatitis (2.6% vs 1%) in KN177 pembrolizumab arm than in RSD. When adjusted for exposure, the above differences tended to be reduced. Most of the AEOSI were grade 1 and 2, with no fatal AEOSI reported. Approximately half of the AEOSI were not resolved as of the data cut-off date. The highest rate of not-resolved AEOSI was hypothyroidism, as expected due to long term hormone thyroid replacement.

Treatment discontinuation due to AEs (all causality and drug related) were more frequently reported in the pembrolizumab arm compared to patients receiving chemotherapy in the SOC arm, as well as compared to pembrolizumab RSD (discontinuation due to drug-related AE: 9.8% vs 5.6% vs 6.9%, respectively). However, after adjusting for exposure, discontinuations in the pembrolizumab KN177 arm were lower than the other two datasets. Of the 15 patients who discontinued pembrolizumab due to drug related AEs, 13 were due to gastrointestinal and hepatic events.

The proportion of participants with AEs resulting in death was similar in the KN177 pembrolizumab and SOC safety datasets (6 participants [3.9%] vs 7 participants [4.9%]). Additionally, 3 deaths were reported in patients receiving pembrolizumab in the crossover phase. None of the deaths were considered related to pembrolizumab by investigator. Clarifications have been requested regarding two AEs leading to death: for the first one 'pseudobulbar palsy', the MAH stated that pseudobulbar palsy is impacted by the confounding factor of amyotrophic lateral sclerosis, although this diagnosis is not included in the past medical history and it is unclear whether this diagnosis was made during the study. With regard to a subjects who died due to aggravating diarrhoea 'without infection focus', from a regulatory and retrospective perspective, it appears that the patient experienced autoimmune hepatitis, worsening of pre-existing autoimmune disease (psoriasis) and very likely also immune-related colitis, the latter however was not further investigated (e.g. colonoscopy) and no immunosuppressive therapy was initiated, so this cannot be finally determined. Nonetheless, the MAH's interpretation that this event is unlikely related to pembrolizumab is not shared. The omission of further diagnostic and therapeutic intervention during the course of non-infectious, aggravating and finally fatal diarrhoea remains worrisome and underlines that physicians' awareness of the risk of potential autoimmune colitis appears clinically relevant (see colitis below).

The MAH performed a separate analysis for the events of colitis . In the pembrolizumab KN177 arm 10 patients experienced colitis (6.5%), vs none in the SOC arm. The incidence of colitis was higher also compared to the RSD (2%). Half (n=5) of the colitis events were G3-4, which is however similar to what observed in the RSD (60% were G3-4) (but when taking into account G4 only events these are more common in KN177 study). Difference remains after adjusting for exposure although less pronounced, but still incidences of all grade and severe colitis are about 50% higher for patients with CRC than in the RSD. On one side, it might not be fully appropriate to argue the clinical relevance of higher colitis AEs away by referring to the lower differences in exposure-adjusted event rates (since most of the AEs overall are expected to occur during the early treatment phase). On the other side, the longer exposure could be important in the incidence of colitis, taking into account that the median time to onset of colitis was approximately 6 months (range 3 to 18 months). Four G4 colitis events were considered treatmentrelated SAEs, and colitis led to pembrolizumab discontinuation in four patients. The median duration was about 2.4 months (range 15 days to 1 year). Corticosteroids were administered in 8/10 cases. It is reassuring that in 9/10 patients, colitis was resolved at the cut-off date. The argument that the role of metastatic CRC as a risk factor for colitis is unclear is understood. Nonetheless, while colitis is a known AEOSI to pembrolizumab already included in the SmPC, higher incidences were observed for pembrolizumab in Study KEYNOTE-177 compared to the RSD, and physicians should be informed about

<div style=\"page-break-after: always\"></div>

this. Awareness might be especially relevant in the context of the underlying disease, since clinical symptoms of colitis might be more easily misinterpreted (and remain untreated). The observed incidences of all grade and Grade 3-5 colitis events in patients with CRC in KEYNOTE-177 has been included by the MAH in the SmPC section 4.8, immune-related colitis.

The MAH was requested to discuss hepatic toxicity . In the KN177 pembrolizumab arm, among the AEOSI, 4 patients experienced hepatitis (2.6%), all grade 3 and all leading to treatment discontinuation. Reassuringly, all the 4 events of hepatitis resolved at the data cut-off date. In the RSD, the incidence of hepatitis was lower (1%), but when adjusted for exposure, hepatitis was similar between pembrolizumab arm in KN-177 and RSD (all grades and grade 3-5). Hepatitis is a known AEOSI associated to pembrolizumab and reported in the SmPC. None of the participants in KN177 (in either arm) had laboratory values that satisfied the protocol-specified criteria for potential drug-induced liver injury, however participants in the KEYNOTE-177 pembrolizumab safety dataset compared with the RSD reported a higher frequency of ALT increased (14.4% vs 6.6%), AST increased (15.7% vs 6.5%), and blood bilirubin increased (4.6% vs 2.1%). When adjusted for exposure, the difference was overall comparable. The incidence of liver investigation abnormalities does not seem to be related with the liver metastases. Based on the overall data, no change in the SmPC is warranted.

No major concerns are raised based on the analysis of safety by subgroups based on intrinsic factors (age, sex, ECOG).

A higher incidence ( â¥ 12% point) of Grade 3 to 5 AEs and SAEs was noted in the â¥ 65 years age group of the KEYNOTE-177 pembrolizumab safety dataset compared to the participants &lt;65 years of age. A less pronounced difference was observed between the age groups in the RSD. However, AE incidences for pembrolizumab in the higher age group did not exceed the rates of those in the SOC arm.

## 2.5.2. Conclusions on clinical safety

Overall, the safety profile of pembrolizumab remains unchanged and no new safety concerns were identified in the KEYNOTE-177 study. Pembrolizumab showed a favourable safety overall relative to polychemotherapy SOC, with a different AE profile as expected.

Compared to the known safety profile of pembrolizumab in RSD, in some cases a trend toward worse toxicity and higher rate of discontinuations were observed in the CRC MSI-H pembrolizumab treated population of KN177. However, in most cases this appears to be due to the longer exposure, which was almost doubled in the KN177 dataset compared to RSD, as shown based on exposure-adjusted safety analyses. The safety profile of pembrolizumab was characterized by an increased gastrointestinal toxicity, especially diarrhoea and abdominal pain, compared to the known pembrolizumab safety profile. The incidence of immune-related colitis observed in CRC patients in KEYNOTE-177 study is included in the SmPC section 4.8.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 29 is acceptable.

The CHMP endorsed the Risk Management Plan version 29 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related adverse reactions (including immune related pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies)                                                                                                                                                                                      |
| Important potential risks    | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information          | None                                                                                                                                                                                                                                                                                                              |

No new safety concerns have been identified from the submitted data supporting the new indication.

Existing pharmacovigilance plan and risk minimisations measures remain sufficient to mitigate the risks of the product in all approved indications.

## Pharmacovigilance plan

## On-Going and Planned Additional Pharmacovigilance Activities

| Study Status                                                  | Study/activity Type, title and category                                                                                                                                       | Summary of Objectives                                                                                                              | Safety concerns addressed                                                                                        | Milestones                                                    | Due dates                                                     |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                      | Category 3 - Required additional pharmacovigilance activities                                                    | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| Planned                                                       | Cumulative review of literature, clinical trial and post-marketing cases for the risk of GVHD after pembrolizumab administration in patients with a history of allogeneic SCT | To monitor, identify and evaluate reports of GVHD after pembrolizumab administration in patients with a history of allogeneic SCT. | Important potential risk of GVHD after pembrolizumab administration in patients with a history of allogeneic SCT | PSUR                                                          | 2019                                                          |

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                               | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks: Immune-Related Adverse Reactions                                                                 | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                                                                                                                                                           | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                          |
| Immune-related adverse reactions (including immune- related pneumonitis, colitis, hepatitis, nephritis and endocrinopathies) | Routine risk minimisation measures: â¢ The risk of the immune- related adverse reactions (including immune-related pneumonitis colitis, hepatitis, nephritis, and endocrinopathies) associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Routine pharmacovigilance activities Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire for spontaneous postmarketing reports of all adverse events |
|                                                                                                                              | Additional risk minimisation measures: Patient educational materials                                                                                                                                                                                                                                                                                   | Additional pharmacovigilance including: â¢ Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumour types                                                                    |

<div style=\"page-break-after: always\"></div>

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                                                | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                        | Important Potential Risks                                                                                                                                                                                                                                                                                                                                                                |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: â¢ For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: â¢ Safety monitoring in the ongoing HL trials (KN087,                                                                                                                                                                                                                                                        |
| GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                          | Routine risk minimisation measures: â¢ GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted                                                                   | Routine pharmacovigilance activities Additional pharmacovigilance including: â¢ Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumour types â¢ Cumulative review of literature, clinical trial and post-marketing cases of GVHD after pembrolizumab administration in patients with a history of allogeneic SCT with PSUR submission in 2019. |

## 2.7. Changes to the Product Information

As a result of this variation, section(s) 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are being updated. The Package Leaflet (PL) is updated accordingly.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The changes to the package leaflet are limited; in particular, the key messages for the safe use of the medicinal product are not impacted. Furthermore, the design, layout and format of the package leaflet will not be affected by the proposed revisions. Therefore, these proposed revisions do not constitute

<div style=\"page-break-after: always\"></div>

significant changes that would require the need to conduct a new user consultation or abridged focus testing.

## 2.7.2. Additional monitoring

Pursuant to Article 23(3) of Regulation No (EU) 726/2004, Keytruda (pembrolizumab) has been removed from the additional monitoring list with the renewal procedure five years after the Union reference date.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The final indication is 'KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults'

## 3.1.2. Available therapies and unmet medical need

Combination chemotherapy in the form of FOLFOX (oxaliplatin, 5-FU, and leucovorin/folinic acid) or FOLFIRI (irinotecan, 5-FU, and leucovorin/folinic acid) has been established as first-line SOC chemotherapy options for metastatic CRC and may be used interchangeably depending on the physician's recommendation and regional preference.

The treatment of mCRC patients should be seen as a continuum of care in which the determination of the goals of the treatment is important: prolongation of survival, cure, improving tumour-related symptoms, stopping tumour progression and/or maintaining quality of life 15 .

## 3.1.3. Main clinical studies

KEYNOTE-177 is an ongoing, two-arm, multicenter, international, randomized, open-label, controlled study of pembrolizumab monotherapy vs standard chemotherapy in participants with Stage IV MSIH/dMMR CRC. The dual primary objectives of the study are PFS per RECIST 1.1 by BICR and OS. A total of 307 participants were randomized in a 1:1 ratio to receive pembrolizumab 200 mg Q3W (n=153) or investigator's choice of SOC (6 regimens allowed: mFOLFOX6 or FOLFIRI alone or in combination with bevacizumab or cetuximab) (n=154).

The MAH submitted the Interim Analysis 2 (i.e. final PFS and interim OS analysis) results with data cutoff date of 19-FEB-2020 (median survival follow-up 27 months).

## 3.2. Favourable effects

- Statistically significant and clinically relevant PFS advantage of pembrolizumab vs SOC: HR 0.60 (95%CI 0.45, 0.80), p=0.0002, median PFS 16.5 (95%CI 5.4, 32.4) vs 8.2 (95%CI 6.1, 10.2) months. Kaplan-Meier PFS curves demonstrate an increasingly pronounced separation after month 6

15  Van Cutsem E et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(suppl 3):iii1-iii9.

<div style=\"page-break-after: always\"></div>

(PFS rate at 12 months 55.3% vs 37.3%, PFS rate at 24 months 48.3% vs 18.6%). PFS results were consistent across sensitivity analyses.

- A favourable OS trend was observed: HR 0.77 (95% CI 0.54, 1.09), p=0.0694, median OS NR vs 34.8 months (95%CI 26.3, NR).
- A trend toward higher ORR with pembrolizumab compared to SOC was seen [43.8% (95% CI: 35.8, 52.0) vs 33.1% (95% CI: 25.8, 41.1], including higher CR rate (11.1% versus 3.9%).
- Durable responses with pembrolizumab compared to SOC: median DOR NR in the pembrolizumab vs 10.6 months in the SOC group, proportion of patients with DOR â¥ 12 months 85.1% vs 43.8%.
- PFS2 advantage is seen with pembrolizumab compared to SOC (HR 0.63, 95%CI 0.45, 0.88).
- Trend toward improvement in QoL and most of the functioning and symptoms score in the pembrolizumab arm compared to SOC, supporting the overall efficacy and safety data.

## 3.3. Uncertainties and limitations about favourable effects

- A crossing of the OS KM curves up to month 8, with greater Hazard rates in the pembrolizumab arm compared with the SOC arm for the first 4 months, is observed. Number of patients is too small to firmly identify risk factors of early death. Text in the SmPC section 4.4 reporting that 'in Keynote-177, the  hazard  rates  for  overall  survival  events  were  greater  for  pembrolizumab  compared  with chemotherapy  for  the  first  4  months  of  treatment,  followed  by  a  long-term  survival  benefit  for pembrolizumab' has been added, and OS KM curves are shown in section 5.1 of the SmPC.
- Similar efficacy of pembrolizumab and SOC is observed, but with better safety profile in patients beyond the age of 75 years. Data in this age group is however limited. This is reflected in the SmPC.

## 3.4. Unfavourable effects

- Drug-related AEs were reported in 79.7% of pembrolizumab treated MSI-H CRC patients in KN177 study. The most commonly (&gt;10%) observed drug-related AEs were diarrhoea (24.8%), fatigue (20.9%), pruritus (13.7%), nausea (12.1%), AST increased (11.1%), rash (11.1%), arthralgia (10.5%) and hypothyroidism (10.5%).
- Drug-related G3-5 AEs occurred in 21.6% of subjects, being ALT increase, colitis, diarrhoea and fatigue the most frequent (2% each).
- The incidence of drug-related SAEs was 16.3%, with colitis as the most frequent (2%).
- AEOSI occurred in 30.7% of patients, most common being hypothyroidism (12.4%) and colitis (6.5%).
- Drug-related AEs leading to discontinuation of pembrolizumab in 9.8% (n=15) of patients. Autoimmune colitis, Colitis, Hepatitis and ALT increase cause discontinuation of treatment in 2 patients each.
- Compared to the known pembrolizumab safety profile, an increased frequency of gastrointestinal toxicity, in particular diarrhoea and abdominal pain, as well as a higher incidence of the AEOSI colitis was evident in KN177. The argument that the role of metastatic CRC as a risk factor for colitis is unclear is understood. Difference in incidence of colitis between arms is reduced when adjusted for exposure, but still awareness might be especially relevant in the context of the underlying disease, since clinical symptoms of colitis might be more easily misinterpreted (and remain untreated). The

<div style=\"page-break-after: always\"></div>

incidence of immune-related colitis in CRC patients from KEYNOTE-177 has been added by the MAH in the SmPC section 4.8.

## 3.5. Uncertainties and limitations about unfavourable effects

No new uncertainties have been introduced with this application (see RMP).

## 3.6. Effects Table

Table 2. Effects Table for Keytruda in first line metastatic MSI-H/dMMR CRC (data cut-off: 19FEB-2020)

| Effect                       | Short description                                                                                                                              | Unit                             | Treatment Pembro 200 mg Q3W                         | Control Investigato r's choice SOC   | Uncertainties / Strength of evidence                                                                                                                                                                            | Refe renc es   |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Favourable Effects           | Favourable Effects                                                                                                                             |                                  |                                                     |                                      |                                                                                                                                                                                                                 |                |
| PFS (by BICR per RECIST 1.1) | Time from randomization to first documented disease progression per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first | months (95% CI) HR p-value       | 16.5 (5.4, 32.4) 0.60 (95%CI 0.45, 0.0002 (boundary | 8.2 (6.1, 10.2) 0.80) â¤ 0.0117)      | Statistically significant and clinically relevant advantage in PFS. Consistent sensitivity analyses results / apparent reduced efficacy in patients with lung metastases, but limited number to draw conclusion | CSR KN- 177    |
| OS                           | Time from randomization to death due to any cause                                                                                              | months (95% CI) HR P-value0.0694 | NR (NR, NR) 0.77 (95%CI 0.54, (boundary             | 34.8 (26.3, NR) 1.09) â¤ 0.0053)      | Trend toward OS benefit although not statistically significant (60% of crossover in SOC arm) /early crossing of OS curves                                                                                       |                |
| ORR                          | Confirmed CR or PR (by BICR per RECIST 1.1)                                                                                                    | % (95% CI)                       | 43.8 (35.8, 52.0)                                   | 33.1 (25.8, 41.1)                    | Trend toward higher ORR and CR/ less SD and more PD                                                                                                                                                             |                |
| DOR                          | Time from first response to PD or death due to any cause, whichever occurs first, in subjects who achieve a PR or CR                           | months (range)                   | NR (2.3+ -41.4+)                                    | 10.6 (2.8 -37.5+)                    | Durable responses                                                                                                                                                                                               |                |
| PFS2                         | Time from randomization to disease progression on the next line of therapy, or death from any cause, whichever occurs first                    | months (95% CI)                  | NR (NR, NR)                                         | 23.5 (16.6, 32.6)                    | Advantage in PFS2                                                                                                                                                                                               |                |
| Unfavourable Effects         | Unfavourable Effects                                                                                                                           |                                  |                                                     |                                      |                                                                                                                                                                                                                 |                |
| AE summary                   | AE drug related AE AE                                                                                                                          | % % % %                          | 97.4 79.7 56.2                                      | 99.3 98.6 77.6 65.7                  | Pembrolizumab safety profile compared favourably with SOC. Higher discontinuation due to AE in pembrolizumab than SOC arm possibly due to longer                                                                | CSR KN- 177    |
| AE summary                   | G3-5                                                                                                                                           |                                  |                                                     |                                      |                                                                                                                                                                                                                 |                |
| AE summary                   | drug related G3-5 AE                                                                                                                           |                                  | 21.6                                                |                                      |                                                                                                                                                                                                                 |                |
| AE summary                   | SAE                                                                                                                                            | %                                | 40.5                                                | 52.4                                 |                                                                                                                                                                                                                 |                |
| AE summary                   | drug related SAE                                                                                                                               | %                                | 16.3                                                | 28.7                                 |                                                                                                                                                                                                                 |                |
| AE summary                   | death due to AE                                                                                                                                | %                                | 3.9                                                 | 4.9                                  | exposure.                                                                                                                                                                                                       |                |
| AE summary                   | death due to drug related AE                                                                                                                   | %                                | 0                                                   | 0.7                                  | Consistent safety profile                                                                                                                                                                                       |                |
| AE summary                   | discontinuation due to AE                                                                                                                      | %                                | 13.7                                                | 11.9                                 |                                                                                                                                                                                                                 |                |
| AE summary                   | discontinuation due to drug related AE                                                                                                         | %                                | 9.8                                                 | 5.6                                  | compared to the reference safety dataset, with the exception of a higher                                                                                                                                        |                |
| AEOSI                        | hypothyroidism                                                                                                                                 | %                                | 12.4                                                | 2.1                                  | incidence of colitis.                                                                                                                                                                                           |                |
| AEOSI                        | colitis                                                                                                                                        | %                                | 6.5                                                 | 0                                    | No new safety concerns identified.                                                                                                                                                                              |                |

Abbreviations: PFS: progression free survival; OS: overall survival; ORR: objective response rate; DOR: duration of response; RECIST: BICR: blinded central imaging review; NR: not reached; CI: confidence interval; AE: adverse event; SAE: serious adverse event; AEOSI: Adverse Events of Special Interest; CRS: clinical study report

<div style=\"page-break-after: always\"></div>

Notes:

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In the open-label study KEYNOTE-177, pembrolizumab demonstrated a statistically significant and clinically meaningful PFS benefit for patients with metastatic MSI-H/ dMMR mCRC. The median PFS in the pembrolizumab arm was almost doubled compared to the SOC arm, with a gain of about 8 months.

OS curves showed initial crossing with greater hazard rates in the pembrolizumab arm compared with the SOC arm for the first 4 months. Some imbalances in baseline characteristics of patients who died early in the two arms are observed, although the small number of patients prevent to identify risk factors for early death with pembrolizumab. OS KM curves in section 5.1 as well as text in section 4.4 of the SmPC have been included to inform prescribers.

Safety analyses broadly confirmed the already well-known and different toxicity profiles of pembrolizumab, which compared favourably to polychemotherapy regimens. An increased incidence of GI toxicity was on reported, in particular the AEOSI of Colitis.

## 3.7.2. Balance of benefits and risks

The efficacy data of pembrolizumab monotherapy as demonstrated in study KEYNOTE-177 support its benefit as first line treatment of metastatic MSI-H/dMMR CRC outweighing the established risks of treatment. The wording of the indication was updated to include only patients actually enrolled in the clinical trial (i.e. metastatic).

## 3.7.3. Additional considerations on the benefit-risk balance

The MAH is requesting to approve the 400 mg Q6W as alternative dose for the sought indication, as done for the other pembrolizumab monotherapy indications, which is considered acceptable.

## 3.8. Conclusions

The overall B/R of Keytruda is positive.

The following measures are considered necessary to address issues related to efficacy:

The MAH agreed to submit the final OS analysis for KEYNOTE-177 as part of the final CSR when available (estimated Q3 2021), as an Annex II condition in the Product Information in order to confirm interim OS data.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

C.I.6 -Extension of indication to include first-line treatment of metastatic microsatellite instability-high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults for Keytruda based on the results from KEYNOTE-177 (an international, randomised, open-label Phase 3 trial of pembrolizumab versus chemotherapy in MSI-H or dMMR Stage IV Colorectal Carcinoma).  As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, a minor correction has been made in section 4.4, 'Immune related endocrinopathies' subsection. Version 29.0 of the RMP has also been submitted.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Keytruda-H-C-3820-II-0091'.